Oncology — Therapeutic Area Intelligence | Humanexa Signals

RegulatoryAugust 6, 2026

FDA Accepts Supplemental NDA for Mekinist by Novartis

The FDA has accepted a supplemental NDA for Mekinist (trametinib dimethyl sulfoxide) submitted by Novartis.

ClinicalAugust 6, 2026

Phase 1 Trial of TSLPR-CART in Refractory B-ALL Shows Promise for Targeting TSLPR Overexpression

A clinical trial is underway to evaluate TSLPR-CART therapy in adults with recurrent or refractory B-ALL characterized by TSLPR overexpression.

ClinicalAugust 5, 2026

BI 764532 Dose Tolerance Study in DLL3-Positive Brain Tumor Patients Initiated

A clinical trial is underway to evaluate the tolerability of BI 764532 in adults with DLL3-positive brain tumors.

ClinicalAugust 5, 2026

YH32364 Trial Targets EGFR Overexpressing Solid Tumors in Advanced Cancer Patients

A clinical trial is underway to evaluate the efficacy of YH32364 in patients with locally advanced or metastatic EGFR overexpressing solid tumors.

RegulatoryAugust 5, 2026

FDA Accepts Supplement for Pluvicto (Lutetium Lu-177) by Novartis

The FDA has accepted a supplemental application for Pluvicto, a radioligand therapy for oncology.

ClinicalAugust 5, 2026

VR Program for Heart Health Education in Breast Cancer Survivors Undergoing Treatment

A study is underway to evaluate VR program aimed at improving heart health knowledge among breast cancer survivors receiving anthracyclines or trastuzumab.

RegulatoryAugust 5, 2026

Innovation Passports Granted for Liver Cancer and Dementia Products

The Innovative Licensing and Access Pathway has granted Innovation Passports to investigational products targeting liver cancer and dementia.

ClinicalAugust 5, 2026

Selinexor shows promise in high-risk multiple myeloma with XVRd regimen

The study evaluates the efficacy and safety of the XVRd regimen in newly diagnosed multiple myeloma patients with high-risk factors.

CompetitiveAugust 5, 2026

Advancements in Prostate Cancer Diagnostics: AI and Liquid Biopsies Show Promise

Innovations in prostate cancer diagnostics include PSMA-directed imaging and AI-driven methods, enhancing lesion detection.

RegulatoryAugust 5, 2026

Boehringer Ingelheim's Zongertinib NDA219042 Receives AP Status from FDA

The FDA has granted an Approval Pending (AP) status for Boehringer Ingelheim's supplemental NDA for Zongertinib.

RegulatoryAugust 5, 2026

FDA Accepts Supplement for LYNOZYFIC (BLA761400) from Regeneron

The FDA has accepted a supplemental application for LYNOZYFIC (BLA761400) submitted by Regeneron Pharmaceuticals.

ClinicalAugust 5, 2026

AIM/CD5L as a potential immunomodulator in feline injection-site sarcoma

AIM/CD5L may promote an immunosuppressive tumor microenvironment in feline injection-site sarcoma by influencing macrophage behavior.

ClinicalAugust 5, 2026

Management of BRAF Inhibitors in Glioma: Addressing Toxicity and Resistance

BRAF inhibitors are effective for BRAF-altered gliomas, but resistance and toxicity management are critical challenges.

StrategyAugust 5, 2026

Pfizer Raises 2026 Revenue Guidance by $500 Million Amid Strong Q2 Results

Pfizer reported a 3% increase in Q2 2026 revenues, raising its full-year revenue guidance by $500 million due to strong performance in non-COVID products.

RegulatoryAugust 5, 2026

FDA Accepts Supplement Application for Sodium Thiosulfate by Hope Pharms

The FDA has accepted a supplemental application for Sodium Thiosulfate (NDA203923) submitted by Hope Pharms.

StrategyAugust 5, 2026

FDA Approval Process Update for Capecitabine ANDA204345 by Dr. Reddy's

Reddy's has submitted an Abbreviated New Drug Application (ANDA) for Capecitabine, currently under standard review.

RegulatoryAugust 5, 2026

FDA Grants Approval Status for Capecitabine ANDA204741 by Amneal Pharmaceuticals

The FDA has granted an approval status of 'AP' for Amneal Pharmaceuticals' ANDA204741 for Capecitabine.

ClinicalAugust 5, 2026

NCI Launches Screening for High Genetic Risk Cancer Studies

The National Cancer Institute is conducting a screening survey to recruit participants for six open clinical genetics studies focused on cancer susceptibility.

ClinicalAugust 5, 2026

Pilot Trial for Simulation-Free Celiac Plexus Pain Ablation Using SBRT Shows Novel Workflow

A pilot feasibility trial is assessing a novel simulation-free adaptive radiotherapy workflow for celiac plexus SBRT.

RegulatoryAugust 4, 2026

FDA grants approval status for Leuprolide Acetate ANDA215336

The FDA has granted an approval status (AP) for the ANDA215336 application for Leuprolide Acetate submitted by Amneal.

RegulatoryAugust 4, 2026

FDA Accepts Supplement Application for ELIGARD Kit by TOLMAR

The FDA has accepted a supplemental application for the ELIGARD Kit, which contains leuprolide acetate.

RegulatoryAugust 4, 2026

FDA Approves Supplement for Leuprolide Acetate by PH Health

The FDA has approved a supplemental application for Leuprolide Acetate submitted by PH Health.

RegulatoryAugust 4, 2026

FDA Accepts Supplement Application for TECVAYLI (BLA761291)

The FDA has accepted a supplemental biologics license application for TECVAYLI (teclistamab-cqy), indicating ongoing development.

RegulatoryAugust 4, 2026

FDA grants approval status for Leuprolide Acetate ANDA217957

The FDA has granted an approval status (AP) for the ANDA217957 application for Leuprolide Acetate submitted by UBI.

RegulatoryAugust 4, 2026

FDA grants AP status for Leuprolide Acetate ANDA215826 by Zydus Pharms

The FDA has granted approval status (AP) for the ANDA submission of Leuprolide Acetate by Zydus Pharms.

ClinicalAugust 4, 2026

Phase II Trial of Ivonescimab in High-Risk Localized Clear Cell Renal Cell Cancer

A phase II trial is investigating the efficacy of ivonescimab as a pre-surgical treatment for high-risk localized clear cell renal cell cancer.

ClinicalAugust 4, 2026

Study on Biomarkers in AML Patients Post-Stem Cell Transplantation with Menin Inhibition

The study focuses on biomarkers in AML patients who have relapsed post-allogeneic stem cell transplantation and are treated with menin inhibitors.

ClinicalAugust 4, 2026

Phase I Study of Inavolisib in PIK3CA-Mutant Solid Tumors and Breast Cancer

A Phase I study is evaluating inavolisib's safety and pharmacokinetics in PIK3CA-mutant solid tumors, including breast cancer.

ClinicalAugust 4, 2026

Study on Palbociclib Combinations in HR+HER2-MBC Initiated in Africa and Middle East

A non-interventional study is underway to gather data on treatment patterns and outcomes for palbociclib in HR+ HER2-positive metastatic breast cancer.

ClinicalAugust 4, 2026

Study on NGS Testing to Monitor B-ALL Relapse Post CART Therapy in Children

A study is evaluating the effectiveness of NGS testing and monitoring of B-cell recovery in children with B-ALL post CART therapy.

ClinicalAugust 4, 2026

HRS-5041 Tablets Show Promise in Advanced Prostate Cancer Therapy

A study is underway to assess the efficacy and safety of HRS-5041 tablets in combination with antitumor therapy for advanced prostate cancer.

CompetitiveAugust 4, 2026

RO7771950 Shows Promise Against Tucatinib in HER2-Positive Breast Cancer Trial

A clinical trial is underway to evaluate RO7771950 in combination with trastuzumab and capecitabine against tucatinib with the same regimen.

ClinicalAugust 4, 2026

ASP1570 Study in Advanced Solid Tumors with Pembrolizumab and Standard Therapies

A clinical trial is underway to evaluate the safety, tolerability, and dosing of ASP1570 in adults with advanced solid tumors, both alone and in combination with pembrolizumab and standard therapies.

ClinicalAugust 4, 2026

Study on mSEPT9 Biomarker for Early Detection of Hepatocellular Carcinoma in Cirrhosis Patients

A clinical trial is evaluating the mSEPT9 biomarker's ability to predict hepatocellular carcinoma in cirrhosis patients.

RegulatoryAugust 4, 2026

Lilly's olomorasib receives FDA Breakthrough Therapy designation for advanced pancreatic cancer

The FDA has granted Breakthrough Therapy designation to olomorasib for advanced pancreatic cancer.

RegulatoryAugust 4, 2026

FDA Accepts Supplemental NDA for Eligard Kit by Tolmar

The FDA has accepted a supplemental NDA for the Eligard Kit, which contains leuprolide acetate.

RegulatoryAugust 4, 2026

FDA grants AP status for Leuprolide Acetate ANDA212963 by Eugia Pharma

The FDA has granted Abbreviated Approval (AP) status for Eugia Pharma's ANDA212963 for Leuprolide Acetate.

RegulatoryAugust 4, 2026

FDA Accepts Supplemental BLA for TALVEY (TALQUETAMAB-TGVS) by Janssen

The FDA has accepted a supplemental Biologics License Application (BLA) for TALVEY, an investigational T-cell engager.

RegulatoryAugust 4, 2026

FDA Accepts Supplemental NDA for ZOLADEX by TERSERA

The FDA has accepted a supplemental NDA for ZOLADEX, an oncology drug containing goserelin acetate, submitted by TERSERA.

RegulatoryAugust 4, 2026

FDA Accepts Supplement for ZOLADEX (Goserelin) by TERSERA

The FDA has accepted a supplemental application for ZOLADEX (goserelin) submitted by TERSERA.

RegulatoryAugust 4, 2026

FDA Grants AP Status for Sandoz's Leuprolide Acetate Supplement

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status to Sandoz for a supplement of Leuprolide Acetate.

RegulatoryAugust 4, 2026

FDA Grants AP Status for Leuprolide Acetate ANDA213829

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Leuprolide Acetate submitted by Somerset Therapies LLC.

RegulatoryAugust 4, 2026

FDA Accepts Supplemental NDA for Eligard Kit by Tolmar

The FDA has accepted a supplemental NDA for the Eligard Kit, which contains leuprolide acetate.

ClinicalAugust 4, 2026

Elranatamab and Iberdomide Combination Study in Relapsed/Refractory Multiple Myeloma Initiated

A clinical trial is underway to evaluate the safety and tolerability of elranatamab combined with iberdomide in patients with relapsed or refractory multiple myeloma.

ClinicalAugust 4, 2026

Study on ctDNA and HPV DNA Detection in High-risk Head and Neck Cancer Initiated

A study is underway to evaluate the feasibility of real-time detection of ctDNA and HPV DNA in patients with high-risk locally advanced head and neck squamous cell carcinoma.

RegulatoryAugust 3, 2026

FDA Accepts Supplement for Leuprolide Acetate by Sun Pharma

The FDA has accepted a supplemental application for Leuprolide Acetate submitted by Sun Pharma.

RegulatoryAugust 3, 2026

FDA grants AP status for Leuprolide Acetate ANDA075471 by Meitheal

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Leuprolide Acetate submitted by Meitheal.

RegulatoryAugust 3, 2026

FDA Accepts Supplemental Application for ZOLADEX by TERSERA

The FDA has accepted a supplemental application for ZOLADEX (Goserelin Acetate) submitted by TERSERA.

RegulatoryAugust 3, 2026

FDA Accepts Supplement Application for ELIGARD Kit by TOLMAR

The FDA has accepted a supplemental application for the ELIGARD Kit, containing leuprolide acetate.

RegulatoryAugust 3, 2026

FDA Submission Update for Leucovorin Calcium by Epic Pharma

Epic Pharma's ANDA074544 for Leucovorin Calcium has received an Abbreviated Approval (AP) status.

RegulatoryAugust 3, 2026

FDA Approves Leucovorin Calcium Supplement Application by Ingenus Pharmaceuticals

The FDA has approved the supplemental application ANDA211132 for Leucovorin Calcium submitted by Ingenus Pharmaceuticals.

RegulatoryAugust 3, 2026

FDA Approval Process Update for Leucovorin Calcium by Hikma

The FDA has an active application (ANDA072733) for Leucovorin Calcium submitted by Hikma, currently under standard review.

StrategyAugust 3, 2026

FDA Grants Approval for Leucovorin Calcium ANDA072734 by Hikma

The FDA has granted approval for Hikma's ANDA072734 for Leucovorin Calcium.

RegulatoryAugust 3, 2026

FDA Approval Process Update for Leucovorin Calcium by Hikma

The FDA has an active application for Leucovorin Calcium (ANDA072735) submitted by Hikma, currently under standard review.

RegulatoryAugust 3, 2026

FDA grants approval status for Leucovorin Calcium ANDA072736

The FDA has granted an approval status (AP) for the ANDA072736 application for Leucovorin Calcium submitted by Hikma.

RegulatoryAugust 3, 2026

ANI Pharmaceuticals receives AP status for Leucovorin Calcium supplement

ANI Pharmaceuticals has received an Abbreviated New Drug Application (ANDA) approval status for Leucovorin Calcium.

RegulatoryAugust 3, 2026

FDA Approves Leucovorin Calcium Supplement Application by Barr

The FDA has approved the supplemental application for Leucovorin Calcium submitted by Barr.

RegulatoryAugust 3, 2026

FDA Approval Process Update for Leucovorin Calcium by Barr

The FDA has an active application (ANDA071199) for Leucovorin Calcium submitted by Barr, currently under standard review.

ClinicalAugust 3, 2026

Study on PBMC Collection for T Cell Expansion in Cancer Therapy

A clinical trial is underway to collect peripheral blood mononuclear cells from healthy volunteers to expand T cells for adoptive cell therapy targeting tumors.

RegulatoryAugust 3, 2026

FDA Approval Status for Leucovorin Calcium Supplement

The FDA has granted an approval status of 'AP' for ANDA213929, a supplement for Leucovorin Calcium.

RegulatoryAugust 3, 2026

FDA Approval Process Update for Ondansetron Hydrochloride Preservative Free

The FDA has updated the submission status for ANDA078945 for Ondansetron Hydrochloride Preservative Free to Approved (AP).

ClinicalAugust 3, 2026

Phase II Trial of Cladribine and Rituximab for Hairy Cell Leukemia

A phase II trial is investigating the efficacy and safety of cladribine combined with rituximab in hairy cell leukemia patients.

ClinicalAugust 3, 2026

Phase I Trial of Triapine in Uterine Cancers Shows Potential for Enhanced Treatment

An early phase I trial is investigating the efficacy of triapine in treating uterine cancers, potentially enhancing outcomes when combined with standard therapies.

ClinicalAugust 3, 2026

Study on MR-Guided Adaptive Therapy for Endometrial Cancer Initiated

A clinical trial is evaluating the safety and efficacy of MR-guided adaptive pelvic IMRT in endometrial cancer patients.

RegulatoryAugust 3, 2026

FDA Accepts NDA for Trabectedin by Apotex

The FDA has accepted the New Drug Application (NDA) for Trabectedin submitted by Apotex.

ClinicalAugust 3, 2026

Phase I Trial of ONC206 for Newly Diagnosed and Recurrent Malignant CNS Tumors

A phase I trial is investigating ONC206's efficacy in treating newly diagnosed and recurrent diffuse midline gliomas.

ClinicalAugust 3, 2026

Phase II Trial of Carboplatin in Metastatic Prostate Cancer with HR Pathway Alterations

A phase II trial is underway to assess carboplatin's efficacy in metastatic castration-resistant prostate cancer with HR pathway gene alterations.

RegulatoryAugust 2, 2026

FDA Accepts NDA for Vepdegestrant by Arvinas Operations

The FDA has accepted the New Drug Application (NDA) for Vepdegestrant (NDA219835) submitted by Arvinas Operations.

ClinicalAugust 2, 2026

Exploratory Study of SHR-A1811 in HER2-Positive Advanced Breast Cancer

The study evaluates the efficacy and safety of SHR-A1811 administered through various routes in patients with HER2-positive advanced breast cancer.

ClinicalAugust 2, 2026

Phase II Study of Alpelisib in PIK3CA-related Overgrowth Spectrum Initiated

A Phase II single-arm study is underway to evaluate the efficacy and safety of alpelisib in patients with PROS.

RegulatoryAugust 2, 2026

FDA Accepts Supplement for Lazertinib Mesylate by Janssen Biotech

The FDA has accepted a supplemental application for Lazertinib Mesylate (NDA219008) from Janssen Biotech.

RegulatoryAugust 2, 2026

FDA Approves Methotrexate Sodium Application ANDA219865

The FDA has approved the application ANDA219865 for Methotrexate Sodium submitted by Hetero Labs Ltd.

ClinicalAugust 2, 2026

Phase 1/2 Study of TROP2 CAR NK Cells with Belzutifan in Pancreatic Cancer

A Phase I/II study is underway to evaluate TROP2 CAR/IL-15 engineered NK cells combined with belzutifan in pancreatic cancer.

ClinicalAugust 2, 2026

Phase II Trial on Adaptive Radiation Planning in NSCLC to Reduce Toxicity

A phase II trial is investigating adaptive radiation planning to minimize side effects in patients with stage II-IV non-small cell lung cancer.

RegulatoryAugust 2, 2026

FDA Approves Lutetium Lu 177 VIPIVOTIDE for Metastatic Prostate Cancer

The FDA has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for use in combination with androgen receptor pathway inhibitors in adults with PSMA-positive metastatic prostate cancer.

ClinicalAugust 2, 2026

Phase I/II Trial of Olaparib and Radium-223 in Advanced Prostate Cancer

This trial is investigating the safety and efficacy of olaparib in combination with radium-223 for patients with metastatic castration-resistant prostate cancer.

ClinicalAugust 2, 2026

Phase II Study on HIPEC's Impact on PD-L1 in Advanced Gastric Cancer

The study aims to evaluate the upregulation of PD-L1 expression in peritoneal metastases from gastric cancer following HIPEC treatment.

StrategyAugust 2, 2026

Budget Impact of Dostarlimab in First-Line Endometrial Cancer Treatment in Saudi Arabia

The budget impact of dostarlimab combined with carboplatin-paclitaxel as a first-line treatment for endometrial cancer was assessed.

ClinicalAugust 2, 2026

CHAF1A Emerges as Biomarker and Target in Burkitt Lymphoma

CHAF1A has been identified as a candidate biomarker and potential therapeutic target in Burkitt lymphoma through bioinformatics and histopathological analysis.

ClinicalAugust 2, 2026

Phase I Trial of Triapine with Radiation for Recurrent Glioblastoma or Astrocytoma

A phase I trial is evaluating the safety and efficacy of triapine combined with radiation therapy for recurrent glioblastoma or astrocytoma.

ClinicalAugust 2, 2026

Study on Liver Volume Variation Impact on SBRT Planning for Abdominal Malignancies

A prospective study will investigate the impact of liver volume variations on SBRT planning for upper abdominal malignancies.

ClinicalAugust 2, 2026

NCI Study on Neurofibromatosis Type 1 Aims to Improve Early Detection of Malignant Tumors

A study sponsored by the National Cancer Institute is investigating methods for early detection of malignant tumors in patients with neurofibromatosis type 1 using advanced imaging and genetic testing.

RegulatoryAugust 2, 2026

Fresenius Kabi's Ondansetron Hydrochloride Preservative Free Receives AP Status

Fresenius Kabi USA's application for Ondansetron Hydrochloride Preservative Free has received an Abbreviated Approval (AP) status from the FDA.

ClinicalAugust 1, 2026

First-in-human study of EP102 in advanced solid tumors initiated

The first-in-human study for EP102 aims to evaluate safety, tolerability, and antitumor activity in advanced solid tumors.

ClinicalAugust 1, 2026

Phase I Trial of Atezolizumab with Chemo for Relapsed/Refractory DLBCL

A pilot phase I trial is evaluating the combination of atezolizumab with rituximab, gemcitabine, and oxaliplatin in patients with relapsed/refractory transformed diffuse large B-cell lymphoma.

ClinicalAugust 1, 2026

Phase II Trial of Nivolumab and Cabozantinib for Mucosal Melanoma Recurrence Prevention

A phase II trial is underway to evaluate the efficacy of nivolumab alone or in combination with cabozantinib in preventing mucosal melanoma recurrence post-surgery.

ClinicalAugust 1, 2026

New Clinical Study on Advanced Desmoplastic Small Round Cell Tumor (DSRCT) Initiated

A clinical study has been initiated for adult and young adult patients with advanced DSRCT, focusing on treatment until progression or severe side effects.

RegulatoryAugust 1, 2026

Fresenius Kabi's Ondansetron Hydrochloride ANDA076974 Receives AP Status

Fresenius Kabi USA has received an Abbreviated New Drug Application (ANDA) approval status for Ondansetron Hydrochloride.

ClinicalAugust 1, 2026

Phase I/II Trial of Atezolizumab and Cabozantinib in Recurrent Glioblastoma

A phase I/II trial is evaluating the safety and efficacy of atezolizumab combined with cabozantinib in patients with recurrent glioblastoma.

ClinicalAugust 1, 2026

Phase I/II Trial of Iadademstat with Atezolizumab or Durvalumab in Extensive Stage Small Cell Lung Cancer

The trial evaluates the safety and efficacy of iadademstat combined with atezolizumab or durvalumab in extensive stage small cell lung cancer.

ClinicalAugust 1, 2026

Trial of Cancer Lysate Vaccine with N-803 for PD-L1 Negative NSCLC Post-Surgery

A clinical trial is evaluating the combination of a cancer lysate vaccine and N-803 as adjuvant therapy for patients with PD-L1 negative non-small cell lung cancer (NSCLC) post-surgery.

ClinicalAugust 1, 2026

Pilot Study on Intermittent Fasting with Immune Checkpoint Inhibitors Initiated

A pilot study is underway to assess the feasibility and safety of intermittent fasting in patients undergoing ICI therapy.

RegulatoryAugust 1, 2026

FDA Approves Supplement for Cytarabine by Hospira

The FDA has approved a supplemental application for Cytarabine submitted by Hospira.

ClinicalAugust 1, 2026

Phase II/III Trial of Atezolizumab with Chemotherapy for Advanced Neuroendocrine Carcinomas

A phase II/III trial is evaluating the efficacy of atezolizumab combined with standard chemotherapy in advanced or metastatic neuroendocrine carcinomas originating outside the lung.

RegulatoryAugust 1, 2026

FDA Grants AP Status for Fosaprepitant Dimeglumine ANDA203939

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Fosaprepitant Dimeglumine submitted by Caplin.

ClinicalAugust 1, 2026

Phase II Trial of Cabazitaxel, Carboplatin, and Cetrelimab for Aggressive Variant Prostate Cancer

A phase II trial is investigating the combination of cabazitaxel, carboplatin, and cetrelimab followed by niraparib in patients with metastatic aggressive variant prostate cancer.

ClinicalAugust 1, 2026

Selinexor and Radiation Therapy Trial for DIPG and HGG Shows Promise

A phase I/II trial is evaluating the safety and efficacy of selinexor combined with radiation therapy in children with DIPG and HGG.

ClinicalAugust 1, 2026

Mosunetuzumab shows promise in B-cell NHL beyond follicular lymphoma

Mosunetuzumab is approved for follicular lymphoma and has NCCN recommendations for other B-NHL subtypes.

ClinicalAugust 1, 2026

CAFs Enhance Adenosine Production in NSCLC, Impeding T Cell Response

Cancer-associated fibroblasts (CAFs) promote the expression of CD39 and CD73 on T cells, leading to increased adenosine synthesis, which may facilitate tumor immune evasion.

RegulatoryAugust 1, 2026

Datroway Approved in EU for Metastatic TNBC as First TROP2-Directed Therapy

Datroway has been approved in the EU as the only TROP2-directed therapy demonstrating overall survival benefit for first-line treatment in metastatic TNBC patients not eligible for immunotherapy.

RegulatoryAugust 1, 2026

Lupin's Fosaprepitant Dimeglumine Supplement Receives FDA AP Status

The FDA has granted an Abbreviated Approval (AP) status for Lupin's supplemental application for Fosaprepitant Dimeglumine.

RegulatoryAugust 1, 2026

FDA Accepts Supplement Application for VANFLYTA by Daiichi Sankyo

The FDA has accepted a supplemental application for VANFLYTA (quizartinib dihydrochloride) from Daiichi Sankyo.

ClinicalAugust 1, 2026

New Study Proposes Personalized Cardiac Surveillance for HER2 Positive Breast Cancer Patients

A new study will evaluate a personalized cardiac surveillance approach for HER2 positive breast cancer patients, potentially reducing unnecessary heart tests.

ClinicalAugust 1, 2026

Phase I Trial of EGFR/IL13Rα2 CAR T Cells for Recurrent High-Grade Gliomas

A phase I trial is investigating the safety and dosing of EGFR/IL13Rα2 pool-CAR T cells administered locoregionally for recurrent or progressive high-grade gliomas.

RegulatoryJuly 31, 2026

FDA grants TA status for Cyclophosphamide ANDA219271 by Hetero Labs

The FDA has granted Tentative Approval (TA) for Hetero Labs' ANDA219271 for Cyclophosphamide.

RegulatoryJuly 31, 2026

Amgen's BLA761298 for PAVBLU Receives AP Status from FDA

The FDA has granted application BLA761298 for PAVBLU an Approval Pending (AP) status.

ClinicalJuly 31, 2026

Phase I Trial Compares Proton vs. IMRT for Endometrial and Cervical Cancer

The trial evaluates side effects of proton therapy versus intensity modulated radiation therapy in post-surgical patients.

ClinicalJuly 31, 2026

Natural History Study of Squamous Cell Carcinoma in Fanconi Anemia Initiated

A natural history study has been launched to screen individuals with Fanconi anemia for squamous cell carcinoma.

ClinicalJuly 31, 2026

Phase I Trial of THE-0504 in Solid Tumors Initiated

A phase I clinical trial is underway to assess the safety and tolerability of THE-0504 in patients with solid tumors.

RegulatoryJuly 31, 2026

FDA Acceptance of Supplemental Application for Thalidomide by Bristol-Myers

The FDA has accepted a supplemental application for Thalidomide (NDA020785) submitted by Bristol-Myers.

StrategyJuly 31, 2026

Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA

Cipla's application ANDA210435 for Lenalidomide has received an abbreviated approval status from the FDA.

ClinicalJuly 31, 2026

Phase II Trial of Blinatumomab with Nivolumab in Relapsed B-ALL Patients

This phase II trial compares the efficacy of nivolumab combined with blinatumomab versus blinatumomab alone in relapsed B-ALL patients.

CompetitiveJuly 31, 2026

MammoVerse Study to Enhance Emotional Support for Breast Cancer Patients

A focus group study aims to identify gaps in emotional and mental health support for breast cancer patients.

ClinicalJuly 31, 2026

Study of Pembrolizumab Plus MK-1084 in NSCLC with KRAS G12C Mutations

The study aims to evaluate the safety and efficacy of MK-1084 in treating NSCLC patients with KRAS G12C mutations.

RegulatoryJuly 31, 2026

FDA Approves Pomalidomide Supplement by Breckenridge

The FDA has approved a supplemental application for Pomalidomide submitted by Breckenridge.

CompetitiveJuly 31, 2026

Phase 1/2 Study of Investigational Agents with Pembrolizumab in Advanced Esophageal Cancer

A Phase 1/2 study is underway to evaluate investigational agents with or without pembrolizumab in patients with advanced esophageal squamous cell carcinoma.

ClinicalJuly 31, 2026

Study on Long-term Effects of Pediatric CAR-T Cell Therapy Initiated

A prospective study is evaluating the short-term and long-term side effects of CAR-T cell therapy in pediatric patients.

ClinicalJuly 31, 2026

Single-Arm Study of Zeprumetostat with Glofitamab in Relapsed/Refractory DLBCL

A single-arm clinical study is investigating the combination of Zeprumetostat, Glofitamab, and GemOx in patients with relapsed/refractory DLBCL.

ClinicalJuly 31, 2026

Trial Evaluates UWL Detection with GRAIL Galleri for Early Cancer Diagnosis

A prospective trial is assessing the combination of unintentional weight loss tracking and GRAIL Galleri testing for early cancer detection.

ClinicalJuly 31, 2026

Phase II Trial of Nivolumab and Ipilimumab in Kidney Transplant Recipients with Metastatic Skin Cancer

A phase II trial is underway testing nivolumab and ipilimumab combined with sirolimus and prednisone in kidney transplant recipients with unresectable or metastatic skin cancer.

StrategyJuly 31, 2026

HPV Vaccine Hesitancy Among Female Students in China Increases Despite Improved Knowledge

HPV vaccine hesitancy among female university students in China rose from 8.8% to 21.6% between 2022 and 2025, despite improved knowledge.

ClinicalJuly 31, 2026

Study on Neoadjuvant Immunochemotherapy's Impact on Opioid Use in Esophageal Cancer Surgery

This study evaluates the effect of neoadjuvant immunochemotherapy on remifentanil consumption during surgery for esophageal cancer.

ClinicalJuly 31, 2026

Robotic-assisted surgery reduces complications in bladder cancer patients

The study shows that robotic-assisted intracorporeal radical cystectomy with modified ileal conduit significantly reduces the risk of ureteroileal anastomotic stenosis compared to traditional laparoscopic surgery.

ClinicalJuly 31, 2026

Platelet-based delivery of fluorescein enhances sonodynamic therapy in glioblastoma

A novel platelet-based delivery system for fluorescein significantly enhances the efficacy of sonodynamic therapy in glioblastoma models.

ClinicalJuly 31, 2026

Advances in Monoclonal Antibody Therapeutics Targeting Insulin Resistance in Cancer

Monoclonal antibodies targeting IGF-1R, IL-6, IL-1β, TNF-α, PD-1, PD-L1, and CTLA-4 may counteract insulin resistance in cancer.

ClinicalJuly 31, 2026

DNA polymerase theta emerges as a promising target for cancer therapy

DNA polymerase theta (Polθ) is overexpressed in many cancers and is essential for microhomology-mediated end joining, making it a novel therapeutic target.

StrategyJuly 31, 2026

HPV Vaccination Challenges and Strategies in WHO South-East Asia Region Identified

The review identifies uneven HPV vaccination coverage across SEAR countries, with significant barriers to implementation.

CompetitiveJuly 31, 2026

AI Transforming Immune Checkpoint Inhibitor Research: Key Trends Identified

A bibliometric analysis reveals a significant rise in AI applications in immune checkpoint inhibitor research, particularly in predicting treatment responses and managing adverse events.

ClinicalJuly 31, 2026

Novel Rh-catalysed method yields potent antitumor phenanthridinone derivatives

A series of phenanthridinone derivatives were synthesized, with compound 3a showing potent TDP1 inhibitory activity and compound 3c demonstrating strong TOP1 inhibition and antitumor efficacy in vivo.

RegulatoryJuly 31, 2026

FDA Approves Afamitresgene Autoleucel for Synovial Sarcoma, Highlighting TCR Therapy Advances

The FDA has granted accelerated approval for afamitresgene autoleucel, TCR therapy targeting MAGE-A4 in synovial sarcoma.

ClinicalJuly 31, 2026

Fusobacterium nucleatum adhesins linked to colorectal cancer progression

Fusobacterium nucleatum adhesins play a significant role in colorectal cancer progression by mediating tumor growth and immune evasion.

ClinicalJuly 31, 2026

Cost-effectiveness of Tumor Treating Fields in Advanced Pancreatic Cancer Evaluated

The PANOVA-3 trial shows that Tumor Treating Fields combined with gemcitabine and nab-paclitaxel improves overall survival and progression-free survival in locally advanced pancreatic cancer patients.

RegulatoryJuly 31, 2026

FDA Accepts Supplement Application for Lenalidomide by Biocon Pharma

The FDA has accepted a supplemental application for lenalidomide submitted by Biocon Pharma.

StrategyJuly 31, 2026

FDA Grants AP Status for Lenalidomide ANDA210480 by Alvogen

The FDA has granted Abbreviated Approval (AP) status for Alvogen's ANDA210480 for lenalidomide.

RegulatoryJuly 31, 2026

FDA Accepts Lenalidomide Supplement Application from Amneal

The FDA has accepted a supplemental application for lenalidomide (ANDA216213) submitted by Amneal.

RegulatoryJuly 31, 2026

FDA Approves Lenalidomide Supplement Application by Sun Pharma

The FDA has approved the supplemental application ANDA211846 for lenalidomide submitted by Sun Pharma.

RegulatoryJuly 31, 2026

Apotex submits supplemental application for Pomalidomide (ANDA 210164)

Apotex has submitted a supplemental application for Pomalidomide under ANDA 210164.

ClinicalJuly 31, 2026

Efficacy Study of Olutasidenib and Temozolomide in IDH1-Mutant High-Grade Glioma

A study is underway to evaluate the efficacy of olutasidenib combined with temozolomide in treating IDH1-mutant high-grade glioma in pediatric and young adult patients.

ClinicalJuly 31, 2026

AZD0516 Study for Metastatic Prostate Cancer Initiated

A study has been initiated to evaluate the safety and tolerability of AZD0516 in metastatic prostate cancer patients.

ClinicalJuly 31, 2026

Ulixertinib Trial Aims to Assess Blood-Brain Barrier Penetration in Gliomas

A new trial is investigating the ability of ulixertinib to cross the blood-brain barrier in patients with recurrent MAPK-activated gliomas.

CompetitiveJuly 30, 2026

Emavusertib + Zanubrutinib Study Targets CLL Anticancer Activity

The study aims to evaluate the anticancer activity of emavusertib combined with zanubrutinib in CLL patients.

StrategyJuly 30, 2026

FDA Accepts Lenalidomide ANDA Submission from Torrent

The FDA has accepted the ANDA submission for Lenalidomide from Torrent Pharmaceuticals.

RegulatoryJuly 30, 2026

Cipla's Lenalidomide ANDA214618 Receives FDA AP Status

Cipla's ANDA214618 for Lenalidomide has received FDA approval status (AP) for its supplemental application.

RegulatoryJuly 30, 2026

FDA Accepts Supplemental Application for Pomalidomide by Hetero Labs

The FDA has accepted a supplemental application for pomalidomide submitted by Hetero Labs.

RegulatoryJuly 30, 2026

Eugia Pharma submits supplemental application for Pomalidomide (ANDA210249)

Eugia Pharma has submitted a supplemental application for Pomalidomide under ANDA210249, currently marked as AP.

RegulatoryJuly 30, 2026

FDA Accepts Supplement Application for Lenalidomide by Arrow International

The FDA has accepted a supplemental application for lenalidomide submitted by Arrow International.

RegulatoryJuly 30, 2026

FDA Accepts Supplemental Application for Pomalidomide by Teva Pharmaceuticals

Teva Pharmaceuticals has submitted a supplemental application for Pomalidomide, which is currently under review by the FDA.

RegulatoryJuly 30, 2026

FDA Grants Approval for Pomalidomide Supplement by Mylan

The FDA has granted approval for a supplemental application for Pomalidomide submitted by Mylan.

RegulatoryJuly 30, 2026

FDA Grants AP Status for Lenalidomide ANDA217265 by QILU

The FDA has granted approval status (AP) for ANDA217265, a supplemental application for lenalidomide submitted by QILU.

ClinicalJuly 30, 2026

Phase 2 Study of Poziotinib in NSCLC with EGFR/HER2 Mutations Underway

A Phase 2 study is evaluating poziotinib's efficacy and safety in NSCLC patients with specific mutations.

ClinicalJuly 30, 2026

Ibrutinib and Rituximab Show Promise in Relapsed/Refractory Mantle Cell Lymphoma

A phase II trial is investigating the efficacy of ibrutinib and rituximab in treating relapsed or refractory mantle cell lymphoma.

StrategyJuly 30, 2026

FDA Approves LYTENAVA (BLA761320) from Outlook Therapeutics

The FDA has approved LYTENAVA (BLA761320), a new formulation of Bevacizumab by Outlook Therapeutics.

ClinicalJuly 30, 2026

Study on Neoadjuvant vs Adjuvant Stereotactic Radiotherapy for Brain Metastases

This study aims to compare local control rates of neoadjuvant stereotactic radiotherapy versus adjuvant treatment in brain metastases.

ClinicalJuly 30, 2026

Phase Ib/II Trial of Olaparib with AZD2014 or AZD5363 in Recurrent Endometrial and Ovarian Cancer

This trial evaluates the safety and optimal dosing of olaparib in combination with either vistusertib or capivasertib for recurrent cancers.

ClinicalJuly 30, 2026

Duke University Trials Lattice Radiation Therapy for Large Tumors

Duke University is investigating Lattice Radiation Therapy (LRT) in combination with palliative radiation for large tumors.

RegulatoryJuly 30, 2026

FDA Accepts Supplemental Application for XTANDI (Enzalutamide)

The FDA has accepted a supplemental application for XTANDI (enzalutamide) from Astellas.

RegulatoryJuly 30, 2026

EUGIA PHARMA's Lenalidomide ANDA213885 Receives AP Status from FDA

EUGIA PHARMA's application for Lenalidomide (ANDA213885) has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJuly 30, 2026

FDA Accepts Lenalidomide Supplement Application from Novugen

The FDA has accepted a supplemental application for Lenalidomide (ANDA217281) submitted by Novugen.

StrategyJuly 30, 2026

FDA Accepts Lenalidomide Supplement Application from Apotex

The FDA has accepted the supplemental application ANDA211022 for lenalidomide submitted by Apotex.

RegulatoryJuly 30, 2026

FDA Grants AP Status for Lenalidomide ANDA213912 by Mylan

The FDA has granted approval status (AP) for Mylan's abbreviated new drug application (ANDA) for lenalidomide.

RegulatoryJuly 30, 2026

FDA Acceptance of Lenalidomide Supplement Application by Hetero Labs

The FDA has accepted the supplemental application ANDA212414 for lenalidomide submitted by Hetero Labs.

RegulatoryJuly 30, 2026

FDA Accepts Supplement Application for Lenalidomide by Dr. Reddy's

The FDA has accepted a supplemental application for lenalidomide submitted by Dr.

RegulatoryJuly 30, 2026

FDA Accepts Supplemental Application for POMALYST by Bristol

The FDA has accepted a supplemental application for POMALYST (pomalidomide) submitted by Bristol.

RegulatoryJuly 30, 2026

Lupin's Lenalidomide ANDA214398 Receives FDA Approval Status

Lupin's application ANDA214398 for lenalidomide has received an approval status from the FDA.

ClinicalJuly 30, 2026

Personalized Treatment Approach for Malignant Peritoneal Mesothelioma Under Investigation

A clinical trial is evaluating a personalized treatment approach using patient-derived tumor models for Malignant Peritoneal Mesothelioma.

ClinicalJuly 30, 2026

Phase II/III Trial of Haloperidol and Lorazepam for Agitated Delirium in Advanced Cancer Patients

A phase II/III trial is evaluating the efficacy of haloperidol and lorazepam in managing persistent agitated delirium in advanced cancer patients receiving palliative care.

RegulatoryJuly 29, 2026

FDA Grants Approval for Thalidomide Application ANDA213267

The FDA has granted approval for the thalidomide application ANDA213267 submitted by NATCO.

ClinicalJuly 29, 2026

Study on Electronic Symptom Monitoring for Palliative Care in Thoracic Cancer Patients

A clinical trial is evaluating an electronic symptom monitoring program aimed at improving palliative care access for thoracic cancer patients.

ClinicalJuly 29, 2026

Study on Resistance Mechanisms in Metastatic Castration Resistant Prostate Cancer with 177Lu-PSMA

This clinical trial investigates resistance mechanisms to 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer using image-guided biopsies.

ClinicalJuly 29, 2026

AI vs Radiologist in Prostate Cancer Detection: The PRIMER Trial

The PRIMER trial compares an MRI-based AI approach to traditional radiologist readings for prostate cancer detection.

ClinicalJuly 29, 2026

Phase Ib Trial of M3814 with Lutetium Lu 177 Dotatate for Pancreatic Neuroendocrine Tumors

A phase Ib trial is investigating the combination of peposertib and lutetium Lu 177 dotatate for treating pancreatic neuroendocrine tumors.

ClinicalJuly 29, 2026

Phase I Trial of Durvalumab and Olaparib with Radiation for Unresectable Pancreatic Cancer

A phase I trial is underway to evaluate the safety and tolerability of olaparib combined with durvalumab and radiation therapy in patients with locally advanced unresectable pancreatic cancer.

ClinicalJuly 29, 2026

NCI initiates trial for preoperative radiation therapy in recurrent abdominal adrenocortical carcinoma

The National Cancer Institute is testing a new external beam radiation therapy before surgery in patients with resectable recurrent adrenocortical carcinoma.

ClinicalJuly 29, 2026

MyeloMATCH Trial Compares Venetoclax Combinations in Intermediate Risk AML

The MyeloMATCH trial is evaluating the efficacy of venetoclax in combination with standard therapies for younger patients with intermediate risk AML.

RegulatoryJuly 29, 2026

FDA Accepts Supplemental Application for XTANDI (Enzalutamide)

The FDA has accepted a supplemental application for XTANDI (enzalutamide) submitted by Astellas.

RegulatoryJuly 29, 2026

FDA Approves LYTENAVA (BLA761320) for Use

The FDA has approved LYTENAVA, a new formulation of bevacizumab, under application BLA761320.

ClinicalJuly 29, 2026

Phase II/III Trial of BL-B01D1 with Osimertinib in EGFR-mutant NSCLC Initiated

A Phase II/III trial has been initiated to evaluate BL-B01D1 combined with osimertinib in patients with resectable EGFR-mutant non-small cell lung cancer.

RegulatoryJuly 29, 2026

FDA Grants Original Approval for Fludarabine Phosphate by Hisun Pharm

The FDA has granted original approval for Fludarabine Phosphate under application ANDA220196 submitted by Hisun Pharm Hangzhou.

RegulatoryJuly 29, 2026

FDA Approves JIDEYTRO (ZIDESAMTINIB) for Nuvalent Inc.

The FDA has approved JIDEYTRO (ZIDESAMTINIB) under NDA220185 submitted by Nuvalent Inc.

ClinicalJuly 29, 2026

Study on Non-Contrast CT for Opportunistic Breast Cancer Screening Initiated

An observational study led by Fudan University is evaluating non-contrast chest CT for breast cancer screening.

ClinicalJuly 29, 2026

Nivolumab Added to Standard Treatment in Advanced Stomach/Esophageal Cancer Trial

The PARAMUNE trial is evaluating the efficacy of nivolumab combined with paclitaxel and ramucirumab in advanced gastric or esophageal adenocarcinoma.

ClinicalJuly 29, 2026

14-3-3 Proteins Linked to Therapy Resistance in Digestive Cancers

The review identifies specific 14-3-3-client modules that contribute to therapy resistance in gastric, colorectal, pancreatic, and hepatobiliary cancers.

ClinicalJuly 29, 2026

Peptide-1 Shows Antiproliferative Activity Against Non-Small Cell Lung Cancer via METTL3 Targeting

Peptide-1 demonstrated significant growth-inhibitory activity against non-small cell lung cancer cells by targeting METTL3.

ClinicalJuly 29, 2026

Thyroglobulin Antibody Positivity Linked to Delayed Absorption Post-Microwave Ablation in PTC

Preoperative thyroglobulin antibody positivity is associated with delayed absorption after microwave ablation for papillary thyroid carcinoma.

StrategyJuly 29, 2026

Finotonlimab plus bevacizumab unlikely cost-effective vs. sorafenib for HCC in China

Finotonlimab plus bevacizumab showed increased survival benefits but was not cost-effective compared to sorafenib.

RegulatoryJuly 29, 2026

Karyopharm's XPOVIO (Selinexor) NDA212306 Receives Approval Status from FDA

The FDA has granted approval status (AP) for Karyopharm's NDA212306 for XPOVIO (Selinexor).

CompetitiveJuly 29, 2026

AstraZeneca's GEMINI-PeriOp GC Study Targets Locally Advanced Gastroesophageal Adenocarcinoma

AstraZeneca's GEMINI-PeriOp GC study is evaluating novel agents or combinations for perioperative treatment in patients with locally advanced resectable gastroesophageal adenocarcinoma.

RegulatoryJuly 28, 2026

FDA Accepts Supplement for PERJETA (Pertuzumab) by Genentech

The FDA has accepted a supplemental Biologics License Application for PERJETA (pertuzumab) from Genentech.

ClinicalJuly 28, 2026

Phase II Trial of Paclitaxel and Cixutumumab in Metastatic Esophageal Cancer

A randomized phase II trial is evaluating the efficacy of paclitaxel with or without cixutumumab in metastatic esophageal cancer.

ClinicalJuly 28, 2026

Study on Combining Focal Prostate Ablation with Androgen Deprivation Therapy

A clinical trial is investigating the safety and effectiveness of combining focal prostate ablation with androgen deprivation therapy.

ClinicalJuly 28, 2026

Novartis initiates Phase Ib/II study of AMO959 in mCRPC with AAA617 and ARPI

Novartis is conducting Phase Ib/II study to evaluate AMO959 combined with AAA617 and ARPI in mCRPC patients.

ClinicalJuly 28, 2026

Regeneron initiates trial for ubamatamab and REGN7075 in advanced NSCLC

Regeneron is conducting a study to evaluate the efficacy and safety of ubamatamab and REGN7075 in advanced/metastatic NSCLC.

ClinicalJuly 28, 2026

Insights into Precision Therapy for Colorectal Cancer Targeting Key Molecular Pathways

The review discusses critical signaling pathways involved in colorectal cancer, including Wnt/β-catenin and MAPK/ERK, and their role in tumorigenesis.

ClinicalJuly 28, 2026

Sonesitatug vedotin shows significant survival benefit in advanced gastric cancers

Sonesitatug vedotin demonstrated a statistically significant improvement in overall survival for patients with CLDN18.2-positive advanced gastric/GEJ cancers.

StrategyJuly 28, 2026

Sandoz's Enzalutamide ANDA216068 Receives Approval Status from FDA

Sandoz's application for Enzalutamide (ANDA216068) has received an approval status (AP) from the FDA.

ClinicalJuly 28, 2026

NCI Study on New Screening Methods for High-Risk Breast Cancer Women

The National Cancer Institute is conducting a study to explore new screening methods for early detection of breast and ovarian cancer in women with BRCA1 or BRCA2 mutations.

ClinicalJuly 28, 2026

NCI Launches Study on Molecular Analysis of Endocrine Neoplasms

The National Cancer Institute is conducting a study to collect tumor and healthy tissue samples from patients with endocrine neoplasms.

RegulatoryJuly 27, 2026

FDA Grants Approval for Methotrexate Sodium by Alembic

The FDA has granted approval for Methotrexate Sodium under application ANDA220225 submitted by Alembic.

RegulatoryJuly 27, 2026

FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs

The FDA has accepted a supplemental application for Zoledronic Acid submitted by Mylan Labs.

ClinicalJuly 27, 2026

Study Comparing taTME and RTME for Low Rectal Cancer Initiated by Sun Yat-sen University

A prospective, randomized trial will compare transanal total mesorectal excision (taTME) and robotic total mesorectal excision (RTME) for low rectal cancer.

ClinicalJuly 27, 2026

Avelumab Shows Promise in Treating Relapsed Thymoma and Thymic Carcinoma Post-Chemotherapy

A pilot study is investigating the safety and clinical activity of avelumab in patients with thymoma and thymic carcinoma after progression on platinum-based chemotherapy.

CompetitiveJuly 27, 2026

Phase I/II Trial of CD20 CAR T-Cell Therapy for Relapsed/Refractory B Cell Lymphoma

A Phase I/II study is underway to evaluate the safety and efficacy of autologous T cells engineered to express CD20-specific CAR in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

ClinicalJuly 27, 2026

Study on Firmonertinib for EGFR-mutated NSCLC Adjusted by ctDNA Changes

A prospective study is investigating Firmonertinib as a first-line therapy for EGFR-mutated NSCLC, adapting treatment based on ctDNA changes.

ClinicalJuly 27, 2026

Novartis initiates Phase I/II trial for ERW316 in HR+/HER2- breast cancer

Novartis is conducting Phase I/II trial to evaluate the safety and tolerability of ERW316 alone and in combination with endocrine therapies in HR+/HER2- breast cancer.

ClinicalJuly 27, 2026

Study Aims to Characterize MALT Lymphoma for Better Diagnosis and Treatment

A new observational study aims to create a molecular and cellular atlas of MALT lymphoma to identify tumor subtypes and biomarkers.

RegulatoryJuly 27, 2026

FDA Accepts Supplement Application for INQOVI by Taiho Oncology

The FDA has accepted a supplemental application (NDA212576) for INQOVI, which includes the active ingredients cedazuridine and decitabine.

RegulatoryJuly 27, 2026

FDA Approves Ondansetron Hydrochloride Preservative Free Supplement

The FDA has approved the supplement application for Ondansetron Hydrochloride Preservative Free by ONESOURCE SPECIALTY.

ClinicalJuly 27, 2026

BGB-16673 Study Initiated for R/R CLL/SLL vs. Investigator's Choice

A study has been launched to evaluate BGB-16673 against standard treatments in R/R CLL/SLL patients previously treated with cBTKis.

ClinicalJuly 27, 2026

Phase I Trial of Rituximab, Lenalidomide, and Ibrutinib in Follicular Lymphoma

A phase I trial is investigating the combination of rituximab, lenalidomide, and ibrutinib in patients with untreated stage II-IV follicular lymphoma.

ClinicalJuly 27, 2026

Mayo Clinic Trial on CBT for Quality of Life in Stage III-IV Melanoma Patients

A clinical trial is assessing the impact of cognitive behavioral therapy on quality of life for stage III-IV melanoma patients post-treatment.

RegulatoryJuly 26, 2026

FDA Submission Update for ONTRUZANT (BLA761100) by Samsung Bioepis

The FDA has received a supplemental application (BLA761100) for ONTRUZANT, an HER2-targeting biosimilar.

RegulatoryJuly 26, 2026

FDA Approval Status Update for Ondansetron Hydrochloride Supplement

The FDA has granted an approval status (AP) for the Ondansetron Hydrochloride supplement submitted by Onesource Specialty.

RegulatoryJuly 26, 2026

Genentech's ITOVEBI NDA219249 Submission Receives AP Status

The FDA has granted an Approval Pending (AP) status for Genentech's supplemental NDA for ITOVEBI (Inavolisib).

ClinicalJuly 26, 2026

Phase II Trial Evaluates Chemo and Chemo-Immunotherapy for Advanced Head and Neck Cancer

A phase II trial is testing the addition of chemotherapy or chemo-immunotherapy to standard salvage surgery for PD-L1 positive head and neck squamous cell carcinoma.

ClinicalJuly 26, 2026

Study on Clonal Evolution in Follicular Lymphoma by NCI

The National Cancer Institute is conducting a study to collect serial samples from untreated adults with follicular lymphoma to understand disease progression and treatment responses.

CompetitiveJuly 26, 2026

BeOne Medicines Initiates Study of BG-75202 in Advanced Solid Tumors

BeOne Medicines is conducting a study to assess the safety and preliminary efficacy of BG-75202 in advanced solid tumors, including breast cancer.

ClinicalJuly 26, 2026

Study on CHW Support to Enhance Palliative Care in Advanced Cancer Patients

A study is underway to evaluate the impact of community health worker support on palliative care outcomes for African American patients with advanced cancer.

RegulatoryJuly 26, 2026

FDA Accepts Supplement Application for Danziten (Nilotinib Tartrate)

The FDA has accepted a supplemental application for Danziten, an oncology drug containing nilotinib tartrate.

ClinicalJuly 26, 2026

Incyte's INCA33890 Safety Study in Advanced Solid Tumors Initiated

Incyte Corporation is conducting a study to evaluate the safety and tolerability of INCA33890 in patients with advanced or metastatic solid tumors.

ClinicalJuly 26, 2026

ASTX727 and Retifanlimab-dlwr Trial for Advanced Merkel Cell Cancer Initiated

A clinical trial is underway to evaluate the safety and efficacy of ASTX727 combined with retifanlimab in patients with advanced Merkel cell carcinoma after progression on anti-PD-(L)1 therapy.

ClinicalJuly 26, 2026

AstraZeneca initiates post-marketing surveillance for Lynparza in South Korea

AstraZeneca is conducting a post-marketing surveillance study to evaluate the safety and effectiveness of Lynparza in real-world settings in South Korea.

ClinicalJuly 26, 2026

Zanthoxylum nitidum shows multi-target anti-HCC mechanisms via network pharmacology

The study identifies key genes and pathways involved in the anti-HCC mechanisms of Zanthoxylum nitidum, highlighting its potential clinical use.

ClinicalJuly 26, 2026

Study Compares Semaglutide, Surgery, and Lifestyle for Weight Management in Endometrial Cancer

The study evaluates the effectiveness of sleeve gastrectomy, semaglutide, and a lifestyle program for weight management in endometrial cancer patients.

ClinicalJuly 26, 2026

Histotripsy Shows Promise for Noninvasive Treatment of Renal Cell Carcinoma

Histotripsy is a non-invasive ablation technique showing potential for treating renal cell carcinoma, with promising results from animal studies.

ClinicalJuly 26, 2026

Compound Kushen Injection Inhibits Immune Evasion in Hepatocellular Carcinoma via PD-L1 O-GlcNAcylation

Compound Kushen Injection (CKI) inhibits glycolysis and immune evasion in HCC cells by reducing O-GlcNAcylation of PD-L1.

ClinicalJuly 26, 2026

H. pylori variants linked to Wnt/β-catenin signaling in stomach adenocarcinoma progression

Variants of H. pylori HtrA and CagA influence Wnt/β-catenin signaling, impacting stomach adenocarcinoma progression.

ClinicalJuly 25, 2026

Study on Hybrid Intervention for Financial and Health Needs in AYA Cancer Survivors

A clinical trial is underway to evaluate a hybrid intervention aimed at addressing financial and health-related social needs in adolescent and young adult cancer survivors.

ClinicalJuly 25, 2026

Study on SONDA Visual Field Test for Patients with Supra Sellar Tumors

A clinical trial is underway to evaluate the SONDA visual field test's suitability for patients with supra sellar tumors.

ClinicalJuly 25, 2026

Phase 1 Trial of M3T01 Monotherapy and Combination Therapy in Solid Tumors

A Phase 1 first-in-human trial is underway to evaluate M3T01, a monoclonal antibody targeting FasL, in patients with metastatic or unresectable solid tumors.

RegulatoryJuly 25, 2026

Actavis Inc. Submits Supplement for Gemcitabine Hydrochloride (ANDA204549)

Actavis Inc. has submitted a supplemental application for Gemcitabine Hydrochloride under ANDA204549, which is currently under standard review.

ClinicalJuly 25, 2026

Astellas Pharma initiates trial of ASP2138 for HER2-negative gastric cancer

Astellas Pharma is conducting a double-blind study to evaluate ASP2138 in combination with chemotherapy and pembrolizumab for patients with HER2-negative and CLDN18.2-positive gastric or gastroesophageal junction cancer.

ClinicalJuly 25, 2026

NCI Trials B7-H3 CAR T Cell Therapy for Refractory Small Cell Lung Cancer

The National Cancer Institute is testing B7-H3 CAR T cell therapy in patients with refractory small cell lung cancer and extrapulmonary neuroendocrine cancer.

RegulatoryJuly 25, 2026

FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

The FDA has approved zidesamtinib for adults with ROS1-positive NSCLC after prior TKI treatment.

RegulatoryJuly 25, 2026

Sunny Pharmtech Issues Recall of Cyclophosphamide Injection Due to Contamination

Sunny Pharmtech is recalling Cyclophosphamide for Injection due to contamination with particulate matter identified as steel.

ClinicalJuly 25, 2026

Phase II Study of BL-B01D1 with PD-1 Antibody in Advanced Lung Cancer and Other Tumors

A phase II clinical trial is underway to evaluate the efficacy and safety of BL-B01D1 in combination with PD-1 monoclonal antibody.

RegulatoryJuly 25, 2026

FDA Accepts Supplemental NDA for CAMCEVI ETM by ACCORD

The FDA has accepted the supplemental NDA for CAMCEVI ETM, containing leuprolide mesylate.

ClinicalJuly 25, 2026

Florida ASCENT Study Evaluates Patient Navigator for Cancer Care Improvement

The Florida ASCENT Study aims to evaluate the MyCarePulse and ASCENT patient navigator intervention for cancer patients, focusing on food security and dietary behaviors.

ClinicalJuly 25, 2026

Zanubrutinib Plus Anti-CD20 Shows Promise in R/R Follicular and Marginal Zone Lymphoma Study

A study is underway comparing zanubrutinib plus obinutuzumab to lenalidomide plus rituximab in R/R follicular lymphoma and marginal zone lymphoma.

ClinicalJuly 25, 2026

Zolbetuximab in Combination with Chemotherapy for Advanced Biliary Tract Cancers

A clinical trial is investigating zolbetuximab combined with either CAPOX or mFOLFOX6 in patients with advanced biliary tract cancers.

ClinicalJuly 25, 2026

Phase 2 Study of Mosunetuzumab in CLL Patients Post-BTKi Treatment

A Phase 2 study is underway to evaluate the efficacy of mosunetuzumab in CLL patients with detectable disease after BTKi treatment.

ClinicalJuly 25, 2026

New Trial for Pediatric B-cell ALL Aims to Improve Survival Rates

The CCCG-ALL-2025 trial is designed to enhance event-free survival and overall survival in children with intermediate- and high-risk B-cell ALL.

ClinicalJuly 25, 2026

Phase 3 Trial of SRG-514 in Triple Negative Breast Cancer Undergoing Surgery

A Phase 3 trial is underway to evaluate SRG-514, an intraoperative treatment for patients with triple negative breast cancer.

ClinicalJuly 25, 2026

Comparative Study of Raltitrexed and Oxaliplatin in Metastatic Colorectal Cancer

A randomized pharmacokinetic study is underway comparing biweekly and triweekly regimens of raltitrexed and oxaliplatin in metastatic colorectal cancer.

ClinicalJuly 25, 2026

Narlumosbart with SBRT shows promise in NSCLC with bone metastases in new Phase II trial

A Phase II trial is investigating narlumosbart, RANKL-targeting mAb, combined with SBRT and first-line chemotherapy/immunotherapy in NSCLC patients with bone metastases.

ClinicalJuly 25, 2026

Memantine Pilot Study for Cognitive Protection in Pediatric Brain Tumor Patients Undergoing Radiation

A pilot study is underway to evaluate memantine as a neuro-protective agent in children receiving cranial radiation therapy for localized brain tumors.

RegulatoryJuly 24, 2026

FDA Accepts Supplement for CAMCEVI ETM (Leuprolide Mesylate)

The FDA has accepted a supplemental application for CAMCEVI ETM, which contains leuprolide mesylate.

ClinicalJuly 24, 2026

Boehringer Ingelheim's Zongertinib Trial Targets Advanced Cancers with HER2 Alterations

Boehringer Ingelheim is conducting a trial (PANTUMOR-1) to evaluate zongertinib in patients with advanced cancers harboring HER2 alterations.

RegulatoryJuly 24, 2026

FDA Accepts Supplement for OJJAARA (Momelotinib Dihydrochloride) by GlaxoSmithKline

The FDA has accepted a supplemental application for OJJAARA, indicating progress in its regulatory pathway.

StrategyJuly 24, 2026

FDA Approves ANDA for Carfilzomib by MSN

The FDA has approved the ANDA209526 application for Carfilzomib submitted by MSN.

RegulatoryJuly 24, 2026

FDA Submission Update for SCOMARA (Sirolimus) by AFT Pharmaceuticals

AFT Pharmaceuticals has submitted New Drug Application (NDA) for SCOMARA, an sirolimus-based therapy.

CompetitiveJuly 24, 2026

Bruceine D shows potential to overcome EGFR-TKI resistance in lung adenocarcinoma

Bruceine D epigenetically restores SMAD3 expression and suppresses malignant progression in EGFR-TKI-resistant lung adenocarcinoma.

ClinicalJuly 24, 2026

Pola-R-CHP shows promise in treating CD5-positive DLBCL, predicts patient outcomes

Interim PET response of Pola-R-CHP predicts outcomes in untreated CD5-positive DLBCL patients.

RegulatoryJuly 24, 2026

Etcamah Approved in EU for 1st-Line Advanced ER+ Breast Cancer

Etcamah (camizestrant) has been approved in the EU for use in combination with CDK4/6 inhibitors for 1st-line advanced ER-positive breast cancer, based on SERENA-6 trial results.

RegulatoryJuly 24, 2026

FDA Grants Priority Review for TALZENNA Plus XTANDI in Metastatic Prostate Cancer

The FDA has accepted a supplemental New Drug Application for TALZENNA in combination with XTANDI for metastatic castration-sensitive prostate cancer, supported by Phase 3 TALAPRO-3 trial data.

ClinicalJuly 24, 2026

Pembrolizumab Trial for Small Cell Carcinoma of Ovary - Hypercalcemic Type

A clinical trial is investigating pembrolizumab as consolidation therapy for SCCOHT.

RegulatoryJuly 24, 2026

FDA Approves Supplemental Application for OGSIVEO (Nirogacestat Hydro bromide)

The FDA has approved a supplemental application for OGSIVEO, containing Nirogacestat Hydrobromide.

ClinicalJuly 23, 2026

Merck's MK-1045 Under Investigation for Non-Hodgkin Lymphoma Treatment

Merck is conducting a clinical study to evaluate the safety and efficacy of MK-1045 in patients with follicular lymphoma and diffuse large B-cell lymphoma.

StrategyJuly 23, 2026

Pilot Study on Online Tool to Enhance Cascade Screening for Lynch Syndrome

A pilot study is testing an online intervention, Let's Talk, to improve cascade screening uptake among relatives of Lynch syndrome patients.

ClinicalJuly 23, 2026

Phase Ib Trial of Teclistamab and Iberdomide in Relapsed/Refractory Multiple Myeloma

A phase Ib trial is underway to evaluate the safety and dosing of iberdomide combined with teclistamab for relapsed or refractory multiple myeloma.

ClinicalJuly 23, 2026

Patritumab Deruxtecan Study Initiated for Advanced Gastrointestinal Cancers

Merck Sharp & Dohme and Daiichi Sankyo are conducting a study to evaluate the efficacy and safety of patritumab deruxtecan in patients with advanced gastrointestinal cancers.

ClinicalJuly 23, 2026

Inotuzumab Ozogamicin Combined with Chemotherapy Shows Promise in Acute Lymphoblastic Leukemia

A phase I/II trial is evaluating the efficacy and safety of inotuzumab ozogamicin combined with chemotherapy in patients with acute lymphoblastic leukemia.

ClinicalJuly 23, 2026

Iparomlimab and Tovorilimab Combined with Bevacizumab in Advanced Ovarian Cancer Trial

A clinical trial is underway to assess the safety and efficacy of iparomlimab and tovorilimab combined with standard chemotherapy for advanced ovarian cancer.

RegulatoryJuly 23, 2026

FDA Accepts Supplement Application for GLEEVEC (Imatinib Mesylate)

The FDA has accepted a supplemental application for GLEEVEC, indicating ongoing regulatory activity.

RegulatoryJuly 23, 2026

FDA Accepts Supplement Application for Verzenio (Abemaciclib)

The FDA has accepted a supplemental application for Verzenio (abemaciclib) from Eli Lilly.

ClinicalJuly 23, 2026

Exploring m(6)A Modification as Therapeutic Target in Osteosarcoma

The study highlights the role of m(6)A modification in osteosarcoma pathogenesis and its potential as a therapeutic target.

StrategyJuly 23, 2026

Roche Reports Strong H1 2026 Sales Growth and Multiple FDA Priority Reviews

Roche's pharmaceuticals division saw a 6% sales increase in H1 2026, driven by key products and multiple FDA Priority Reviews for new therapies.

StrategyJuly 23, 2026

Roche Reports Strong H1 2026 Sales and Multiple FDA Priority Reviews

Roche's H1 2026 sales increased by 6% at constant exchange rates, driven by strong demand for innovative medicines. The FDA granted Priority Reviews for five key therapies, including giredestrant for breast cancer and Enspryng for thyroid eye disease.

RegulatoryJuly 23, 2026

Roche Reports Strong H1 2026 Sales Growth and Multiple FDA Priority Reviews

Roche received five FDA Priority Reviews for key therapies including giredestrant for early-stage breast cancer and Enspryng for thyroid eye disease.

CompetitiveJuly 23, 2026

AbbVie Initiates Study on Surzetoclax for Relapsed/Refractory Multiple Myeloma

AbbVie is conducting a study to evaluate the safety and efficacy of surzetoclax in combination with other agents for relapsed/refractory multiple myeloma.

ClinicalJuly 23, 2026

Phase I Trial of Lenalidomide and Nivolumab in Primary CNS Lymphoma

A phase I trial is underway to evaluate the safety and efficacy of lenalidomide combined with nivolumab in treating primary CNS lymphoma.

ClinicalJuly 23, 2026

Pembrolizumab and Lenvatinib Trial for Unresectable Cutaneous Angiosarcoma Initiated

A clinical trial is underway to evaluate the efficacy of pembrolizumab and lenvatinib in patients with unresectable cutaneous angiosarcoma.

StrategyJuly 22, 2026

FDA Grants Approval for Romidepsin ANDA219099 by Amneal

The FDA has granted approval for Amneal's ANDA219099 for Romidepsin, indicating a successful submission.

RegulatoryJuly 22, 2026

FDA Grants AP Status for Zydus' Arsenic Trioxide ANDA206228

The FDA has granted approval status (AP) for Zydus Pharmaceuticals' Abbreviated New Drug Application for Arsenic Trioxide.

RegulatoryJuly 22, 2026

FDA Accepts ANDA for Eribulin Mesylate by NATCO

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Eribulin Mesylate submitted by NATCO.

RegulatoryJuly 22, 2026

Sandoz submits ANDA for Pemigatinib, seeking FDA approval

Sandoz Inc. has submitted an Abbreviated New Drug Application (ANDA) for Pemigatinib, currently under standard review.

ClinicalJuly 22, 2026

Phase 2 Study on 124-I-PET/CT Dosimetry in High-Risk Differentiated Thyroid Cancer

A phase 2 pilot study is comparing 124 I-PET/CT dosimetry methods in patients with high-risk differentiated thyroid cancer.

ClinicalJuly 22, 2026

BioNTech's BNT324 and BNT327 Combination Therapy in Advanced Lung Cancer Under Investigation

BioNTech is conducting a clinical study to evaluate the efficacy and safety of BNT324 and BNT327 in advanced lung cancer patients.

ClinicalJuly 22, 2026

JNJ-89402638 Phase 2 Study Initiated for Metastatic Colorectal and Gastric Cancers

A Phase 2 study is underway to assess the safety and optimal administration of JNJ-89402638 in mCRC and mGAC patients.

ClinicalJuly 22, 2026

Phase 2 Trial of Zanzalintinib in Advanced Bone Sarcomas Initiated

A Phase 2 trial is underway to evaluate the efficacy of zanzalintinib monotherapy in patients with advanced or metastatic bone sarcomas.

ClinicalJuly 22, 2026

Psilocybin-Assisted Psychotherapy Trial for Advanced Cancer Patients Launched

A new clinical trial is investigating the feasibility and safety of psilocybin-assisted psychotherapy for advanced cancer patients experiencing depression and anxiety.

ClinicalJuly 22, 2026

Phase II Trial Optimizes Therapy for HER2+ Breast Cancer Patients Post-Surgery

A Phase II trial is testing reduced adjuvant therapy for HER2+ breast cancer patients who achieved a pathologic complete response after neoadjuvant treatment.

ClinicalJuly 22, 2026

Trichodermin shows potent anti-glioblastoma effects, enhancing temozolomide efficacy

Trichodermin exhibits significant anti-glioblastoma activity by inducing cell cycle arrest and apoptosis, while also enhancing the efficacy of temozolomide.

RegulatoryJuly 22, 2026

FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis

The FDA has accepted a supplemental application for AFINITOR (everolimus) submitted by Novartis.

ClinicalJuly 22, 2026

Mayo Clinic's SOS5C Trial Explores AI and Minimally Invasive Methods for Barrett's Esophagus Diagnosis

The SOS5C trial evaluates AI-powered tools and a novel screening test for Barrett's esophagus and esophageal cancer diagnosis.

ClinicalJuly 22, 2026

Spectrum Pharmaceuticals Evaluates Eflapegrastim in Pediatric Cancer Patients

A clinical trial is underway to assess the safety and pharmacokinetics of eflapegrastim in pediatric patients undergoing chemotherapy.

ClinicalJuly 22, 2026

Exelixis initiates trial for XB628 and zanzalintinib in advanced solid tumors

Exelixis is conducting a study to evaluate XB628 alone and with zanzalintinib in patients with recurrent advanced or metastatic solid tumors.

ClinicalJuly 22, 2026

GSK Initiates First-Time-in-Human Study of Remzistotug for Advanced Solid Tumors

GlaxoSmithKline has launched a first-time-in-human study of remzistotug targeting advanced solid tumors.

RegulatoryJuly 21, 2026

FDA Accepts Application for CAVHANZA (Nilotinib) by FLEX PHARMA

The FDA has accepted the New Drug Application (NDA) for CAVHANZA, a nilotinib-based treatment.

ClinicalJuly 21, 2026

Phase I/II Study of GDC-7035 in Advanced Solid Tumors with KRAS G12D Mutation

Genentech is conducting a first-in-human Phase I/II study of GDC-7035 targeting KRAS G12D mutations in advanced solid tumors.

ClinicalJuly 21, 2026

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Mutant Endometrial Cancer

A Phase Ib trial is underway to evaluate the safety and dosing of a combination therapy for RAS pathway mutant endometrial cancer.

RegulatoryJuly 21, 2026

FDA Approves Supplement for HEPZATO by Delcath Systems

The FDA has approved a supplemental application for HEPZATO, containing melphalan hydrochloride.

RegulatoryJuly 21, 2026

FDA Accepts Supplement Application for COLUMVI (GLOFITAMAB-GXBM)

The FDA has accepted the supplemental application for COLUMVI, a bispecific T-cell engager.

ClinicalJuly 21, 2026

Feldan Therapeutics Initiates FLD-103 Trial for Basal Cell Carcinoma

Feldan Therapeutics is conducting a clinical trial to evaluate the safety, tolerability, and efficacy of intralesional FLD-103 in patients with Basal Cell Carcinoma.

ClinicalJuly 21, 2026

AstraZeneca Launches AI Study for Lung Cancer Risk Stratification

AstraZeneca is conducting an observational study to evaluate AI's role in detecting pulmonary nodules and predicting lung cancer risk in high-risk individuals.

ClinicalJuly 21, 2026

Study on ctDNA's Predictive Value in NSCLC Patients Treated with ICIs

The study evaluates the predictive value of ctDNA in response and relapse for NSCLC patients treated with immune checkpoint inhibitors and targeted therapies.

RegulatoryJuly 21, 2026

FDA Accepts Supplement Application for DARZALEX (Daratumumab)

The FDA has accepted a supplemental application for DARZALEX (daratumumab) from Janssen Biotech.

ClinicalJuly 21, 2026

Phase I Study of RO7566802 in Combination with Atezolizumab for Solid Tumors

Genentech is conducting a first-in-human Phase I trial to evaluate RO7566802 alone and with atezolizumab in advanced solid tumors.

ClinicalJuly 21, 2026

Phase 3b Study of CERVAVAC® Vaccine in Women Living with HIV Initiated

A Phase 3b clinical study is underway to evaluate the immunogenicity and safety of the SIIPL qHPV vaccine CERVAVAC® in women living with HIV aged 15-25 years.

ClinicalJuly 21, 2026

AstraZeneca Initiates Phase I/II Study of AZD4512 in B-cell Non-Hodgkin Lymphoma

AstraZeneca is conducting Phase I/II study to assess AZD4512 as monotherapy or in combination with other agents for relapsed/refractory B-NHL.

RegulatoryJuly 21, 2026

FDA Accepts Supplement for IMFINZI (Durvalumab) by AstraZeneca

The FDA has accepted a supplemental application for IMFINZI (Durvalumab) from AstraZeneca.

CompetitiveJuly 21, 2026

Phase 1/2 Study of IPG7236 and Toripalimab in Advanced Solid Tumors Initiated

Nanjing Immunophage Biotech has initiated Phase 1/2 clinical trial evaluating IPG7236 in combination with Toripalimab for advanced solid tumors.

CompetitiveJuly 21, 2026

Lilly to acquire Kelonia Therapeutics for in vivo CAR-T cell therapy advancement

Lilly is acquiring Kelonia Therapeutics to enhance its portfolio in in vivo CAR-T cell therapies, particularly targeting relapsed/refractory multiple myeloma.

RegulatoryJuly 21, 2026

FDA Accepts Supplemental Application for XATMEP (Methotrexate Sodium)

The FDA has accepted a supplemental application for XATMEP, a formulation of methotrexate sodium.

RegulatoryJuly 21, 2026

Alembic's Methotrexate Sodium ANDA217552 Receives AP Status from FDA

Alembic's application for Methotrexate Sodium has received an Abbreviated Approval (AP) status from the FDA.

ClinicalJuly 21, 2026

Janssen's Apalutamide Study Targets mCRPC in Chinese Patients

A study is underway to evaluate the pharmacokinetics and safety of apalutamide in Chinese patients with metastatic castration-resistant prostate cancer.

ClinicalJuly 21, 2026

Brentuximab Vedotin and Pembrolizumab Trial for Metastatic Cancers Initiated

A new clinical trial is investigating the combination of brentuximab vedotin and pembrolizumab in patients with metastatic solid tumors.

RegulatoryJuly 20, 2026

FDA Grants AP Status for Methotrexate Sodium ANDA213343

The FDA has granted Abbreviated Approval (AP) status for ANDA213343, a methotrexate sodium supplement submitted by Accord Healthcare.

RegulatoryJuly 20, 2026

FDA Approves Supplemental Application for Methotrexate Sodium by Hikma

The FDA has approved a supplemental application for Methotrexate Sodium submitted by Hikma.

RegulatoryJuly 20, 2026

FDA Grants AP Status for Methotrexate Sodium ANDA213362

The FDA has granted approval status (AP) for the ANDA213362 application for Methotrexate Sodium submitted by Daito.

RegulatoryJuly 20, 2026

FDA Approval Update for TREXALL (Methotrexate Sodium) by Barr

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for TREXALL, a methotrexate sodium product by Barr.

RegulatoryJuly 20, 2026

FDA Accepts Supplemental Application for Methotrexate Sodium by Strides Pharma

The FDA has accepted a supplemental application for Methotrexate Sodium submitted by Strides Pharma.

RegulatoryJuly 20, 2026

FDA Grants Priority Review for ABBVIE's BLA761460 (DECNUPAZ)

The FDA has granted priority review for ABBVIE's Biologics License Application for DECNUPAZ (BLA761460).

RegulatoryJuly 20, 2026

FDA Grants AP Status for Zydus' Methotrexate Sodium Supplement

The FDA has granted approval status (AP) for Zydus Pharmaceuticals' supplemental application for Methotrexate Sodium.

ClinicalJuly 20, 2026

Efficacy Study of Apalutamide in High-risk Prostate Cancer Underway

A study is assessing the efficacy of apalutamide combined with GnRH agonist in high-risk prostate cancer patients undergoing radiation therapy.

ClinicalJuly 20, 2026

Golidocitinib Pilot Study in Mycosis Fungoides and T-LGLL Initiated

A pilot study of golidocitinib is enrolling patients with advanced-stage mycosis fungoides/Sézary syndrome and T-cell large granular lymphocytic leukemia.

ClinicalJuly 20, 2026

NCI and Lantheus Test PMSA-Based PET Imaging for High-Risk Prostate Cancer

A clinical trial is underway to evaluate the effectiveness of PMSA-based PET/CT imaging in predicting prostate cancer recurrence post-surgery.

ClinicalJuly 20, 2026

Clinical Trial Evaluates AI Communication Aid in Prostate Cancer Care

A clinical trial is assessing the efficacy of LLM-assisted communication in reducing psychological distress in prostate cancer patients compared to standard care.

RegulatoryJuly 20, 2026

FDA Grants AP Status for Methotrexate Sodium ANDA216453

The FDA has granted approval status (AP) for the ANDA216453 application for Methotrexate Sodium submitted by Elite Labs Inc.

RegulatoryJuly 20, 2026

AstraZeneca's Capivasertib NDA218197 Receives AP Status from FDA

The FDA has granted AstraZeneca's NDA218197 for Capivasertib an Approval Pending (AP) status.

RegulatoryJuly 20, 2026

FDA Grants AP Status for Methotrexate Sodium ANDA081099 by Barr

The FDA has granted Abbreviated Approval (AP) status for Barr's ANDA081099 for Methotrexate Sodium.

RegulatoryJuly 20, 2026

Amneal Pharmaceuticals Receives AP Status for Methotrexate Sodium ANDA210040

Amneal Pharmaceuticals has received an Abbreviated New Drug Application (ANDA) approval status for Methotrexate Sodium.

StrategyJuly 20, 2026

Mylan's Methotrexate Sodium ANDA081235 Receives Abbreviated Approval

Mylan's ANDA081235 for Methotrexate Sodium has received an abbreviated approval from the FDA.

RegulatoryJuly 20, 2026

FDA Grants AP Status for Methotrexate Sodium ANDA201749 by Sun Pharma

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Methotrexate Sodium submitted by Sun Pharma.

RegulatoryJuly 20, 2026

FDA Accepts Supplemental NDA for JYLAMVO by SHORLA

The FDA has accepted a supplemental NDA for JYLAMVO, which contains methotrexate as an active ingredient.

RegulatoryJuly 20, 2026

Eugia Pharma's Methotrexate Sodium ANDA210454 Receives AP Status

Eugia Pharma's application for Methotrexate Sodium (ANDA210454) has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJuly 20, 2026

FDA Accepts Supplemental Application for KOSELUGO (Selumetinib)

The FDA has accepted a supplemental application for KOSELUGO (selumetinib) submitted by AstraZeneca.

ClinicalJuly 20, 2026

Phase II Study of Adaptive SBRT for Localized Prostate Cancer Initiated

A phase II international multicenter study is evaluating adaptive stereotactic body radiotherapy for localized prostate cancer.

RegulatoryJuly 20, 2026

FDA Accepts Supplement Application for Imatinib Mesylate by Hetero Labs

The FDA has accepted a supplemental application for Imatinib Mesylate submitted by Hetero Labs.

ClinicalJuly 20, 2026

Phase Ib/II Study of Glofitamab with Atezolizumab or Polatuzumab in B-Cell NHL

A Phase Ib/II study is assessing the safety and efficacy of Glofitamab combined with Atezolizumab or Polatuzumab in relapsed/refractory B-cell NHL.

ClinicalJuly 20, 2026

Janssen's Apalutamide Study Targets High-Risk Prostate Cancer Pre-Radical Prostatectomy

A study is underway to evaluate apalutamide combined with ADT in high-risk prostate cancer patients prior to radical prostatectomy.

RegulatoryJuly 20, 2026

FDA Grants Priority Review for Datopotamab Deruxtecan Supplement

The FDA has granted priority review status for the supplemental application of Datopotamab Deruxtecan by Daiichi Sankyo.

ClinicalJuly 20, 2026

University of Rochester Launches eGAP Study for Older Cancer Patients

The University of Rochester is conducting a feasibility study on the electronic Geriatric Assessment Platform (eGAP) involving 50 older cancer patients.

ClinicalJuly 20, 2026

Trial on Far Infrared Rays and TENS for Head and Neck Cancer Patients

A clinical trial is evaluating the efficacy of far infrared radiation therapy and transcutaneous electrical nerve stimulation in reducing side effects for head and neck cancer patients undergoing chemoradiotherapy.

ClinicalJuly 20, 2026

Phase I/II Trial of Proton-SFRT and Standard Radiation for Retroperitoneal Soft Tissue Sarcoma

A phase I/II trial is investigating the efficacy and safety of proton-spatially fractionated radiotherapy combined with standard radiation therapy for newly diagnosed retroperitoneal soft tissue sarcoma.

ClinicalJuly 20, 2026

Genmab Initiates Phase 2 Trial of Rina-S for Non-Small Cell Lung Cancer

Genmab is conducting Phase 2 study to evaluate the efficacy and safety of Rina-S monotherapy in non-small cell lung cancer patients.

ClinicalJuly 20, 2026

Genmab's GEN1042 Trial Evaluates Anti-tumor Activity in Solid Tumors

The trial aims to assess the safety and anti-tumor activity of GEN1042, both as a monotherapy and in combination with pembrolizumab.

RegulatoryJuly 19, 2026

FDA Approves Supplement for NYVEPRIA (PEGFILGRASTIM-APGF)

The FDA has approved a supplemental application for NYVEPRIA, a pegfilgrastim product.

RegulatoryJuly 19, 2026

Eugia Pharma submits supplemental application for Zoledronic Acid (ANDA209125)

Eugia Pharma has submitted a supplemental application for Zoledronic Acid under ANDA209125, currently under standard review.

ClinicalJuly 19, 2026

Epcoritamab Trial in Japanese R/R B-Cell NHL Shows Safety and Efficacy Potential

A trial is underway to assess the safety and efficacy of epcoritamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

ClinicalJuly 19, 2026

AI-Enhanced MRI Techniques May Improve Prostate Cancer Diagnosis

A study is underway to evaluate the integration of advanced MRI and AI techniques for better prostate cancer classification.

ClinicalJuly 19, 2026

Yale University Launches Pragmatic Trial for Colorectal Cancer Screening Adherence

Yale University is conducting a 4-arm pragmatic trial aimed at enhancing adherence to colorectal cancer screening through a multicomponent intervention.

ClinicalJuly 19, 2026

Study on Real-world Use of Darolutamide in Metastatic Hormone-sensitive Prostate Cancer

A study sponsored by Bayer will analyze real-world data on darolutamide and other ARPIs for mHSPC treatment.

ClinicalJuly 19, 2026

Study Initiated to Develop Exosomal microRNA Biomarker for Colon Cancer Staging

A multicenter study is underway to develop a machine learning-based biomarker panel using exosomal microRNAs for preoperative risk stratification in colon cancer.

RegulatoryJuly 19, 2026

FDA Accepts Supplemental NDA for VENCLEXTA by AbbVie

The FDA has accepted a supplemental NDA for VENCLEXTA (venetoclax) from AbbVie.

ClinicalJuly 19, 2026

Long-term safety and efficacy study of ibrutinib initiated by Janssen

A long-term extension study for ibrutinib has been initiated to gather ongoing safety and efficacy data.

ClinicalJuly 19, 2026

Boehringer Ingelheim Initiates Dose-Exploration Study of BI 1831169 with Anti-PD1 in Advanced Cancer

Boehringer Ingelheim is conducting a study to evaluate the tolerability of BI 1831169 in combination with an anti-PD1 antibody in Japanese adults with advanced cancers.

RegulatoryJuly 19, 2026

Teva Reports Labelling Error for Ponlimsi (Denosumab) 60mg Injection

Teva UK Limited has identified a labelling error on the Ponlimsi (Denosumab) carton, incorrectly stating 'For application to the skin'.

RegulatoryJuly 19, 2026

FDA Accepts Supplement for ZYNYZ (Retifanlimab-Dlwr) by Incyte

The FDA has accepted a supplemental biologics license application for ZYNYZ (retifanlimab-Dlwr) from Incyte Corporation.

RegulatoryJuly 19, 2026

FDA Approves HERCEPTIN HYLECTA Supplement Application

The FDA has approved the supplemental application for HERCEPTIN HYLECTA, which combines trastuzumab and hyaluronidase.

ClinicalJuly 19, 2026

Study on THIO and Cadonilimab for Resectable Hepatocellular Carcinoma Launched

A clinical trial is underway to evaluate the efficacy and safety of cadonilimab alone and in combination with ateganosine for treating resectable HCC.

ClinicalJuly 19, 2026

Mount Sinai Launches Pilot Study on Chemotherapy vs. Surgery for Stage II/III Rectal Cancer

The Quicksilver II pilot study will evaluate if patients with margin-clear Stage II or III rectal cancer can safely skip neo-adjuvant chemotherapy.

ClinicalJuly 19, 2026

Phase 2 Trial of CD70.CAR NK Cells in DLBCL and Hodgkin Lymphoma Initiated

A Phase 2 trial is underway to evaluate the efficacy of CD70.CAR NK cell therapy in patients with primary refractory or early relapsed diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL).

ClinicalJuly 19, 2026

Phase I Study of JS001sc in Advanced Nasopharyngeal Carcinoma Shows Focus on Safety and Tolerability

A phase I clinical study is underway to evaluate the safety and tolerability of JS001sc, both as monotherapy and in combination with gemcitabine and cisplatin.

CompetitiveJuly 19, 2026

Astellas Pharma's ASP5541 Phase 2 Study in Advanced Prostate Cancer Underway

A Phase 2 study is evaluating ASP5541, an injectable form of abiraterone acetate, in men with advanced prostate cancer.

ClinicalJuly 19, 2026

Novel CMC/CeO2 Nanocarriers Enhance Quercetin Delivery in Lung Cancer Cells

A new CMC-based nanocarrier system co-loaded with CeO2 and CQDs shows improved quercetin delivery and anticancer activity against A549 lung cancer cells.

ClinicalJuly 19, 2026

Intramuscular PDX Models Show High Engraftment for Gastric Cancer Drug Testing

An optimized intramuscular patient-derived xenograft (PDX) platform demonstrates high engraftment rates in gastric cancer, enhancing individualized drug testing and biomarker discovery.

ClinicalJuly 19, 2026

SEPTIN9 methylation in ctDNA predicts MRD in colorectal cancer patients post-surgery

The study evaluates SEPTIN9 methylation status in ctDNA as a biomarker for minimal residual disease in colorectal cancer.

ClinicalJuly 19, 2026

Cost-effectiveness of MRI and PET/CT in Prostate Cancer Staging Reevaluated with New Phase 3 Data

Recent Phase 3 trials have provided updated data on the cost-effectiveness of ferumoxtran-enhanced MRI and PSMA-PET/CT compared to ePLND for nodal staging in prostate cancer.

ClinicalJuly 19, 2026

Novel Imaging Biomarker PPAT Thickness Predicts Prostate Cancer in Gray Zone Patients

Normalized periprostatic adipose tissue thickness is introduced as a novel imaging biomarker for predicting prostate cancer in patients with PI-RADS score 3 and PSA levels of 4-10 ng/mL.

ClinicalJuly 19, 2026

Galectin-3+PD-L1+ CECs identified as immunosuppressive drivers in TNBC

The study identifies Galectin-3+PD-L1+ CD71+ erythroid cells as key immunosuppressive components in triple-negative breast cancer.

ClinicalJuly 19, 2026

Study Links Neoadjuvant Immunochemotherapy to Postoperative AHRF Risk in Thoracic Surgery

This multicentre cohort study investigates the association between neoadjuvant immunochemotherapy and the risk of postoperative acute hypoxemic respiratory failure in thoracic surgeries.

RegulatoryJuly 19, 2026

FDA Approves PHESGO Supplement for Genentech's Combination Therapy

The FDA has approved a supplemental application for PHESGO, a combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf.

StrategyJuly 19, 2026

FDA Submission for Palbociclib by Dr. Reddy's Laboratories

Reddy's Laboratories has submitted an original Abbreviated New Drug Application (ANDA) for Palbociclib.

RegulatoryJuly 19, 2026

FDA Grants Priority Review for Tecentriq Hybreza Supplement Application

The FDA has granted priority review for the supplemental application of Tecentriq Hybreza, which combines atezolizumab with hyaluronidase.

ClinicalJuly 19, 2026

Study on 124I-cG250 PET/CT for Early Detection of Therapy Response in Metastatic Renal Cell Carcinoma

A study is evaluating the effectiveness of 124I-cG250 PET/CT scans in detecting early responses to sunitinib or pazopanib in kidney cancer patients.

ClinicalJuly 18, 2026

Nanjing Immunophage initiates Phase 1/2a trial for IPG7236 in advanced solid tumors

Nanjing Immunophage Biotech has launched Phase 1/2a trial to evaluate the safety and preliminary efficacy of IPG7236 in patients with advanced solid tumors.

CompetitiveJuly 18, 2026

Infrastructure Proposal for mHealth Interventions in Cancer Patient Smoking Cessation

A new infrastructure is being proposed to support the development of mobile health tools aimed at reducing smoking among cancer patients.

ClinicalJuly 18, 2026

Mayo Clinic Trial on Health Coaching for Thyroid Cancer Survivors

A clinical trial is evaluating the effectiveness of health and wellness coaching on treatment adherence in thyroid cancer survivors.

ClinicalJuly 18, 2026

Vorasidenib and Temozolomide Combination Study in IDH-mutant Glioma Initiated

A Phase Ib/II study is underway to evaluate the safety and efficacy of vorasidenib combined with temozolomide in IDH-mutant glioma.

ClinicalJuly 18, 2026

NCI Launches Biospecimen Study to Enhance Immunotherapy Research

The National Cancer Institute is conducting a study to collect biospecimens from cancer patients to improve treatment understanding.

ClinicalJuly 18, 2026

Study Evaluates Cilta-cel and Talquetamab Combinations with Daratumumab in Multiple Myeloma

The study aims to assess treatment response rates and potential cure indicators at 5 years post-induction therapy.

ClinicalJuly 18, 2026

Novel MOF P/ZnO Nanocomposite Shows Promise for Targeted Cancer Therapy

A new metal-organic framework (MOF P) integrated with ZnO nanoparticles shows effective cancer cell apoptosis and reduced viability.

ClinicalJuly 18, 2026

DN022150 Trial Initiated for Advanced Pancreatic Cancer with KRAS G12D Mutation

A trial has been initiated to evaluate DN022150 against standard chemotherapy in patients with advanced pancreatic cancer and KRAS G12D mutation.

ClinicalJuly 18, 2026

Mirati's Adagrasib Plus Pembrolizumab Trial for NSCLC Shows Promise

A trial is underway to assess the combination of adagrasib, pembrolizumab, and chemotherapy in KRAS G12C mutated NSCLC.

ClinicalJuly 18, 2026

BRIGHT Trial: Pembrolizumab and Radiation Therapy for Muscle Invasive Bladder Cancer

The BRIGHT trial is a phase II study evaluating pembrolizumab combined with radiation therapy post-chemotherapy to avoid bladder removal in muscle invasive bladder cancer patients.

ClinicalJuly 18, 2026

Merck's Pembrolizumab Study Targets Japanese Pediatric and Adult Cancer Patients

Merck is conducting a study to evaluate the safety and efficacy of pembrolizumab in Japanese pediatric participants with solid tumors and lymphomas, as well as in adults with Merkel cell carcinoma.

RegulatoryJuly 18, 2026

FDA Approves Supplemental Application for Retevmo (Selpercatinib)

The FDA has approved a supplemental application for Retevmo (selpercatinib) submitted by Eli Lilly.

RegulatoryJuly 18, 2026

Apotex submits ANDA for Afatinib Dimaleate, FDA review in progress

Apotex has submitted an Abbreviated New Drug Application (ANDA) for Afatinib Dimaleate, currently under FDA review.

StrategyJuly 18, 2026

FDA Grants Approval for Afatinib Dimaleate ANDA210750

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 210750 for Afatinib Dimaleate submitted by Hetero Labs Ltd.

RegulatoryJuly 18, 2026

FDA Approves REVTORPYK (GEDATOLISIB) for Celcuity Inc.

The FDA has approved REVTORPYK (gedatolisib) under NDA219908 for Celcuity Inc.

RegulatoryJuly 18, 2026

FDA Grants Priority Review for Tecentriq Supplement Application

The FDA has granted priority review for the supplemental application of Tecentriq (atezolizumab) submitted by Genentech.

StrategyJuly 18, 2026

FDA Grants Approval for Dr. Reddy's Venetoclax ANDA214733

The FDA has granted approval for Dr. Reddy's Abbreviated New Drug Application (ANDA) for Venetoclax.

ClinicalJuly 18, 2026

Hutchmed Initiates Study on Food and PPI Effects on HMPL-760 Pharmacokinetics

Hutchmed is conducting a pharmacokinetics study of HMPL-760, evaluating food and proton pump inhibitor effects.

ClinicalJuly 18, 2026

AstraZeneca's Study on Durvalumab and Tremelimumab in HCC with TACE

AstraZeneca is conducting a global study evaluating the combination of durvalumab, tremelimumab, and lenvatinib with TACE in patients with locoregional hepatocellular carcinoma.

ClinicalJuly 18, 2026

Phase II Study of L-Ornithine L-Aspartate and N-Acetylcysteine in HR+/HER2- Advanced Breast Cancer

A Phase II study is evaluating a combination treatment in HR+/HER2- advanced breast cancer patients who have progressed on standard therapies.

RegulatoryJuly 17, 2026

FDA Grants Priority Review for ENHERTU Supplement Application

The FDA has granted priority review for the supplemental application of ENHERTU (fam-trastuzumab deruxtecan-nxki) submitted by Daiichi Sankyo.

StrategyJuly 17, 2026

Sandoz submits ANDA for Tivozanib, marking a new generic entry

Sandoz Inc. has submitted an Abbreviated New Drug Application (ANDA) for Tivozanib.

ClinicalJuly 17, 2026

Novartis initiates real-world study on Pluvicto in metastatic CRPC patients

Novartis is conducting a real-world study to evaluate the effectiveness of Pluvicto in metastatic CRPC patients.

ClinicalJuly 17, 2026

Trial on Respiratory Training in Lower Extremity Lymphedema Initiated by Toros University

A randomized controlled trial is underway to assess the impact of respiratory and relaxation training on patients with lower extremity lymphedema.

ClinicalJuly 17, 2026

AI Model for Predicting Neoadjuvant Chemo Response in Advanced Gastric Cancer

A prospective cohort study is underway to develop an AI model predicting chemotherapy response using imaging and liquid biopsy.

CompetitiveJuly 17, 2026

RPH-002 Shows Comparable Efficacy to Erbitux in Head and Neck Cancer Trial

A comparative study is underway to evaluate RPH-002 against Erbitux® in advanced head and neck squamous cell carcinoma.

ClinicalJuly 17, 2026

Study on Electroacupuncture and Exercise for Chemotherapy-Induced Peripheral Neuropathy

A clinical trial is evaluating the efficacy of combining Electroacupuncture with exercise training for managing CIPN symptoms.

ClinicalJuly 17, 2026

Phase 2a Trial of Riluzole for Cancer-Related Cognitive Impairment Initiated

A phase 2a pilot trial is underway to assess riluzole's effects on BDNF levels in cancer survivors with cognitive impairment.

ClinicalJuly 17, 2026

Dietary Butyrate Enhances Anti-PD-1 Efficacy in NSCLC via Gut Microbiome Modulation

Dietary supplementation with butyrate enhances anti-tumor activity and improves the efficacy of α PD-1 therapy in mice, linked to immune cell modulation.

ClinicalJuly 17, 2026

Link Between Graves' Disease and Prostate Cancer Explored Through Bioinformatics

The study suggests a potential causal association between Graves' disease and increased risk of prostate cancer, highlighting shared immune mechanisms.

ClinicalJuly 17, 2026

CCL2/TIMP1 Axis Identified as Key Driver in Glioblastoma's Immunosuppressive Microenvironment

A high-risk signature centered on CCL2 and TIMP1 was identified, linked to an inflammatory, macrophage-enriched microenvironment in glioblastoma.

ClinicalJuly 17, 2026

KEYTRUDA Shows Significant PFS Improvement in dMMR Endometrial Cancer in Phase 3 Trial

KEYTRUDA (pembrolizumab) improved progression-free survival compared to platinum doublet chemotherapy in dMMR endometrial cancer patients.

ClinicalJuly 17, 2026

Phase I Trial on Hyperpolarized Imaging for CNS Lymphoma Shows Feasibility

A phase I trial is assessing the feasibility and safety of hyperpolarized carbon-13 pyruvate MRI in diagnosing primary CNS lymphoma.

ClinicalJuly 17, 2026

Pilot Study on Rapid Autopsy Program for Small Cell Lung Cancer Initiated

Indiana University is launching a pilot study to establish a rapid autopsy program for Small Cell Lung Cancer.

ClinicalJuly 17, 2026

AstraZeneca's Study on MET Concordance in Treatment-Naïve NSCLC

AstraZeneca is conducting a multicenter study to assess MET concordance and gene profiling in treatment-naïve non-small cell lung cancer (NSCLC).

ClinicalJuly 17, 2026

Study on Sacituzumab Govitecan and Talazoparib in Metastatic Breast Cancer

A clinical trial is evaluating the combination of Sacituzumab Govitecan and Talazoparib in patients with metastatic triple-negative breast cancer.

RegulatoryJuly 16, 2026

FDA Approves Gallium Ga-68 Gozetotide for Diagnostic Use

The FDA has approved the application ANDA219189 for Gallium Ga-68 Gozetotide, submitted by IONETIX.

ClinicalJuly 16, 2026

Adlai Nortye initiates trial for AN4035 in RAS-mutated advanced cancers

Adlai Nortye Biopharma is conducting a clinical trial to evaluate the safety and tolerability of AN4035 in patients with advanced solid tumors harboring RAS mutations and high CEACAM5 expression.

ClinicalJuly 16, 2026

Study on Stereotactic Boost for Recurrent Head and Neck Cancer Initiated

A study is underway to evaluate the effectiveness of stereotactic body radiotherapy for recurrent or metastatic head and neck cancer.

ClinicalJuly 16, 2026

Phase 1 Study of LNK001 in Advanced Clear Cell Renal Cell Carcinoma Initiated

A Phase 1 study of LNK001 is underway to determine the recommended dose and efficacy in advanced ccRCC.

RegulatoryJuly 16, 2026

FDA Accepts Supplement for Gleevec (Imatinib Mesylate) by Novartis

The FDA has accepted a supplemental application for Gleevec (Imatinib Mesylate) from Novartis.

ClinicalJuly 16, 2026

Characterization of PI4K/PIPK Alterations in Solid Tumors for Biomarker Development

The study characterizes genomic alterations in PI4K and PIPK genes across solid tumors and their correlation with clinical outcomes.

ClinicalJuly 16, 2026

DMAMCL Induces Ferroptosis in Neuroblastoma, Targeting HMOX1 and STEAP3

DMAMCL induces ferroptosis in neuroblastoma by targeting HMOX1 in MYCN-amplified subtypes and STEAP3 in MYCN-nonamplified subtypes.

RegulatoryJuly 16, 2026

FDA Accepts Supplemental Application for Verzenio (Abemaciclib)

The FDA has accepted a supplemental application for Verzenio, CDK4/6 inhibitor developed by Eli Lilly.

RegulatoryJuly 16, 2026

FDA Grants Priority Review for BEQALZI (Sonrotoclax) NDA220711

The FDA has granted priority review status for BEQALZI, a novel therapy containing sonrotoclax, submitted by Beone Medicines USA.

RegulatoryJuly 16, 2026

FDA Accepts Supplemental NDA for YONSA by Sun Pharma

The FDA has accepted a supplemental NDA for YONSA, which contains abiraterone acetate as the active ingredient.

ClinicalJuly 16, 2026

Phase 1/2 Study of BH-30643 in NSCLC with EGFR/HER2 Mutations Initiated by BlossomHill Therapeutics

BlossomHill Therapeutics has initiated Phase 1/2 study of BH-30643 targeting NSCLC patients with EGFR and/or HER2 mutations.

ClinicalJuly 16, 2026

NCI Launches Registry for Very Rare Childhood Cancers to Inform Future Treatments

The National Cancer Institute has initiated a registry to collect data on very rare cancers in children, teens, and young adults.

ClinicalJuly 16, 2026

Study on Cognitive Rehabilitation in Adult Lower Grade Gliomas Launched

A new clinical trial is investigating cognitive rehabilitation for patients with lower grade gliomas, addressing cognitive deficits post-treatment.

ClinicalJuly 16, 2026

University of Missouri Initiates Study on Lymphatic Pain and Lymphedema Management

A new clinical trial aims to implement digital assessments and self-care interventions for lymphatic pain and lymphedema in breast cancer patients.

StrategyJuly 15, 2026

Apotex submits ANDA for Everolimus, FDA review in progress

Apotex has submitted an Abbreviated New Drug Application (ANDA) for Everolimus, currently under FDA review.

RegulatoryJuly 15, 2026

FDA Accepts Supplemental Application for OPDIVO QVANTIG by Bristol-Myers Squibb

The FDA has accepted a supplemental application for OPDIVO QVANTIG, which includes nivolumab and hyaluronidase-NVHY.

ClinicalJuly 15, 2026

Phase II Trial of Sacituzumab Tirumotecan and Tagitanlimab in Advanced Esophageal and Gastric Cancers

A phase II trial is underway to assess the efficacy and safety of sacituzumab tirumotecan combined with tagitanlimab in patients with recurrent or metastatic esophageal squamous cell carcinoma and gastric adenocarcinoma.

ClinicalJuly 15, 2026

NCI Study on Immune Suppressor Cells in Cancer Patients Pre- and Post-Chemotherapy

The National Cancer Institute is conducting a study to collect blood samples from cancer patients to analyze immune suppressor cells before and after chemotherapy.

StrategyJuly 15, 2026

FDA Approves First Generics of Gilotrif (afatinib) Tablets

The FDA has approved the first generic versions of Gilotrif (afatinib) for treating metastatic NSCLC with specific EGFR mutations.

RegulatoryJuly 15, 2026

FDA approves gedatolisib with fulvestrant for HR-positive, HER2-negative breast cancer

The FDA has approved gedatolisib in combination with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative breast cancer.

RegulatoryJuly 15, 2026

FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application

The FDA has accepted the supplemental application for KEYTRUDA QLEX, indicating a priority review status.

RegulatoryJuly 15, 2026

FDA grants priority review for PADCEV supplemental application

The FDA has accepted a supplemental application for PADCEV (enfortumab vedotin-ejfv) from Astellas, granting it priority review status.

RegulatoryJuly 15, 2026

FDA Accepts NDA for ZYOGREEN by PROVEPHARM SAS

The FDA has accepted the New Drug Application for ZYOGREEN, an injection containing Indocyanine Green.

ClinicalJuly 15, 2026

Economic Analysis of Early vs Delayed Therapy in CLL/SLL Patients

A trial is underway to analyze healthcare utilization in newly diagnosed asymptomatic high-risk CLL/SLL patients comparing early versus delayed therapy.

ClinicalJuly 15, 2026

Phase 1 Study of Allogeneic CD30.CAR-EBVSTs in Relapsed/Refractory Lymphomas

A clinical trial is investigating the safety and efficacy of allogeneic CD30.CAR-EBVSTs in patients with relapsed or refractory CD30-positive lymphomas.

ClinicalJuly 15, 2026

Tislelizumab and Disitamab-Vedotin Show Promise in Neoadjuvant Therapy for HER2-positive UTUC

A clinical trial is investigating the efficacy and safety of combining tislelizumab and disitamab-vedotin as neoadjuvant therapy for high-risk HER2-positive upper tract urothelial carcinoma.

RegulatoryJuly 15, 2026

FDA grants priority review for KEYTRUDA supplemental application

The FDA has granted priority review for the supplemental application of KEYTRUDA (pembrolizumab) submitted by Merck Sharp & Dohme.

RegulatoryJuly 15, 2026

FDA Accepts Nintedanib Application from Glenmark Pharmaceuticals

The FDA has accepted the application for Nintedanib (ANDA212555) from Glenmark Pharmaceuticals.

RegulatoryJuly 15, 2026

FDA Grants Approval for Nintedanib Esylate ANDA218472

The FDA has granted approval for the ANDA218472 application for Nintedanib Esylate submitted by Humanwell Puracap.

RegulatoryJuly 15, 2026

FDA Accepts Application for SARCLISA (Isatuximab-IRFC) by Sanofi

The FDA has accepted the Biologics License Application for SARCLISA (Isatuximab-IRFC) from Sanofi.

ClinicalJuly 15, 2026

Phase I/II Study of Sacituzumab Govitecan and Berzosertib in Small Cell Lung Cancer

A Phase I/II trial is investigating the combination of sacituzumab govitecan and berzosertib in patients with small cell lung cancer and PARP inhibitor-resistant tumors.

ClinicalJuly 15, 2026

Phase II Trial of Nivolumab and Ipilimumab in dMMR Recurrent Endometrial Carcinoma

A phase II trial is testing the efficacy of nivolumab combined with ipilimumab versus nivolumab alone in patients with dMMR recurrent endometrial carcinoma.

RegulatoryJuly 15, 2026

Long-term Follow-Up Study on Gene Therapy Adverse Events in Pediatric Oncology

A long-term follow-up study will evaluate delayed adverse events in pediatric patients who received gene therapy.

CompetitiveJuly 15, 2026

Boehringer Ingelheim Study on HER2-Altered Metastatic Breast Cancer Treatment Patterns

A new study by Boehringer Ingelheim aims to evaluate treatment patterns and outcomes in HER2-altered metastatic breast cancer patients in the U.S.

RegulatoryJuly 15, 2026

FDA Approves Selpercatinib for RET Fusion-Positive Solid Tumors

The FDA has granted traditional approval for selpercatinib, targeting locally advanced or metastatic RET fusion-positive solid tumors.

ClinicalJuly 15, 2026

UCB NK Cells Enhance Anti-GD2 Therapy Efficacy in Neuroblastoma

Ex vivo expanded umbilical cord blood NK cells improve the efficacy of anti-GD2 antibodies in neuroblastoma, showing promising results in early clinical cases.

ClinicalJuly 15, 2026

TFPI2's Dual Role in Tumor Metastasis: Implications for Targeted Therapy

TFPI2 has a dual role in tumor metastasis, acting as both a suppressor and promoter depending on the context.

RegulatoryJuly 15, 2026

FDA Accepts Supplemental Application for ZIEXTENZO by Sandoz

The FDA has accepted a supplemental application for ZIEXTENZO (PEGFILGRASTIM-BMEZ) from Sandoz.

RegulatoryJuly 15, 2026

FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application

The FDA has granted priority review for the supplemental application of KEYTRUDA QLEX, which includes pembrolizumab and berahyaluronidase alfa-PMPH.

RegulatoryJuly 15, 2026

FDA Submission Update for KEYTRUDA (Pembrolizumab) by Merck

Merck Sharp Dohme has submitted a supplemental application for KEYTRUDA (pembrolizumab) under BLA125514.

RegulatoryJuly 15, 2026

FDA Accepts Supplement Application for OPDIVO (Nivolumab) by Bristol Myers Squibb

The FDA has accepted a supplemental application for OPDIVO (Nivolumab) from Bristol Myers Squibb.

ClinicalJuly 15, 2026

Study on Pain Reporting in Women with Non-metastatic Breast Cancer During Chemotherapy

The study aims to assess pain levels reported by younger versus older women receiving pegfilgrastim during chemotherapy.

ClinicalJuly 15, 2026

Study on Mental Health Services for Older Cancer Patients Launched

A new study is assessing the effectiveness of the Open Door for Cancer approach in connecting older cancer patients with mental health services.

ClinicalJuly 14, 2026

Sumitomo Pharma initiates observational study on ORGOVYX in prostate cancer patients

A multi-center, prospective, observational study is underway to assess the real-world safety and effectiveness of ORGOVYX in prostate cancer patients.

ClinicalJuly 14, 2026

Divarasib Study in Untreated Advanced NSCLC Shows Promise for Safety and Efficacy

A study is underway to evaluate the safety, pharmacokinetics, and activity of divarasib in advanced or metastatic NSCLC.

ClinicalJuly 14, 2026

Study on Quality of Life Recovery in Cervical Cancer Patients Post-Radiotherapy

A longitudinal observational study is assessing Quality of Life recovery in cervical cancer patients after radiotherapy.

ClinicalJuly 14, 2026

TACE with QS-GMP shows promise for canine lower urinary tract carcinomas

Transarterial chemoembolization using quick-soluble gelatin microparticles resulted in a median tumor volume reduction of 76.41% in dogs with lower urinary tract carcinomas.

ClinicalJuly 14, 2026

AI-Driven Insights on Gut Microbiome's Role in Colorectal Cancer Therapy

The gut microbiome significantly influences tumor development and treatment outcomes in colorectal cancer, highlighting its potential as a biomarker.

RegulatoryJuly 14, 2026

FDA Grants Priority Review for BIZENGRI Supplement by Merus N.V.

The FDA has granted priority review for the supplemental application of BIZENGRI (ZENOCUTUZUMAB-ZBCO) submitted by Merus N.V.

ClinicalJuly 14, 2026

NCI Study on Genetic Variants in Cancer Patients with Immunologic Disorders

The National Cancer Institute is conducting a study to analyze genetic variants in cancer patients with immunologic diseases like HIV.

ClinicalJuly 14, 2026

Sitagliptin Combined with Gemcitabine and Paclitaxel in PDAC Patients

A clinical trial is investigating the efficacy of sitagliptin in combination with gemcitabine and albumin-bound paclitaxel for pancreatic ductal adenocarcinoma.

ClinicalJuly 14, 2026

Expanded Access Program for Bezuclastinib and Sunitinib in GIST Patients

Cogent Biosciences is initiating an expanded access program for bezuclastinib to be used with sunitinib in GIST patients.

ClinicalJuly 14, 2026

Phase II Trial Evaluates 18F-FET PET/CT for Glioma Diagnosis

A Phase II trial is assessing the diagnostic performance of 18F-FET PET/CT compared to traditional MRI in glioma patients.

CompetitiveJuly 14, 2026

Neladalkib (NVL-655) shows promise in Phase 3 trial for ALK-positive NSCLC

Phase 3 study aims to show neladalkib's superiority over alectinib in PFS for ALK-positive NSCLC.

StrategyJuly 14, 2026

AstraZeneca licenses novel EGFR inhibitor Zegfrovy for lung cancer

AstraZeneca has secured an exclusive global license for Zegfrovy, an oral EGFR inhibitor for lung cancer.

ClinicalJuly 14, 2026

Exploring BMX as Target for Cancer Therapy: Mechanisms and Inhibitors

BMX is implicated in tumorigenesis across various cancers and is a promising target for therapeutic intervention.

ClinicalJuly 14, 2026

Protein Palmitoylation Linked to Disease Pathogenesis and Therapeutic Opportunities

Protein palmitoylation affects protein stability and signaling, with implications in diseases like diabetes and cancer.

CompetitiveJuly 14, 2026

Novel CDK7 Inhibitor 7a Shows Potent Antitumor Activity in Colorectal Cancer Models

Compound 7a is a highly selective CDK7 inhibitor with an IC50 of 1.9 nM, demonstrating significant antitumor efficacy in HCT116 models.

RegulatoryJuly 14, 2026

FDA Accepts Supplement for Mekinist (Trametinib) by Novartis

The FDA has accepted a supplemental application for Mekinist (trametinib) from Novartis.

ClinicalJuly 14, 2026

Phase II Trial of Obinutuzumab Combinations in Relapsed/Refractory Follicular Lymphoma

A phase II trial is evaluating the efficacy of obinutuzumab with or without umbralisib, lenalidomide, or chemotherapy in patients with relapsed or refractory grade I-IIIa follicular lymphoma.

ClinicalJuly 14, 2026

NCI Study Evaluates Gemcitabine, Carboplatin, and Lenalidomide for Urothelial Cancer

A clinical trial is assessing the safety and efficacy of a combination of gemcitabine, carboplatin, and lenalidomide for treating advanced urothelial cancer.

ClinicalJuly 14, 2026

Study on Immune Function in BRCA1/2 Mutation Carriers Initiated

A clinical trial is evaluating immune function in healthy individuals with BRCA1/2 mutations.

RegulatoryJuly 13, 2026

FDA Accepts Supplement Application for Sodium Thiosulfate by Hope Pharmaceuticals

The FDA has accepted a supplemental application for Sodium Thiosulfate from Hope Pharmaceuticals.

StrategyJuly 13, 2026

FDA Grants AP Status for Dr. Reddy's Capecitabine ANDA204345

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Dr. Reddy's Capecitabine.

ClinicalJuly 13, 2026

MyeloMATCH Screening Study to Enhance Treatment Matching for Myeloid Cancer Patients

The MyeloMATCH study aims to improve patient enrollment in clinical trials for myeloid cancers by using biomarker testing.

ClinicalJuly 13, 2026

Phase II Trial of DNA-guided Therapy for High Residual Risk ER+ HER-2 Negative Breast Cancer

A Phase II trial is underway evaluating DNA-guided second line adjuvant therapy for patients with high residual risk ER+ HER-2 negative breast cancer.

ClinicalJuly 13, 2026

NCI initiates trial for Aza-TdC in advanced solid tumors

A clinical trial is underway to evaluate the safety and dosing of Aza-TdC in patients with advanced solid tumors.

CompetitiveJuly 13, 2026

Amneal Pharmaceuticals submits supplemental ANDA for Capecitabine

Amneal Pharmaceuticals has submitted a supplemental abbreviated new drug application (ANDA) for Capecitabine.

RegulatoryJuly 13, 2026

FDA Accepts BLA for ENNUMO (PEGFILGRASTIM-PCCG) by Accord Biopharma

The FDA has accepted the Biologics License Application for ENNUMO, a pegylated form of filgrastim.

ClinicalJuly 13, 2026

Phase II Trial of Palbociclib in Cancers with CCND Amplifications Shows Potential Targeted Treatment

The MATCH-Subprotocol Z1B trial is evaluating palbociclib's efficacy in cancers with CCND1, 2, or 3 amplifications.

ClinicalJuly 13, 2026

IL-15 Superagonist N-803 Combined with Vaccine ETBX-071 in Recurrent Prostate Cancer Trial Launched

A clinical trial is underway to evaluate the efficacy of N-803 alone and in combination with ETBX-071 in patients with biochemically recurrent prostate cancer post-radiation.

ClinicalJuly 13, 2026

Genentech's GDC-1261 Study Targets Advanced Prostate Cancer Safety and Activity

Genentech is conducting a study to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-1261 in advanced or metastatic prostate cancer.

RegulatoryJuly 13, 2026

FDA Accepts Supplement Application for TECVAYLI by Janssen Biotech

The FDA has accepted a supplemental application for TECVAYLI (teclistamab-cqy) from Janssen Biotech.

RegulatoryJuly 13, 2026

FDA Grants AP Status for Leuprolide Acetate ANDA215336 by Amneal

The FDA has granted Abbreviated Approval (AP) status for Amneal's ANDA215336 for Leuprolide Acetate.

RegulatoryJuly 13, 2026

FDA Grants AP Status for Leuprolide Acetate ANDA217957

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Leuprolide Acetate submitted by UBI.

RegulatoryJuly 13, 2026

FDA Grants AP Status to Zydus' Leuprolide Acetate ANDA215826

The FDA has granted approval status (AP) for Zydus Pharmaceuticals' ANDA215826 for Leuprolide Acetate.

RegulatoryJuly 13, 2026

FDA Approves Supplemental Applications for ELIGARD Kit

The FDA has approved supplemental applications for the ELIGARD Kit, which contains leuprolide acetate.

RegulatoryJuly 13, 2026

EUGIA PHARMA's Leuprolide Acetate ANDA Submission Receives AP Status

EUGIA PHARMA has received an Abbreviated New Drug Application (ANDA) approval status for Leuprolide Acetate.

RegulatoryJuly 13, 2026

FDA Accepts Supplemental Application for ZOLADEX by TERSERA

The FDA has accepted a supplemental application for ZOLADEX, indicating ongoing development and potential label expansion.

RegulatoryJuly 13, 2026

FDA Accepts Supplemental Application for ZOLADEX by TERSERA

The FDA has accepted a supplemental application for ZOLADEX, an oncology drug containing goserelin acetate.

ClinicalJuly 13, 2026

MRI and Multiomics Integration for Precision Treatment in Luminal Breast Cancer

A study is underway to integrate MRI and multiomics data for non-invasive molecular typing in luminal breast cancer.

ClinicalJuly 13, 2026

AstraZeneca's Rilvegostomig Study Targets Advanced Solid Tumors with Subcutaneous Administration

AstraZeneca is investigating the pharmacokinetics and safety of subcutaneous rilvegostomig in adults with advanced solid tumors.

ClinicalJuly 13, 2026

Gut Microbiota's Role in Colorectal Cancer: Insights for Targeted Therapies

The review highlights how gut microbiota influences colorectal cancer through mutations and immune microenvironment alterations.

ClinicalJuly 13, 2026

Brentuximab vedotin shows effectiveness over standard chemotherapy in relapsed Hodgkin lymphoma

A multicenter cohort study evaluates the real-world effectiveness and safety of brentuximab vedotin compared to standard chemotherapy in relapsed or refractory Hodgkin lymphoma.

ClinicalJuly 13, 2026

Challenges and Strategies in Nanomedicine-based Cancer Immunotherapy

Nanomedicine-based cancer immunotherapy faces significant translational barriers despite its preclinical promise.

ClinicalJuly 13, 2026

LYTACs: A New Strategy to Combat Cancer Drug Resistance

Lysosome-targeting chimeras (LYTACs) can selectively degrade proteins associated with cancer drug resistance, offering a novel therapeutic approach.

StrategyJuly 13, 2026

FDA Grants Approval for Leuprolide Acetate ANDA213829

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 213829 for Leuprolide Acetate submitted by Somerset Therap LLC.

RegulatoryJuly 13, 2026

FDA Grants AP Status for Leuprolide Acetate ANDA078885 by Sun Pharma

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Leuprolide Acetate submitted by Sun Pharma.

RegulatoryJuly 13, 2026

FDA grants AP status for Leuprolide Acetate ANDA075471

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Leuprolide Acetate submitted by Meitheal.

StrategyJuly 12, 2026

FDA Grants AP Status for Leuprolide Acetate ANDA217437

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Leuprolide Acetate submitted by PH Health.

RegulatoryJuly 12, 2026

FDA Accepts ANDA for Leucovorin Calcium by Ingenus Pharmaceuticals

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Leucovorin Calcium submitted by Ingenus Pharmaceuticals.

RegulatoryJuly 12, 2026

Hikma's Leucovorin Calcium ANDA072736 Receives AP Status from FDA

Hikma's ANDA for Leucovorin Calcium has received an Abbreviated Approval (AP) status from the FDA.

StrategyJuly 12, 2026

Hikma's Leucovorin Calcium ANDA072733 Receives Abbreviated Approval

Hikma has received an Abbreviated Approval (AP) for its ANDA072733 application for Leucovorin Calcium.

StrategyJuly 12, 2026

FDA Grants Approval for Leucovorin Calcium ANDA072734 by Hikma

The FDA has granted approval for Hikma's abbreviated new drug application for Leucovorin Calcium.

StrategyJuly 12, 2026

Hikma's Leucovorin Calcium ANDA072735 Receives Abbreviated Approval

Hikma's application ANDA072735 for Leucovorin Calcium has received abbreviated approval from the FDA.

RegulatoryJuly 12, 2026

FDA Grants Approval for Leucovorin Calcium Supplement Application

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Leucovorin Calcium submitted by Barr.

StrategyJuly 12, 2026

FDA Grants Approval for Leucovorin Calcium ANDA071199 by Barr

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Leucovorin Calcium submitted by Barr.

ClinicalJuly 12, 2026

First-in-Human Study of BG-C0979 in Advanced Solid Tumors Initiated

BeOne Medicines has initiated Phase 1 study to evaluate BG-C0979 in adults with advanced solid tumors.

ClinicalJuly 12, 2026

Phase II Trial of Dabrafenib and Trametinib in BRAF V600-Mutant High-Grade Glioma

A phase II trial is investigating the efficacy of dabrafenib and trametinib following radiation therapy in patients with BRAF V600-mutant high-grade glioma.

ClinicalJuly 12, 2026

Phase 2 Study of Tislelizumab in MSI-H or dMMR Solid Tumors by BeiGene

A Phase 2 study is underway evaluating Tislelizumab in patients with MSI-H or dMMR solid tumors.

ClinicalJuly 12, 2026

LncRNA AC008406.3 Enhances Docetaxel Sensitivity in Breast Cancer via Cuproptosis

The study identifies LncRNA AC008406.3 as a regulator of docetaxel sensitivity in breast cancer through cuproptosis.

RegulatoryJuly 12, 2026

FDA Grants AP Status for Leucovorin Calcium ANDA213929

The FDA has granted approval status (AP) for the ANDA213929 application for Leucovorin Calcium.

RegulatoryJuly 12, 2026

FDA Grants AP Status to Epic Pharma's Leucovorin Calcium Supplement

The FDA has granted approval status (AP) for Epic Pharma's ANDA074544 for Leucovorin Calcium.

ClinicalJuly 12, 2026

Phase 1/2 Study of Gemcitabine/Nab-paclitaxel and Radiation in Advanced Pancreatic Cancer

A phase 1/2 study is evaluating the safety and efficacy of gemcitabine and nab-paclitaxel combined with radiation therapy in advanced pancreatic cancer patients.

ClinicalJuly 12, 2026

BeOne Medicines initiates trial for BG-75098 in advanced solid tumors

A clinical trial is underway to assess the safety and efficacy of BG-75098, both alone and in combination with other agents.

ClinicalJuly 12, 2026

Text Messaging Improves Adherence to Oral Chemotherapy in ALL Patients

A study by the University of Chicago is evaluating the impact of text messaging on adherence to oral chemotherapy in patients with acute lymphoblastic leukemia.

RegulatoryJuly 12, 2026

FDA Accepts NDA for Trabectedin by Apotex

The FDA has accepted the New Drug Application (NDA) for Trabectedin submitted by Apotex.

CompetitiveJuly 12, 2026

Divarasib Study Targets KRAS G12C-Positive NSCLC Post-Chemoimmunotherapy

A study is underway to evaluate divarasib's efficacy against standard immunotherapy options in NSCLC patients.

ClinicalJuly 12, 2026

Phase II Trial of Osimertinib for NSCLC with EGFR Exon 20 Mutations

A phase II trial is underway to evaluate the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.

ClinicalJuly 12, 2026

NCI Study on High-Risk Breast/Ovarian Cancer Families to Enhance Genetic Understanding

The National Cancer Institute is conducting a study on families at high risk for breast and ovarian cancer, focusing on genetic and behavioral factors.

ClinicalJuly 12, 2026

Study on Predictors of Recurrence in Papillary Thyroid Carcinoma Initiated

An observational study aims to identify factors associated with recurrence in papillary thyroid carcinoma post-treatment.

ClinicalJuly 12, 2026

Single-cell analysis reveals immune evasion pathways in thyroid cancer metastasis

This study identifies LAG3 and TIGIT as critical immune checkpoints in thyroid cancer, challenging the efficacy of PD-1 blockade.

StrategyJuly 12, 2026

HPV Vaccination Shows Moderate Effectiveness in Women Aged 18-45 in China

A study found that HPV vaccination provides moderate protection against high-risk HPV DNA positivity in women aged 18-45 in China, with effectiveness increasing over time since vaccination.

ClinicalJuly 12, 2026

Immune Profiling in dMMR/MSI-H CRC Reveals Prognostic Insights and Immunotherapeutic Potential

The study identifies significant differences in immune cell infiltration and expression of IDO1 in dMMR/MSI-H CRC based on tumor stage, suggesting varying prognostic implications.

RegulatoryJuly 12, 2026

FDA Approves KEYTRUDA and KEYTRUDA QLEX for Muscle-Invasive Bladder Cancer

The FDA has approved KEYTRUDA and KEYTRUDA QLEX in combination with Padcev for MIBC treatment before and after surgery.

ClinicalJuly 12, 2026

EBV Reprograms Immune Escape in Nasopharyngeal Carcinoma, Impacting Immunotherapy Efficacy

EBV-driven immune reprogramming in NPC leads to poor responses to anti-PD-1 therapies due to alternative checkpoint exploitation.

RegulatoryJuly 12, 2026

FDA Accepts NDA for Vepdegestant by Arvinas Operations

The FDA has accepted the New Drug Application (NDA) for Vepdegestant, indicating progress towards potential approval.

ClinicalJuly 12, 2026

Galleri Test Trial in NHS Aims to Reduce Late-stage Cancer Diagnoses

The Galleri test, developed by GRAIL, Inc., is being evaluated in a large-scale trial to assess its effectiveness in early cancer detection.

ClinicalJuly 12, 2026

Phase II Trial Evaluates Radiation Therapy Plus Cisplatin for Head and Neck Cancer

A phase II trial is investigating the efficacy of radiation therapy with or without cisplatin in patients with stage III-IVA squamous cell carcinoma of the head and neck post-surgery.

ClinicalJuly 12, 2026

IL-12 GEMys Trial for Relapsed Solid Tumors Initiated by NCI

A clinical trial is underway to evaluate genetically engineered myeloid cells producing IL-12 in patients with relapsed or refractory solid tumors.

ClinicalJuly 12, 2026

Surufatinib Combination Trial for High-Risk Pancreatic Cancer Initiated

A trial is underway to evaluate surufatinib combined with gemcitabine and nab-paclitaxel in high-risk pancreatic cancer patients.

ClinicalJuly 11, 2026

Peptostreptococcus as a potential biomarker and therapeutic target in colorectal cancer

The oral bacterium Peptostreptococcus may influence colorectal cancer progression and serves as a potential biomarker.

RegulatoryJuly 11, 2026

FDA Grants AP Status for Ondansetron Hydrochloride Preservative Free

The FDA has granted approval status (AP) for the ANDA078945 application for Ondansetron Hydrochloride Preservative Free by Avet Lifesciences.

RegulatoryJuly 11, 2026

FDA Accepts Supplement Application for LAZCLUZE (Lazertinib Mesylate)

The FDA has accepted the supplemental application for LAZCLUZE, an EGFR inhibitor.

ClinicalJuly 11, 2026

Merck's Sacituzumab Tirumotecan in TNBC Shows Potential in Combination with Pembrolizumab

A study is evaluating sacituzumab tirumotecan alone and in combination with pembrolizumab for treating TNBC.

ClinicalJuly 11, 2026

Merck and Daiichi Sankyo Trial of Ifinatamab Deruxtecan in Advanced Esophageal Cancer

A clinical trial is underway to evaluate ifinatamab deruxtecan (I-DXd) for treating advanced esophageal squamous cell carcinoma.

ClinicalJuly 11, 2026

Advancements and Challenges in HPV Vaccine Development for Cancer Treatment

The review highlights significant progress in HPV vaccine development while addressing challenges like type replacement and the need for gender-inclusive vaccination.

StrategyJuly 11, 2026

FDA Grants Approval for Methotrexate Sodium ANDA219865 by Hetero Labs

The FDA has granted approval for the ANDA219865 application for Methotrexate Sodium submitted by Hetero Labs.

RegulatoryJuly 11, 2026

Lupin's ANDA for Fosaprepitant Dimeglumine Receives AP Status from FDA

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Lupin's Fosaprepitant Dimeglumine.

ClinicalJuly 11, 2026

Atebimetinib + GnP Study for Metastatic Pancreatic Adenocarcinoma Initiated

A clinical trial is underway to assess atebimetinib combined with modified GnP versus standard of care GnP in metastatic pancreatic adenocarcinoma.

ClinicalJuly 11, 2026

Study on Prebiotic Diet to Enhance Immunotherapy Response in Melanoma

A clinical trial is investigating the effects of a prebiotic food-enriched diet on the gut microbiome in melanoma patients undergoing immune checkpoint blockade therapy.

ClinicalJuly 11, 2026

Immunotherapy Shows Promise in Treating Soft-Tissue Sarcoma with Combination Strategies

Soft-tissue sarcoma (STS) is primarily immune-cold, but combination therapies and neoadjuvant strategies show promise in enhancing checkpoint inhibition responses.

RegulatoryJuly 11, 2026

FDA Submission for Cyclophosphamide by Hetero Labs Limited

Hetero Labs Limited has submitted an original application for Cyclophosphamide under ANDA219271 with standard review priority.

ClinicalJuly 11, 2026

Study Evaluates Tobacco Treatment Strategies for Cancer Survivors

A two-arm pragmatic cluster randomized trial is underway to compare the effectiveness of informatics-enabled strategies for tobacco treatment in cancer survivors.

ClinicalJuly 11, 2026

Study on Bioelectrical Impedance Analysis in Colorectal Cancer Surgery

A study is evaluating bioelectrical impedance analysis for assessing fluid balance in colorectal cancer surgery patients.

ClinicalJuly 11, 2026

AI Model Enhances STAS Detection in NSCLC for Improved Diagnostic Accuracy

A deep learning model for detecting spread through air spaces (STAS) in NSCLC shows high accuracy and agreement with pathologists.

RegulatoryJuly 11, 2026

Project Orbis Aims to Accelerate Cancer Drug Approvals

Project Orbis is designed to expedite the review and approval process for promising cancer therapies.

RegulatoryJuly 11, 2026

FDA Approves Pembrolizumab Combinations for Muscle Invasive Bladder Cancer

The FDA has approved pembrolizumab alone or in combination with berahyaluronidase alfa-pmph and enfortumab vedotin-ejfv for muscle invasive bladder cancer.

ClinicalJuly 11, 2026

Interfant-21 Study on Blinatumomab for Infants with KMT2A-rearranged ALL

The Interfant-21 study evaluates blinatumomab in infants under 1 year with KMT2A-rearranged acute lymphoblastic leukemia.

ClinicalJuly 11, 2026

Phase II/III Trial Evaluates Surgery vs. High-Dose Radiation for Limited Metastatic Breast Cancer

A randomized phase II/III trial is assessing the efficacy of adding stereotactic radiosurgery or surgery to standard care in limited metastatic breast cancer.

ClinicalJuly 11, 2026

GSK's Mo-Rez Evaluated in 1L Maintenance for HRd Ovarian Cancer in BEHOLD-Ovarian03 Trial

The BEHOLD-Ovarian03 trial is assessing the efficacy and safety of mocertatug rezetecan (Mo-Rez) in combination with bevacizumab versus bevacizumab alone in first-line maintenance treatment of HRd ovarian cancer.

ClinicalJuly 11, 2026

Study on Palliative Care Integration in Pediatric Oncology Phase 1 Trials

A study is proposed to evaluate the feasibility and impact of integrating pediatric palliative care in phase 1 oncology trials.

ClinicalJuly 11, 2026

Digital Tomosynthesis Mammography Shows Promise in Breast Cancer Screening

A randomized phase III trial suggests that digital tomosynthesis mammography may be superior to digital mammography for breast cancer screening.

RegulatoryJuly 11, 2026

FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment

The FDA has approved PADCEV in combination with Keytruda as a neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, regardless of cisplatin eligibility.

ClinicalJuly 11, 2026

Phase I/II Trial of STAR15 Combination Therapy for Metastatic Colorectal Cancer

A Phase I/II study is underway to evaluate a combination of four experimental therapies for metastatic colorectal cancer.

ClinicalJuly 11, 2026

Study to Develop Risk Prediction Model for Medication-Related Osteonecrosis of the Jaw

A prospective study aims to create a risk prediction model for medication-related osteonecrosis of the jaw using multimodal data.

ClinicalJuly 11, 2026

BeOne Medicines Initiates Study of BGB-16673 in CLL/SLL Patients Post-BTK and BCL2 Inhibitor Treatment

A clinical trial is underway to assess the efficacy and safety of BGB-16673 versus standard treatments in CLL/SLL patients previously treated with BTK and BCL2 inhibitors.

ClinicalJuly 11, 2026

Study on Plasma Tumor DNA as Predictor in Early-Stage Breast Cancer Treatment

A study is investigating the use of plasma tumor DNA to predict treatment response in early-stage breast cancer patients undergoing neoadjuvant therapy.

ClinicalJuly 10, 2026

Surufatinib plus FOLFOX/FOLFIRI shows potential in mCRC second-line therapy

A randomized phase-II trial is assessing surufatinib combined with FOLFOX/FOLFIRI against FOLFOXIRI for mCRC.

ClinicalJuly 10, 2026

POU2F2 identified as a key oncogenic and immunomodulatory factor in kidney cancer

POU2F2 is upregulated in kidney renal clear cell carcinoma and correlates with poor prognosis and macrophage polarization.

ClinicalJuly 10, 2026

Microbiota and Metabolites Influence Immunotherapy Response in Triple-Negative Breast Cancer

Microbiota and their metabolites may modulate immune responses and efficacy of immunotherapy in TNBC.

ClinicalJuly 10, 2026

AstraZeneca Evaluates Surovatamig for CLL/SLL Consolidation Therapy

AstraZeneca is conducting a trial to assess the safety and efficacy of Surovatamig as consolidation therapy in CLL/SLL patients with unmutated IGHV.

ClinicalJuly 10, 2026

NCI Launches Study on Malignant Mesothelioma for Tissue Procurement and Natural History

The National Cancer Institute is conducting a study to procure tissue samples from patients with malignant mesothelioma and other cancers expressing mesothelin.

ClinicalJuly 10, 2026

Intraoperative Fluid Exposure Affects Early Bowel Recovery in Colorectal Cancer Surgery

The study suggests that intraoperative fluid exposure may impact the time to first flatus after laparoscopic colorectal cancer surgery.

ClinicalJuly 10, 2026

Digital Health Intervention for Young Adult Cancer Survivors Under Study

A study is underway to evaluate a digital health intervention aimed at improving well-being in young adult cancer survivors.

ClinicalJuly 10, 2026

Phase II Trial of Neratinib and Palbociclib in HER2+ Solid Tumors Initiated

A phase II trial is underway to compare neratinib alone versus its combination with palbociclib in HER2 positive solid tumors.

ClinicalJuly 10, 2026

Novel ALA-HPO hybrids show enhanced efficacy in photodynamic therapy for superficial tumors

The study presents ALA-HPO derivatives that significantly improve PpIX yield and phototoxicity in treating superficial tumors.

ClinicalJuly 10, 2026

New Workflow for Isolating Microbiota from Pancreatic Tumors and Duodenum

A novel workflow for isolating bacteria and fungi from pancreatic tumors and duodenum has been developed, enabling functional studies of tumor-associated microbiota.

ClinicalJuly 10, 2026

FT-IR Spectroscopy Identifies Non-Invasive Biomarkers for Kidney Cancer Detection

FT-IR spectral analysis of urine and serum reveals biomarkers correlating with kidney cancer histological grade.

ClinicalJuly 10, 2026

Phase II Trial of HAL-PDT vs Surgery for High-Grade Squamous Intraepithelial Lesions

A Phase II trial is evaluating hexaminolevulinate photodynamic therapy (HAL-PDT) against immediate surgery for HSIL.

ClinicalJuly 10, 2026

Phase 3 Trial of SHR-8068, Adebrelimab, and Bevacizumab in Hepatocellular Carcinoma

A Phase 3 clinical trial is underway to assess the combination of SHR-8068, Adebrelimab, and Bevacizumab with TACE in patients with incurable hepatocellular carcinoma.

ClinicalJuly 10, 2026

Pembrolizumab Plus Enzalutamide Trial in mCRPC Shows Promise for Overall Survival

A study is underway to evaluate the efficacy of pembrolizumab combined with enzalutamide in mCRPC patients.

ClinicalJuly 10, 2026

Epcoritamab + Lenalidomide and Rituximab Outperforms Chemoimmunotherapy in R/R Follicular Lymphoma

Epcoritamab combined with lenalidomide and rituximab showed superior response rates and survival outcomes compared to standard chemoimmunotherapy.

ClinicalJuly 10, 2026

Phase III Trial of Tislelizumab and Lenvatinib in Unresectable Intrahepatic Cholangiocarcinoma

A Phase III trial is underway to compare the efficacy of TACE plus tislelizumab and lenvatinib against GEMCIS plus tislelizumab in patients with unresectable intrahepatic cholangiocarcinoma.

ClinicalJuly 10, 2026

Traditional Chinese Medicine Enhances Efficacy of Immune Checkpoint Inhibitors

Traditional Chinese medicine (TCM) can enhance the efficacy of immune checkpoint inhibitors (ICIs) and reduce their toxicity.

ClinicalJuly 10, 2026

Fluoxetine Janus dendrimer shows potent anticancer activity against MCF-7 cells

Fluoxetine Janus dendrimers demonstrated significant cytotoxicity against MCF-7 cancer cells, indicating potential for new treatment strategies.

RegulatoryJuly 10, 2026

FDA Grants Priority Review for KISQALI FEMARA Co-Packaged Product

The FDA has granted priority review for the co-packaged product KISQALI FEMARA, which includes letrozole and ribociclib succinate.

ClinicalJuly 10, 2026

Phase 2 Trial of Chemoimmunotherapy with DC Vaccines for Recurrent Ovarian Cancer

A Phase 2 trial is evaluating the combination of locoregional chemoimmunotherapy and DC vaccines in advanced ovarian cancer.

ClinicalJuly 10, 2026

Novartis initiates study on Alpelisib and Fulvestrant for advanced HR+ breast cancer

Novartis is conducting a study to evaluate the efficacy and safety of alpelisib plus fulvestrant in HR-positive, HER2-negative advanced breast cancer patients who have progressed after prior treatments.

RegulatoryJuly 9, 2026

FDA Grants Priority Review for KISQALI Supplement by Novartis

The FDA has granted priority review for the supplemental NDA for KISQALI (ribociclib succinate) submitted by Novartis.

RegulatoryJuly 9, 2026

Study on Pharmacokinetics and Drug Side Effects by NCI

The National Cancer Institute is collecting blood samples from patients experiencing significant drug side effects to study their pharmacokinetics.

ClinicalJuly 9, 2026

Phase I Study of [14C]Zorifertinib Shows Promising Safety and Pharmacokinetics

[14C]Zorifertinib is undergoing Phase I study to evaluate its safety and pharmacokinetics in healthy males.

ClinicalJuly 9, 2026

Study on PCSK9 and PD-1 Inhibitors in Locally Advanced Rectal Cancer

A clinical study is evaluating the efficacy and safety of combining PCSK9 inhibitors and PD-1 inhibitors with neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.

ClinicalJuly 9, 2026

Correlative Study on Epcoritamab in CLL and Richter Syndrome by NHLBI

A correlative study is being conducted to analyze the pharmacodynamic effects of epcoritamab in patients with chronic lymphocytic leukemia and Richter syndrome.

ClinicalJuly 9, 2026

Novel compound AG3 shows promise for targeting p53-Y220C mutation in gastric cancer

AG3, a compound with zinc chelation and Michael acceptor properties, effectively reactivates p53-Y220C in gastric cancer cells.

ClinicalJuly 9, 2026

Trial of Traditional Chinese Medicine Patch for Cancer-Related Fatigue in Radiotherapy Patients

A randomized controlled trial is evaluating the efficacy of a traditional Chinese medicine patch on cancer-related fatigue during radiotherapy.

ClinicalJuly 9, 2026

Pilot Study Combining Immunotherapy and Thermal Therapy in HER2-Negative Breast Cancer

A pilot study is underway to evaluate the combination of neoadjuvant chemotherapy, immunotherapy, and multimodal thermal therapy in HER2-negative breast cancer patients.

ClinicalJuly 9, 2026

Phase 2b Study of JX-594 in Advanced Liver Cancer Patients Failing Sorafenib

A Phase 2b study is evaluating the efficacy of JX-594 (Pexa-Vec) combined with best supportive care in advanced HCC patients who have not responded to sorafenib.

ClinicalJuly 9, 2026

Phase I/II Trial of Iberdomide in Relapsed Neuroblastoma Shows Potential Efficacy

A phase I/II trial is investigating the safety and efficacy of iberdomide combined with chemoimmunotherapy in patients with relapsed or refractory neuroblastoma.

ClinicalJuly 9, 2026

Phase II Trial of TPST-1495 in Familial Adenomatous Polyposis Patients

The NCI is conducting an open-label phase II trial to evaluate the efficacy of TPST-1495 in reducing polyps in FAP patients.

ClinicalJuly 9, 2026

Study on Diabetes Care Improvement for Breast Cancer Patients

A clinical trial is investigating the impact of trained diabetes care nurses on breast cancer patients with diabetes.

ClinicalJuly 9, 2026

Advancements in Single-Cell and Spatial Transcriptomics for Pancreatic Cancer Insights

The review highlights the potential of single-cell RNA sequencing and spatial transcriptomics to uncover mechanisms of therapeutic resistance in pancreatic ductal adenocarcinoma.

ClinicalJuly 9, 2026

HPV Vaccination Shows High Efficacy Against Cancer and Precancer Outcomes

HPV vaccination demonstrates 99% efficacy against HPV16/18 infection and significant reductions in cervical cancer rates.

StrategyJuly 9, 2026

FDA Accepts ANDA for Capecitabine by Reliance Life

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Capecitabine submitted by Reliance Life.

ClinicalJuly 9, 2026

Phase I Trial of Adze1.C in Advanced Melanoma Shows Promise

A Phase I clinical trial is underway to evaluate the safety and preliminary efficacy of Adze1.C in patients with metastatic melanoma.

ClinicalJuly 9, 2026

Music Therapy May Alleviate Pain and Distress in Lung Cancer Surgery Patients

A study is evaluating the effectiveness of music therapy in reducing distress and pain for lung cancer patients undergoing surgery.

StrategyJuly 9, 2026

FDA Grants AP Status for Capecitabine ANDA210203 by Hetero Labs

Hetero Labs has received an Abbreviated Approval (AP) for their ANDA210203 application for Capecitabine.

ClinicalJuly 9, 2026

Study on Cyberknife for Melanoma Brain Metastasis Aims to Improve Treatment Strategies

A clinical trial is underway to evaluate the effectiveness of stereotactic radiosurgery combined with immunotherapy or targeted therapy for melanoma brain metastases.

ClinicalJuly 9, 2026

NCI Launches Study on Outcomes and Risks of Rare CNS Tumors

The National Cancer Institute is conducting a study to assess outcomes and risks in patients with 12 rare CNS tumors.

ClinicalJuly 9, 2026

NCI Study Provides Standard Cancer Care for Non-Trial Patients

The NCI is offering standard cancer care to patients not enrolled in active treatment protocols, focusing on those with complex needs.

ClinicalJuly 9, 2026

Phase II/III Trial Evaluates Docetaxel-Cetuximab with Atezolizumab in High-Risk Head and Neck Cancer

A phase II/III trial is assessing the efficacy of combining radiation therapy with docetaxel, cetuximab, and atezolizumab in high-risk head and neck cancer patients.

CompetitiveJuly 9, 2026

City of Hope Initiates Liquid Biopsy Study for Early Colorectal Cancer Detection

A new study is underway to develop a non-invasive liquid biopsy assay using cf-circRNAs for early detection of colorectal cancer.

ClinicalJuly 9, 2026

Phase II Trial of Canakinumab in High-Risk Former Smokers Launched

A phase II trial is underway to evaluate canakinumab's effects on former smokers at increased cancer risk.

ClinicalJuly 9, 2026

FAST-GO Study Evaluates Physical Function in Gastroesophageal Cancer Patients Undergoing Chemotherapy

The FAST-GO study assesses the impact of systemic therapy on physical function in adults with Stage I-III gastroesophageal cancer.

ClinicalJuly 8, 2026

Case Study: Melanoma Patient with Brain Metastases and DVT Managed with Immunotherapy and Thrombectomy

A 62-year-old melanoma patient with brain metastases and DVT was treated with combination immunotherapy and mechanical thrombectomy.

ClinicalJuly 8, 2026

UBE2C identified as a key driver in pancreatic cancer via PI3K/Akt/mTOR pathway

UBE2C is overexpressed in pancreatic cancer, promoting progression through the PI3K/Akt/mTOR pathway.

ClinicalJuly 8, 2026

Bristol-Myers Squibb Evaluates Pomalidomide Outcomes in Relapsed/Refractory Multiple Myeloma

A retrospective study will assess clinical outcomes of pomalidomide regimens in relapsed/refractory multiple myeloma.

RegulatoryJuly 8, 2026

FDA Grants Approval for Everolimus ANDA219464

The FDA has granted approval for the ANDA219464 application for Everolimus submitted by I3 PHARMS.

RegulatoryJuly 8, 2026

FDA Accepts Supplement Application for ERLEADA (Apalutamide)

The FDA has accepted a supplemental application for ERLEADA, a drug developed by Janssen Biotech.

RegulatoryJuly 8, 2026

FDA Approves Supplemental Application for TRUXIMA (Rituximab-ABBS)

The FDA has approved a supplemental application for TRUXIMA, a biosimilar to Rituximab, developed by Celltrion.

RegulatoryJuly 8, 2026

FDA Approves Supplemental NDA for HEPZATO by Delcath Systems

The FDA has approved a supplemental NDA for HEPZATO, which contains melphalan hydrochloride.

ClinicalJuly 8, 2026

Brentuximab Vedotin Study in CD30-positive Lymphoma Launched by Takeda

A new study has been initiated to evaluate the safety and usage of brentuximab vedotin in adults with CD30-positive lymphoma.

ClinicalJuly 8, 2026

Preclinical SNAP™-TIL therapy shows promise for broader cancer treatment efficacy

The SNAP™ technology platform enhances TIL therapy by enriching T cells with personalized neoantigens, leading to improved efficacy in cancer models.

RegulatoryJuly 8, 2026

Teva's Nilotinib Hydrochloride ANDA219134 Receives AP Status from FDA

Teva Pharmaceuticals has received an Abbreviated New Drug Application (ANDA) approval status for Nilotinib Hydrochloride.

RegulatoryJuly 8, 2026

FDA Accepts Supplement for COLUMVI (GLOFITAMAB-GXBM) by Genentech

The FDA has accepted a supplemental biologics license application for COLUMVI, a bispecific T-cell engager.

CompetitiveJuly 8, 2026

Phase II Study of JS212 Plus JS111 in EGFR-Mutant NSCLC Initiated by Shanghai Junshi Bioscience

A Phase II study is underway to evaluate JS212 in combination with JS111 for advanced NSCLC patients with EGFR mutations.

ClinicalJuly 8, 2026

Bayer's Study on Darolutamide in Advanced Prostate Cancer to Assess Real-World Effectiveness

Bayer is conducting a multicenter observational study to evaluate darolutamide's effectiveness in metastatic hormone-sensitive prostate cancer.

ClinicalJuly 8, 2026

Multicenter Trial Comparing Surgery and Systemic Therapy in Stage IV Breast Cancer

A national multicenter trial is underway to compare 5-year overall survival between surgery followed by systemic therapy and systemic therapy alone in Stage IV breast cancer patients with solitary bone metastases.

ClinicalJuly 8, 2026

Phase II Trial of Becotatug Vedotin with Tislelizumab and Lenvatinib in Advanced ESCC

A Phase II trial is underway to evaluate the combination of Becotatug Vedotin, Tislelizumab, and low-dose Lenvatinib in patients with advanced ESCC post first-line treatment failure.

ClinicalJuly 8, 2026

Catch-up vaccination safe and effective in children with Kaposiform hemangioendothelioma on sirolimus

Catch-up vaccinations in children with Kaposiform hemangioendothelioma treated with sirolimus were safe and immunogenic.

RegulatoryJuly 8, 2026

FDA Accepts Supplement Application for VANFLYTA (Quizartinib)

The FDA has accepted a supplemental application for VANFLYTA, a drug containing quizartinib dihydrochloride.

RegulatoryJuly 8, 2026

FDA Accepts Application for PAVBLU (Aflibercept-AYYH) from Amgen

The FDA has accepted the application for PAVBLU, a biologic therapy containing Aflibercept-AYYH.

ClinicalJuly 8, 2026

Study on MyCap App for Monitoring Radiation Dermatitis in Head and Neck Cancer Patients

A study is underway to evaluate the MyCap mobile app for tracking radiation-induced skin rash in head and neck cancer patients.

ClinicalJuly 8, 2026

Phase 1 Trial of LMP744 in Recurrent Glioblastoma Shows Potential for New Treatment

A clinical trial is underway to evaluate the safety and efficacy of LMP744, a novel indenoisoquinolone inhibitor, in patients with recurrent glioblastoma.

ClinicalJuly 8, 2026

PG2 Study to Evaluate Survival Benefits in Early Breast Cancer Patients Undergoing Adjuvant Therapy

The PG2 study aims to assess the survival benefits of adding APS to adjuvant chemotherapy in breast cancer patients.

ClinicalJuly 8, 2026

177Lu-DOTA-EB-TATE Trial for Metastatic Hurthle-Cell Thyroid Cancer Initiated

A clinical trial is underway to evaluate 177Lu-DOTA-EB-TATE in adult patients with metastatic Hurthle-cell thyroid cancer.

ClinicalJuly 8, 2026

Study on JNJ-56021927 and Abiraterone in Metastatic Prostate Cancer

The study aims to evaluate drug-drug interactions and safety of JNJ-56021927 with abiraterone acetate and prednisone.

ClinicalJuly 7, 2026

TGFA identified as key regulator in cervical cancer progression via DSG2 interaction

TGFA promotes cervical cancer progression by interacting with DSG2, enhancing cell proliferation and metastasis.

ClinicalJuly 7, 2026

Thyroid cancer exosomal SPP1 drives macrophage M2 polarization and tumor progression

Thyroid cancer-derived exosomal SPP1 promotes macrophage M2 polarization, contributing to tumor progression.

CompetitiveJuly 7, 2026

Apotex submits supplemental ANDA for Pomalidomide

Apotex has submitted a supplemental abbreviated new drug application (ANDA) for Pomalidomide.

RegulatoryJuly 7, 2026

FDA Acceptance of Lenalidomide Supplement by Alvogen

The FDA has accepted the supplemental application for Lenalidomide submitted by Alvogen.

RegulatoryJuly 7, 2026

FDA Accepts Supplement for Lenalidomide by Biocon Pharma

The FDA has accepted a supplemental application for Lenalidomide submitted by Biocon Pharma.

ClinicalJuly 7, 2026

Pilot Study of Optune for Recurrent Atypical and Anaplastic Meningioma Initiated

A pilot study is underway to evaluate the effects of the Optune device on recurrent atypical and anaplastic meningioma, which currently lacks effective treatments.

ClinicalJuly 7, 2026

Evaluation of 18F-AIPF-1026 PET/CT in MAO-A-Related Diseases

A clinical trial is underway to assess the utility of 18F-AIPF-1026 PET/CT for diagnosing lesions in MAO-A-related diseases.

ClinicalJuly 7, 2026

Merck and Daiichi Sankyo Launch ESCC Combination Therapy Study with Pembrolizumab

Merck Sharp & Dohme and Daiichi Sankyo are conducting a study on combination therapies for esophageal squamous cell carcinoma, evaluating pembrolizumab with investigational agents and chemotherapy.

ClinicalJuly 7, 2026

Janssen initiates rollover study for long-term safety in multiple cancers

Janssen is conducting a rollover study to gather long-term safety data for participants with various cancers.

ClinicalJuly 7, 2026

Janssen's Amivantamab Study in Advanced NSCLC Evaluates Safety and Efficacy

The study aims to assess the safety and efficacy of Amivantamab as a monotherapy and in combination with lazertinib and chemotherapy in advanced NSCLC.

CompetitiveJuly 7, 2026

Novel bispecific T-cell engagers show promise against EGFR resistance in cancer

New bispecific T-cell engagers targeting EGFR escape variants show effective T cell-mediated cytotoxicity.

RegulatoryJuly 7, 2026

FDA Accepts Supplement Application for Lenalidomide by Zydus Pharmaceuticals

The FDA has accepted a supplemental application for lenalidomide submitted by Zydus Pharmaceuticals.

ClinicalJuly 7, 2026

Phase 1b/2 Study of JNJ-90014496 for B-Cell Non-Hodgkin Lymphoma Initiated by Janssen

Janssen is conducting Phase 1b/2 study of prizloncabtagene autoleucel, CAR T-cell therapy targeting CD20 and CD19 in B-NHL.

ClinicalJuly 7, 2026

Janssen initiates study on erdafitinib intravesical delivery for bladder cancer in Japan

A clinical trial is underway to assess the tolerability of an intravesical delivery system for erdafitinib in Japanese patients with bladder cancer.

ClinicalJuly 7, 2026

JNJ-87562761 Phase 2 Study Initiated for Relapsed/Refractory Multiple Myeloma

Janssen is conducting a study to establish the recommended phase 2 dose and assess safety of JNJ-87562761 in relapsed or refractory multiple myeloma patients.

ClinicalJuly 7, 2026

Study on Biomarkers for Predicting Recurrence in Colorectal Cancer Launched

A new study aims to explore biomarkers for predicting local recurrence and distant metastasis in colorectal cancer.

ClinicalJuly 7, 2026

Bayer's Study on ARPI Use in mHSPC Patients in Australia Aims to Inform Clinical Practice

Bayer is conducting a retrospective observational study to analyze real-world data on Androgen Receptor Pathway Inhibitors in men with metastatic hormone-sensitive prostate cancer in Australia.

ClinicalJuly 7, 2026

Study on Utidelone's Efficacy in HER-2 Negative Advanced Breast Cancer

A randomized controlled study is evaluating the efficacy of Utidelone Capsule versus Utidelone Injection in combination with Capecitabine for HER-2 negative advanced breast cancer.

ClinicalJuly 7, 2026

Phase 2 Study of Lisaftoclax and Pirtobrutinib in Relapsed Mantle Cell Lymphoma

A phase 2 study is underway to assess the efficacy and safety of lisaftoclax combined with pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma after BTK-targeted therapy.

ClinicalJuly 7, 2026

Janssen's Amivantamab and Docetaxel Combo in NSCLC Enters Phase 1/2 Trials

Janssen is conducting Phase 1/2 study to evaluate the combination of amivantamab and docetaxel in metastatic NSCLC patients without oncogenic driver mutations.

ClinicalJuly 7, 2026

Phase Ib/II Study of Becotatugvedotin with Gemcitabine in Advanced PDAC

A Phase Ib/II trial is evaluating the combination of becotatugvedotin and gemcitabine in patients with advanced second-line pancreatic ductal adenocarcinoma.

ClinicalJuly 7, 2026

Phase III Trial of Toripalimab and Lenvatinib for Advanced HCC Initiated

A Phase III study has been initiated to evaluate Toripalimab combined with Lenvatinib versus placebo in advanced HCC.

ClinicalJuly 7, 2026

Circular RNAs as Potential Biomarkers in Cancer Diagnosis and Prognosis

Circular RNAs (circRNAs) are dysregulated in cancer and may serve as biomarkers for diagnosis and prognosis.

ClinicalJuly 7, 2026

KIBRA identified as a tumor suppressor in osteosarcoma via Wnt/β-catenin inhibition

KIBRA overexpression suppresses osteosarcoma cell proliferation and migration while impairing DNA damage repair.

ClinicalJuly 7, 2026

RBM15B/FOXM1/AURKA/TPX2 axis identified as key driver in endometrial cancer progression

RBM15B-mediated m6A modification of FOXM1 promotes endometrial cancer progression via the AURKA/TPX2 axis.

StrategyJuly 7, 2026

Amneal's Lenalidomide ANDA216213 Receives Abbreviated Approval

Amneal's abbreviated new drug application (ANDA216213) for Lenalidomide has received approval from the FDA.

RegulatoryJuly 7, 2026

FDA Accepts Supplement Application for Lenalidomide by Accord Healthcare

The FDA has accepted a supplemental application for Lenalidomide submitted by Accord Healthcare.

StrategyJuly 7, 2026

Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA

Cipla has received an abbreviated approval (AP) for its ANDA210435 application for Lenalidomide.

StrategyJuly 7, 2026

FDA Approves ANDA for Pomalidomide by Hetero Labs

The FDA has approved ANDA210236 for pomalidomide submitted by Hetero Labs.

RegulatoryJuly 7, 2026

EUGIA PHARMA receives AP status for POMALIDOMIDE supplement

EUGIA PHARMA has received an Abbreviated Approval (AP) for a supplement related to POMALIDOMIDE.

RegulatoryJuly 7, 2026

Teva Pharmaceuticals submits supplemental application for Pomalidomide

Teva Pharmaceuticals has submitted a supplemental application for Pomalidomide under ANDA209956.

ClinicalJuly 7, 2026

Phase 2 Trial of Botensilimab + Balstilimab in Chemo-refractory Colorectal Cancer

A Phase 2 trial is investigating the efficacy and safety of botensilimab and balstilimab in patients with unresectable colorectal adenocarcinoma.

RegulatoryJuly 6, 2026

FDA Accepts Supplement Application for Lenalidomide by QILU

The FDA has accepted a supplemental application for Lenalidomide submitted by QILU.

StrategyJuly 6, 2026

FDA Accepts Lenalidomide ANDA217281 Submission from Novugen

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Lenalidomide submitted by Novugen.

ClinicalJuly 6, 2026

SonoCloud-9 Enhances Carboplatin Delivery in Recurrent Glioblastoma Trial

The SonoCloud-9 device aims to enhance the delivery of carboplatin to brain tumors by temporarily opening the blood-brain barrier.

ClinicalJuly 6, 2026

Study on Laparoscopic Techniques for Gastric Cancer Quality of Life

A clinical trial is underway to compare the short-term quality of life outcomes between two surgical techniques for gastric cancer.

ClinicalJuly 6, 2026

PRX5 identified as key regulator in colorectal cancer stem cell formation

The study highlights PRX5's role in sustaining colorectal cancer stem cell identity and tumorigenicity.

ClinicalJuly 6, 2026

New Orthotopic Model Reveals CD8⁺ T Cell Dysfunction in Colorectal Cancer Immunotherapy

A novel orthotopic organoid-based model for colorectal cancer demonstrates CD8⁺ T cell dysfunction and responsiveness to anti-PD-1 therapy.

RegulatoryJuly 6, 2026

FDA Accepts Supplement Application for Lenalidomide by Apotex

The FDA has accepted a supplemental application for lenalidomide submitted by Apotex.

RegulatoryJuly 6, 2026

FDA Acceptance of Lenalidomide Supplement Application by Mylan

The FDA has accepted Mylan's supplemental application for Lenalidomide under ANDA213912.

RegulatoryJuly 6, 2026

FDA Accepts Supplement Application for Lenalidomide by Dr. Reddy's

The FDA has accepted a supplemental application for lenalidomide submitted by Dr.

StrategyJuly 6, 2026

Cipla's Lenalidomide ANDA213165 Receives AP Status from FDA

Cipla's Abbreviated New Drug Application (ANDA) for Lenalidomide has received an Approval Pending (AP) status from the FDA.

StrategyJuly 6, 2026

Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval

Lupin has received abbreviated approval for its ANDA214398 application for Lenalidomide.

RegulatoryJuly 6, 2026

FDA Approves Supplemental Application for Thalidomide (Thalomid)

The FDA has approved a supplemental application for Thalomid (thalidomide) submitted by Bristol-Myers.

RegulatoryJuly 6, 2026

FDA Acceptance of POMALIDOMIDE Supplement by Breckenridge

The FDA has accepted the supplemental application for POMALIDOMIDE submitted by Breckenridge.

ClinicalJuly 6, 2026

NCI Study on Specimen Collections from HIV and KSHV Patients

The National Cancer Institute is conducting a study to collect various biological samples from participants with HIV and KSHV infections, as well as related cancers.

CompetitiveJuly 6, 2026

Corcept initiates study of nenocorilant with nivolumab in advanced solid tumors

Corcept Therapeutics is conducting a dose-finding study of nenocorilant combined with nivolumab in advanced solid malignancies.

ClinicalJuly 6, 2026

Phase I Trial of Novobiocin Targets Cancer with DNA Repair Gene Alterations

A phase I trial is underway to evaluate the safety and optimal dosing of novobiocin in cancer patients with DNA repair gene alterations.

StrategyJuly 6, 2026

FDA Grants Approval for Thalidomide ANDA213267 by NATCO

The FDA has granted approval for ANDA213267, a generic version of Thalidomide, submitted by NATCO.

ClinicalJuly 6, 2026

Magrolimab and Pembrolizumab Combination Study in Hodgkin Lymphoma Initiated

A clinical trial is underway to evaluate the safety and efficacy of magrolimab combined with pembrolizumab in relapsed or refractory classic Hodgkin lymphoma.

ClinicalJuly 6, 2026

Phase I Trial of CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies

A phase I trial is investigating the efficacy and safety of CD19/CD22 CAR T cells combined with chemotherapy in children and young adults with recurrent or refractory B acute lymphoblastic leukemia.

ClinicalJuly 6, 2026

Study on Panitumumab-IRDye800 for Pediatric Tumor Detection in Neurosurgery

A study is underway to evaluate the safety of panitumumab-IRDye800 in pediatric patients during neurosurgical procedures.

ClinicalJuly 6, 2026

Study on Semiconductor Headbands for Cognitive Impairment in Cancer Patients

A clinical trial is investigating the feasibility and effectiveness of semiconductor embedded headbands for cognitive impairment in breast and gynecological cancer patients.

ClinicalJuly 5, 2026

Study Compares Induction Plus Consolidation vs. Consolidation-Only in NSCLC Immunotherapy

The study evaluates the efficacy and safety of two immunotherapy sequencing strategies in unresectable stage III NSCLC.

RegulatoryJuly 5, 2026

Karyopharm's XPOVIO (Selinexor) NDA Supplement Receives Approval from FDA

The FDA has approved the NDA supplement for Karyopharm's XPOVIO (Selinexor), indicating a successful submission.

RegulatoryJuly 5, 2026

FDA Accepts Supplemental Application for PERJETA by Genentech

The FDA has accepted a supplemental application for PERJETA (pertuzumab) from Genentech.

ClinicalJuly 5, 2026

Study on Glutamine and Thalidomide for Radiation-Induced Oral Mucositis

A clinical trial is underway to assess the efficacy of glutamine combined with thalidomide in preventing radiation-induced oral mucositis.

ClinicalJuly 5, 2026

Genentech's Belvarafenib Trial in NRAS-mutant Advanced Melanoma Initiated

A study is underway to evaluate belvarafenib's safety and activity as a monotherapy and in combination with cobimetinib and nivolumab in NRAS-mutant advanced melanoma patients.

ClinicalJuly 5, 2026

Phase I Trial of CAR T Cells with Chlorotoxin for MMP2+ Recurrent Glioblastoma

A phase I trial is underway to evaluate CAR T cells targeting MMP2+ glioblastoma, focusing on safety and dosing.

ClinicalJuly 5, 2026

Kyowa Kirin initiates first-in-human trial for KK2223 in T Cell Non-Hodgkin Lymphoma

Kyowa Kirin is conducting a first-in-human study to evaluate KK2223 in patients with relapsed or refractory T cell lymphoma.

ClinicalJuly 5, 2026

Phase II/III Trial of Nivolumab and Ipilimumab for Advanced Melanoma Initiated

A Phase II/III trial is investigating the efficacy and safety of nivolumab and ipilimumab with or without sargramostim in patients with unresectable advanced melanoma.

ClinicalJuly 5, 2026

NCI Trials CD19/CD22 CAR T Cells for Refractory B Cell Malignancies in Young Patients

A clinical trial is underway testing a novel CD19/CD22 bicistronic CAR T-cell therapy for children and young adults with recurrent or refractory B cell malignancies.

ClinicalJuly 5, 2026

Tyra Biosciences initiates Phase 2A/B trial of Dabogratinib for Low Grade Upper Tract Urothelial Carcinoma

Tyra Biosciences is conducting Phase 2A/B trial to evaluate the efficacy and safety of Dabogratinib in patients with Low Grade Upper Tract Urothelial Carcinoma.

ClinicalJuly 5, 2026

Study on Respiratory Muscle Strength Training in Breast Cancer Surgery Patients

A clinical trial is investigating the efficacy of respiratory muscle strength training to prevent muscle weakness in adults newly diagnosed with breast cancer undergoing surgery.

ClinicalJuly 5, 2026

Study on Incidental Thyroid Cancer in Autoimmune Thyroiditis Patients Launched

A new clinical trial has been initiated to evaluate the incidence of thyroid cancer in patients with autoimmune thyroiditis.

ClinicalJuly 5, 2026

Nursing-led Mobile Health Study Aims to Improve Outcomes in Breast Cancer Chemotherapy

A study is underway to evaluate the impact of mobile health information combined with nursing support on breast cancer patients undergoing chemotherapy.

ClinicalJuly 5, 2026

Neoadjuvant Therapy Trial for Head and Neck Squamous Cell Carcinoma Initiated

A clinical trial is evaluating the safety and tolerability of a combination of immune-targeted therapy and lysogenic HSV-based virotherapy in patients with resectable head and neck squamous cell carcinoma.

ClinicalJuly 5, 2026

Discovery of EGFR L858R-targeting peptide shows promise against ovarian cancer

Peptide-1 demonstrates strong binding affinity to EGFR L858R and antiproliferative activity against ovarian cancer cells.

ClinicalJuly 5, 2026

Novel tumor inflammation score predicts outcomes in NSCLC patients treated with pembrolizumab and gemcitabine

A novel tumor inflammation score based on Treg/T cell relationships predicts treatment outcomes better than traditional biomarkers in NSCLC.

ClinicalJuly 5, 2026

CENPI identified as a promoter of hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway

CENPI is linked to hepatocellular carcinoma progression through activation of the PI3K/AKT/mTOR-CDK2 cascade.

StrategyJuly 5, 2026

Sandoz Receives FDA Approval for Enzalutamide ANDA216068

Sandoz has received FDA approval for its Abbreviated New Drug Application (ANDA) for Enzalutamide.

ClinicalJuly 5, 2026

Trial on EBUS-TBNA with Suction for Lung Cancer Sample Collection

This trial evaluates the efficacy of EBUS-TBNA with suction in improving sample quality from suspected metastatic lung cancer patients.

ClinicalJuly 5, 2026

Phase 2 Trial of Pembrolizumab for Poor-Prognosis CUP Patients Initiated

A Phase 2 trial has been initiated to evaluate pembrolizumab in treatment-naïve patients with poor-prognosis carcinoma of unknown primary site.

ClinicalJuly 5, 2026

NCI Launches Repository for Pediatric and Adult Common Childhood Cancers Samples

The National Cancer Institute is establishing a tissue repository for samples from patients with common childhood cancers.

CompetitiveJuly 5, 2026

Nurix Therapeutics initiates NX-5948 study for relapsed CLL/SLL post-BTK and BCL-2 therapy

Nurix Therapeutics is conducting a trial for NX-5948 in patients with relapsed/refractory CLL/SLL who have previously been treated with BTK and BCL-2 inhibitors.

RegulatoryJuly 4, 2026

Alembic's Methotrexate Sodium ANDA220225 Receives AP Status from FDA

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Methotrexate Sodium submitted by Alembic.

RegulatoryJuly 4, 2026

Evaluation of RonovoTM Robotic Surgical Platform in Oncological Procedures

A prospective registry is assessing the safety and performance of the RonovoTM robotic platform in oncological surgeries.

ClinicalJuly 4, 2026

BMS initiates trial for Imzokitug in NSCLC with Pumitamig and chemotherapy

Bristol-Myers Squibb is conducting a study to evaluate Imzokitug combined with Pumitamig and PDCT in NSCLC.

ClinicalJuly 4, 2026

Study on Predictive Model for Pancreatic Cancer Prognosis Using Multimodal Data

An observational study aims to evaluate the efficacy of a predictive model combining CT scans, blood tests, and pathology reports for pancreatic cancer prognosis.

ClinicalJuly 4, 2026

SHR-8068 Trial in Resectable Hepatocellular Carcinoma Shows Promise

A trial is evaluating SHR-8068 combined with Adebrelimab and Apatinib for resectable hepatocellular carcinoma.

RegulatoryJuly 4, 2026

FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs

The FDA has accepted the supplemental application ANDA205254 for Zoledronic Acid submitted by Mylan Labs.

ClinicalJuly 4, 2026

Study on Blood Markers for Early Detection of Pancreatic Cancer Initiated

A study is underway to collect blood samples for detecting potential pancreatic cancer markers and creating a biobank.

ClinicalJuly 4, 2026

Study on Femtosecond Laser Imaging for Intraoperative Lung Diagnosis

A multicenter study is evaluating femtosecond laser imaging combined with AI for lung tumor diagnosis, comparing it to standard methods.

ClinicalJuly 4, 2026

Pilot Study on Immune Response After SABR in Stage I NSCLC

This pilot study aims to assess immune-mediated tumor recognition following SABR in stage I NSCLC using TCR sequencing.

ClinicalJuly 4, 2026

Study on 188Re-SSS Lipiodol SIRT for Non-Operable Liver Cancer Initiated

A monocentric interventional study is underway to evaluate the efficacy of 188Re-SSS lipiodol selective internal radiation therapy (SIRT) in patients with non-operable hepatocellular carcinoma (HCC).

ClinicalJuly 4, 2026

BrainChild Bio Initiates CAR T Therapy Study for DIPG Patients

BrainChild Bio is evaluating BCB-276, B7-H3-targeted CAR T cell therapy, in a clinical trial for DIPG patients.

ClinicalJuly 4, 2026

Phase 2 Study on Locally Ablative Therapy for Oligo-progressive Solid Tumors Initiated

A phase 2 study is underway to assess the benefits of combining systemic therapy with locally ablative therapies for oligo-progressive solid tumors.

StrategyJuly 4, 2026

Study Reveals Barriers to HPV Vaccine Uptake in South Quito, Ecuador

A qualitative study identified key barriers to HPV vaccine uptake among parents and healthcare providers in Quito, Ecuador, including misinformation and fear of side effects.

ClinicalJuly 4, 2026

Study on Vidutolimod and Nivolumab in Melanoma Treatment

The study aims to assess the efficacy of nivolumab alone versus in combination with Vidutolimod (CMP-001) in treating melanoma.

ClinicalJuly 4, 2026

IBR733 Cell Injection Shows Promise in Relapsed/Refractory Acute Myeloid Leukemia

The phase Ia study of IBR733 cell injection is evaluating its safety, tolerability, and preliminary efficacy in relapsed/refractory AML.

ClinicalJuly 4, 2026

Discovery of DP8α Tregs in Colorectal Cancer Reveals New Immune Suppression Mechanism

DP8α regulatory T cells are significantly enriched in colorectal cancer tumors and exhibit a suppressive phenotype.

ClinicalJuly 4, 2026

Integrating Immune Landscape Insights to Enhance Breast Cancer Management

The study highlights the heterogeneity of breast cancer and the potential of integrating immune parameters into treatment decision-making.

ClinicalJuly 4, 2026

Chimeric CCL2 and CCL8 Peptides Show Antitumor Activity in Breast Cancer

Chimeric peptides combining CCL2 and CCL8 with diphtheria toxin demonstrate effective antitumor activity against human breast tumors.

ClinicalJuly 4, 2026

Insights into RNA Polymerase II Phosphorylation Dynamics and Disease Implications

Disruption of RNA polymerase II phosphorylation dynamics is linked to various diseases, including cancer and neurodegeneration.

RegulatoryJuly 4, 2026

FDA Grants AP Status for Ondansetron Hydrochloride Preservative Free

The FDA has granted approval status (AP) for Ondansetron Hydrochloride Preservative Free submitted by ONESOURCE SPECIALTY.

StrategyJuly 4, 2026

FDA Grants Approval for Ondansetron Hydrochloride ANDA078257

The FDA has granted approval for ANDA078257, a generic formulation of Ondansetron Hydrochloride by ONESOURCE SPECIALTY.

RegulatoryJuly 4, 2026

FDA Accepts Supplement Application for ONTRUZANT (Trastuzumab-DTTB)

The FDA has accepted the supplemental application for ONTRUZANT, a biosimilar to trastuzumab.

RegulatoryJuly 4, 2026

FDA Accepts Supplement for Inavolisib by Genentech

The FDA has accepted a supplemental NDA for Inavolisib submitted by Genentech.

ClinicalJuly 4, 2026

Study on CD3-CD20 Bispecific Antibody with CD19-CAR T Cells in B-NHL

A clinical study is underway to evaluate the safety and efficacy of CD3-CD20 bispecific antibody therapy combined with CD19-CAR T cells in relapsed refractory B-NHL.

ClinicalJuly 3, 2026

Feasibility Study of RestoreMe App for Cancer Patient Nutrition and Activity

Montefiore Medical Center is conducting a feasibility study to assess the RestoreMe app for cancer patients, recruiting 150 participants.

ClinicalJuly 3, 2026

Bristol-Myers Squibb Compares Iberdomide to Lenalidomide in Multiple Myeloma Maintenance Therapy

A clinical trial is underway to evaluate iberdomide maintenance therapy against lenalidomide maintenance following ASCT in NDMM patients.

ClinicalJuly 3, 2026

Dizal Pharmaceuticals initiates trial for DZD8586 in relapsed B-cell Non-Hodgkin Lymphoma

Dizal Pharmaceuticals is conducting a study on DZD8586 for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma.

ClinicalJuly 3, 2026

Ruthenium-based metallodrug shows promise against cisplatin-resistant osteosarcoma

A novel ruthenium organometallic compound, Ru3, shows stronger cytotoxicity than cisplatin in osteosarcoma models.

ClinicalJuly 3, 2026

Novartis initiates trial for JDQ443 in KRAS G12C-mutated NSCLC

Novartis is evaluating JDQ443 as a first-line treatment for KRAS G12C-mutated NSCLC with low PD-L1 expression.

ClinicalJuly 3, 2026

Bicycle Therapeutics Launches Continued Access Protocol for Investigational Products

Bicycle Therapeutics has initiated Continued Access Protocol (BiCAP) for patients benefiting from investigational treatments including zelenectide pevedotin, nuzefatide pevedotin, and BT7480.

ClinicalJuly 3, 2026

NCI Launches Study on Early Life Agricultural Exposures and Cancer Risk

The National Cancer Institute is conducting a study to assess the impact of early life agricultural exposures on cancer risk among children and adults.

ClinicalJuly 3, 2026

Genentech initiates study on cevostamab and elranatamab for relapsed/refractory multiple myeloma

Genentech is evaluating the safety and pharmacokinetics of cevostamab in combination with elranatamab for R/R MM.

ClinicalJuly 3, 2026

Phase 2 Study of Zanidatamab with Chemotherapy in HER2-positive Breast Cancer

A Phase 2 study is underway to evaluate the safety and efficacy of zanidatamab combined with chemotherapy in HER2-positive breast cancer.

ClinicalJuly 3, 2026

Modeling Hyperthermia-Enhanced Delivery of Doxorubicin in Solid Tumors

Mathematical modeling shows that timing hyperthermia with peak plasma TSL-DOX levels can double intracellular doxorubicin concentration.

ClinicalJuly 3, 2026

Phase II Trial Compares Continuous vs Intermittent Dabrafenib and Trametinib in Advanced Melanoma

A phase II trial is evaluating the efficacy of continuous versus intermittent dosing of dabrafenib and trametinib in patients with unresectable stage III-IV melanoma with BRAF mutations.

CompetitiveJuly 3, 2026

Phase Ib/II Trial of Ipilimumab, Nivolumab, and Nogapendekin Alfa in NSCLC

A phase Ib/II trial is underway to evaluate the combination of ipilimumab, nivolumab, and nogapendekin alfa in patients with advanced NSCLC.

RegulatoryJuly 3, 2026

FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC)

The FDA has approved a supplemental application for SARCLISA, a monoclonal antibody targeting CD38.

RegulatoryJuly 3, 2026

FDA Approves Supplemental Applications for TRELSTAR

The FDA has approved supplemental applications for TRELSTAR, a triptorelin pamoate product.

RegulatoryJuly 3, 2026

FDA Accepts Supplement for Romvimza (Vimselitinib) by Deciphera Pharmaceuticals

The FDA has accepted a supplemental NDA for Romvimza (Vimselitinib) from Deciphera Pharmaceuticals.

RegulatoryJuly 3, 2026

FDA Approves BLA761530 (LUMVOA) from Viridian Therapeutics

The FDA has approved BLA761530, known as LUMVOA, submitted by Viridian Therapeutics.

ClinicalJuly 3, 2026

Phase II Trial of Pembrolizumab and Trastuzumab in HER2-positive Esophagogastric Adenocarcinoma

A phase II trial is underway to evaluate the efficacy of a combination of pembrolizumab, trastuzumab, and FLOT in HER2-positive localized esophagogastric adenocarcinoma.

ClinicalJuly 3, 2026

Study on AKI Prevention in Liver Cancer Patients Undergoing Therapy

A study is underway to develop an AKI risk prediction model and assess proactive nursing interventions for liver cancer patients.

ClinicalJuly 3, 2026

Phase II Trial of Nivolumab and Ipilimumab Before Surgery in Sarcomatoid Mesothelioma

A phase II trial is evaluating the safety and effectiveness of nivolumab and ipilimumab before surgery in patients with stage I-IIIa sarcomatoid mesothelioma.

ClinicalJuly 3, 2026

Study on Genetic Aberrations in Wild Type GIST Patients in Taiwan

A pilot study aims to evaluate genetic aberrations in wild type GIST patients in Taiwan using an oncopanel test.

ClinicalJuly 3, 2026

Merck's Sacituzumab Tirumotecan and Pembrolizumab Combo Trial in NSCLC Underway

A clinical trial is comparing sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone in NSCLC patients.

ClinicalJuly 3, 2026

Phase II Study of HER2 Imaging as Biomarker for T-DM1 in Advanced Breast Cancer

The ZEPHIR-02 trial will evaluate 89Zr-trastuzumab PET/CT as a predictive biomarker for T-DM1 treatment in HER2-positive mBC patients post T-DXd progression.

ClinicalJuly 3, 2026

Inotuzumab Ozogamicin Combined with Chemotherapy in Young Adults with B-ALL

A phase III trial is evaluating the efficacy and safety of inotuzumab ozogamicin combined with frontline chemotherapy in young adults with newly diagnosed B acute lymphoblastic leukemia.

RegulatoryJuly 3, 2026

FDA Accepts Supplement Application for Danziten (Nilotinib Tartrate)

The FDA has accepted a supplemental application for Danziten, which contains nilotinib tartrate.

ClinicalJuly 3, 2026

Pharmacogenomics Trial for Alectinib in NSCLC Examines SNP Impact

A new clinical trial is investigating the impact of ALK and CYP4503A4 gene SNPs on the efficacy and side effects of Alectinib in NSCLC patients.

ClinicalJuly 3, 2026

Phase II Trial of HIPEC with Cisplatin and Paclitaxel for High-Risk Gastric Cancer

A phase II trial is evaluating the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin and paclitaxel for patients with gastric or gastroesophageal junction adenocarcinoma at high risk of peritoneal recurrence.

ClinicalJuly 3, 2026

Phase 1 Study of YZJ-5053 Tablets in Advanced Solid Tumors Initiated

A Phase 1 clinical trial is underway to assess the safety and efficacy of YZJ-5053 tablets in patients with advanced solid tumors.

ClinicalJuly 2, 2026

Bruceine D inhibits STAT3-mediated glycolysis, suppressing NSCLC progression

Bruceine D suppresses non-small-cell lung cancer progression by inhibiting STAT3-mediated glycolysis in vitro and in vivo.

ClinicalJuly 2, 2026

Pilot Study of Inhaled Cromolyn Sodium in Locally Advanced Lung Cancer

A pilot study is evaluating inhaled cromolyn sodium for safety and feasibility in patients with locally advanced lung cancer.

ClinicalJuly 2, 2026

Phase II Trial of Tislelizumab and Surufatinib in Unresectable Stage III NSCLC

A phase II trial is underway to assess the efficacy and safety of hypofractionated chemoradiotherapy combined with tislelizumab and surufatinib in patients with unresectable Stage III NSCLC.

ClinicalJuly 2, 2026

Phase 1 Study of TROP2 CAR-NK Cells for Platinum Resistant Ovarian Cancer

A Phase 1 trial is investigating TROP2 CAR-engineered NK cells delivered intraperitoneally for patients with platinum-resistant ovarian cancer.

ClinicalJuly 2, 2026

Merck's MK-2870 Study Targets Advanced Gastrointestinal Cancers

Merck is conducting a clinical study to evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) for advanced or unresectable gastrointestinal cancers.

RegulatoryJuly 2, 2026

MHRA Approves Gemcitabine Delivery System for High-Risk Bladder Cancer

The MHRA has authorized a new intravesical delivery system for gemcitabine aimed at adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer.

ClinicalJuly 2, 2026

Phase II Trial of Azacitidine and Gemtuzumab Ozogamicin in Older AML Patients

A phase II trial is investigating the combination of azacitidine and gemtuzumab ozogamicin for older patients with untreated acute myeloid leukemia.

ClinicalJuly 2, 2026

Blinatumomab Plus Low-Dose DLI in High-Risk B-ALL Post-Transplantation

A prospective study is set to evaluate the safety and efficacy of blinatumomab combined with low-dose DLI in high-risk B-ALL patients after transplantation.

StrategyJuly 2, 2026

Washington University launches multi-site trial on CARE Tool for cancer cost navigation

A multi-site randomized trial is underway to evaluate the CARE Tool, which assists cancer patients in navigating costs and insurance.

ClinicalJuly 2, 2026

Epizyme's Tazemetostat Shows Promise in Follicular Lymphoma Trial

Stage 1 of the trial assessing Tazemetostat in combination with Lenalidomide and Rituximab has been completed, focusing on safety and tolerability.

ClinicalJuly 2, 2026

Study on Personalized Supportive Care for Cancer-Related Fatigue in Lymphoma Patients

A health services study will evaluate a multidisciplinary intervention program for fatigue in lymphoma patients.

ClinicalJuly 2, 2026

Study on mFOLFOX6+Bevacizumab+PD-1 in Local Advanced MSS CRC Initiated

A clinical trial is underway to evaluate the safety and efficacy of mFOLFOX6 combined with Bevacizumab and PD-1 monoclonal antibody in patients with local advanced pMMR/MSS colorectal cancer.

ClinicalJuly 2, 2026

Study on Hepzato Kit and Opdualag for Metastatic Melanoma Initiated

A clinical trial is underway to evaluate the safety and efficacy of Hepzato Kit combined with Opdualag in metastatic melanoma patients with liver metastasis.

ClinicalJuly 2, 2026

RNA Modifications as Key Regulators in Cancer Translational Control and Therapeutic Strategies

RNA modifications play a critical role in regulating protein synthesis in cancer cells, influencing therapeutic design.

ClinicalJuly 2, 2026

Phase III Trial of Atezolizumab Post-Surgery for Stage I NSCLC Shows Promise

The AASI-NSCLC trial is evaluating atezolizumab's effectiveness in preventing recurrence of stage I NSCLC after surgery.

ClinicalJuly 2, 2026

Phase III Trial Compares Ibrutinib/Rituximab vs. Chemo in CLL/SLL

A phase III trial is evaluating the efficacy of ibrutinib and rituximab against standard chemotherapy in untreated CLL/SLL patients.

CompetitiveJuly 2, 2026

Phase III Trial Compares Rituximab and Mosunetuzumab in Low Tumor Burden Follicular Lymphoma

A phase III trial is underway to compare the effectiveness of rituximab and mosunetuzumab in treating low tumor burden follicular lymphoma.

CompetitiveJuly 2, 2026

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial

The Phase III Krascendo 1 trial demonstrated that divarasib significantly improves progression-free and overall survival compared to existing KRAS G12C inhibitors.

ClinicalJuly 2, 2026

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial

ClinicalJuly 2, 2026

Phase I/II Study of LBL-024 in Advanced Malignant Tumors Initiated by Nanjing Leads Biolabs

Nanjing Leads Biolabs has initiated Phase I/II clinical trial for LBL-024 targeting advanced malignant tumors.

ClinicalJuly 2, 2026

Pilot Study on Neoadjuvant Dapagliflozin in High-Risk Prostate Cancer

A pilot study is assessing the safety and tolerability of dapagliflozin in patients with high-risk prostate cancer prior to surgery.

RegulatoryJuly 1, 2026

FDA Accepts Supplemental NDA for TRELSTAR by Verity

The FDA has accepted a supplemental NDA for TRELSTAR, an injectable formulation of triptorelin pamoate.

RegulatoryJuly 1, 2026

FDA Accepts Supplement for SARCLISA (Isatuximab-IRFC) by Sanofi

The FDA has accepted a supplemental application for SARCLISA, a monoclonal antibody targeting CD38.

RegulatoryJuly 1, 2026

FDA Accepts Supplemental NDA for Romvimza (Vimselitinib) by Deciphera Pharmaceuticals

The FDA has accepted a supplemental NDA for Romvimza (vimselitinib) submitted by Deciphera Pharmaceuticals.

ClinicalJuly 1, 2026

Phase II Trial of Multi-epitope Vaccine in Triple Negative Breast Cancer Shows Promise

A randomized phase II trial is investigating the efficacy of a multi-epitope folate receptor alpha peptide vaccine combined with GM-CSF and cyclophosphamide in preventing recurrence of triple negative breast cancer.

ClinicalJuly 1, 2026

University of Florida Tests PINPOINT Intervention for Cervical Cancer Prevention

The University of Florida is adapting and testing the PINPOINT intervention to improve cervical cancer prevention among high-risk patients.

ClinicalJuly 1, 2026

Study identifies SALL2 as a potential therapeutic target in breast cancer progression

The study explores the role of SALL2 in breast cancer progression, highlighting its potential as a therapeutic target.

ClinicalJuly 1, 2026

Rising Research on ICI-Associated Cardiotoxicity: 2016-2025 Bibliometric Analysis

Research output on immune checkpoint inhibitor-associated cardiotoxicity has surged from 9 publications in 2016 to 236 in 2025, indicating heightened academic focus.

ClinicalJuly 1, 2026

Study on Voicing My CHOiCES Tool for Advanced Care Planning in Young Adults with Cancer

The study aims to evaluate the effectiveness of the Voicing My CHOiCES document in improving communication and reducing anxiety among young adults with advanced cancer.

ClinicalJuly 1, 2026

Mobile Health Intervention Trial for AYA Leukemia Adherence

A micro-randomized clinical trial is underway to assess a mobile health intervention aimed at improving oral chemotherapy adherence among adolescents and young adults with acute lymphoblastic leukemia.

ClinicalJuly 1, 2026

Study on Animated Video and Booklet to Enhance Breast Cancer Awareness in Palestinian Women

A randomized controlled trial will evaluate the effectiveness of an animated video versus an educational booklet in increasing breast cancer knowledge among Palestinian women aged 40-69.

ClinicalJuly 1, 2026

Phase 2 Trial of Lisocabtagene Maraleucel Targets Minimal Residual Disease in Large B-cell Lymphoma

A Phase 2 trial is underway to evaluate lisocabtagene maraleucel in preventing recurrence of large B-cell lymphoma in patients with minimal residual disease.

ClinicalJuly 1, 2026

LTβR as Novel Target for Cancer Immunotherapy: Mechanisms and Therapeutic Potential

LTβR plays a crucial role in tumor immune regulation and shows promise as a target for cancer immunotherapy, especially in combination with immune checkpoint inhibitors.

ClinicalJuly 1, 2026

Phase III Trial of Ixazomib and Lenalidomide in Solitary Plasmacytoma Post-Radiation

A phase III trial is underway comparing ixazomib citrate, lenalidomide, dexamethasone, and zoledronic acid versus zoledronic acid alone after radiation therapy for solitary plasmacytoma of bone.

ClinicalJuly 1, 2026

Deep Learning Model Enhances Prognostic Prediction in Stage III Colon Cancer

A deep learning model using CD3 histological slides significantly improved prognostic stratification in stage III colon cancer.

ClinicalJuly 1, 2026

Sex-based differences in TLR agonist efficacy for early-stage melanoma treatment

Intradermal delivery of TLR9 agonist CPG7909 shows sex-based differences in immune response, with men exhibiting superior dendritic cell maturation. TLR7/8 agonist resiquimod shows better activation in female patients.

ClinicalJuly 1, 2026

Innovative Targeted Proteoform Degradation Enhances Precision Drug Design and Delivery

Targeted proteoform degradation (TPfD) offers a refined approach to drug design by addressing functional heterogeneity in proteins.

ClinicalJuly 1, 2026

Merck's MK-1045 Combined with Rituximab in Follicular Lymphoma Trial Launched

Merck is conducting a clinical trial to evaluate the safety and efficacy of MK-1045 in combination with rituximab for treating follicular lymphoma.

ClinicalJuly 1, 2026

Phase I Trial of Peposertib with Radiation and Temozolomide in Glioblastoma

A Phase I trial is investigating the safety and efficacy of Peposertib in combination with radiation and temozolomide for newly diagnosed MGMT unmethylated glioblastoma.

ClinicalJune 30, 2026

Raloxifene identified as potential inhibitor for pediatric acute myeloid leukemia via ANP32B targeting

Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene.

ClinicalJune 30, 2026

Licensed Viral Vaccines Show Promise as Anti-Cancer Therapies

Licensed viral vaccines are emerging as a viable alternative to oncolytic viruses for cancer therapy, leveraging established safety profiles.

ClinicalJune 30, 2026

Nitazoxanide shows potential as a ferroptosis inducer in triple-negative breast cancer

Nitazoxanide, an FDA-approved drug, may be repurposed to induce ferroptosis in triple-negative breast cancer.

ClinicalJune 30, 2026

Dana-Farber initiates CV Care program for prostate cancer patients on ADT

The CV Care program aims to assess and manage cardiovascular risk factors in prostate cancer patients undergoing androgen deprivation therapy.

ClinicalJune 30, 2026

Trial on Radiation Planning Aims to Reduce Neurocognitive Impairments in Pediatric Patients

A clinical trial is assessing whether targeted radiation planning can minimize cognitive impairments in pediatric patients undergoing treatment for brain tumors.

ClinicalJune 30, 2026

Phase Ib Trial of Aldesleukin with Nivolumab for Gastric Cancer with Peritoneal Metastasis

A phase Ib trial is investigating the combination of aldesleukin, nivolumab, and standard chemotherapy for gastric cancer with peritoneal metastasis.

RegulatoryJune 30, 2026

FDA Accepts Supplemental Application for ORSERDU (Elacestrant Hydrochloride)

The FDA has accepted a supplemental application for ORSERDU (elacestrant hydrochloride) from Stemline Therapeutics.

RegulatoryJune 30, 2026

FDA Approval Update for IBRANCE (Palbociclib) by Pfizer

The FDA has accepted the supplemental application for IBRANCE (palbociclib) from Pfizer.

RegulatoryJune 30, 2026

FDA Accepts Supplemental Application for KEYTRUDA QLEX

The FDA has accepted a supplemental application for KEYTRUDA QLEX, which includes pembrolizumab and berahyaluronidase alfa-PMPH.

RegulatoryJune 30, 2026

FDA Accepts Supplemental Application for IBRANCE (Palbociclib)

The FDA has accepted a supplemental application for IBRANCE (palbociclib) submitted by Pfizer.

RegulatoryJune 30, 2026

FDA Approves Supplement for KEYTRUDA (pembrolizumab) by Merck

The FDA has approved a supplemental application for KEYTRUDA (pembrolizumab) from Merck.

RegulatoryJune 30, 2026

FDA Accepts Supplement for Trodelvy (Sacituzumab Govitecan-Hziy)

The FDA has accepted a supplemental application for Trodelvy, indicating ongoing development and potential label expansion.

RegulatoryJune 30, 2026

FDA Accepts NDA for NAVITRUX by AVYXA HOLDINGS

The FDA has accepted the New Drug Application (NDA) for NAVITRUX, an antiemetic containing fosaprepitant.

ClinicalJune 30, 2026

Immunomic Therapeutics Initiates Phase I Trial of ITI-1001 for Newly Diagnosed Glioblastoma

Immunomic Therapeutics has launched Phase I trial to assess ITI-1001 in patients with newly diagnosed glioblastoma.

ClinicalJune 30, 2026

Phase Ib Trial of M1774 and ZEN-3694 in Recurrent Ovarian and Endometrial Cancer

A phase Ib trial is underway to evaluate the safety and efficacy of M1774 combined with ZEN-3694 in recurrent ovarian and endometrial cancer.

ClinicalJune 30, 2026

Study on Managing Hyperlipidemia in ALK+ NSCLC Patients on Lorlatinib

A study is underway to evaluate management strategies for hyperlipidemia in patients with ALK-positive NSCLC receiving lorlatinib as first-line treatment.

ClinicalJune 30, 2026

Phase II Trial of Dose-Escalated MR-Guided Radiotherapy for Prostate Cancer Initiated

A multi-centre randomized trial is underway to evaluate the safety and efficacy of dose-escalated MR-guided radiotherapy for localized prostate cancer.

ClinicalJune 30, 2026

Study Links Chronic Psychological Stress to Outcomes in Pancreatic Cancer

A prospective study will assess the impact of chronic psychological stress on disease progression and treatment outcomes in pancreatic cancer patients.

ClinicalJune 30, 2026

Rucaparib Monoclonal Antibody Trial for Lorlatinib-Induced Hypercholesterolemia in NSCLC

A clinical trial is underway to evaluate recakimab in patients with lorlatinib-induced hypercholesterolemia associated with NSCLC.

ClinicalJune 30, 2026

Cabozantinib plus Nivolumab Shows Promise in Advanced Non-Clear Cell RCC

In a study of 62 patients with advanced non-clear cell renal cell carcinoma, cabozantinib plus nivolumab achieved an objective response rate of 45.2% and a disease control rate of 93.6%.

RegulatoryJune 30, 2026

Enhertu Secures EU Approval as First Tumour Agnostic HER2 Therapy

Enhertu has been approved in the EU as the first tumour agnostic HER2-directed therapy for previously treated HER2-positive metastatic solid tumours.

ClinicalJune 30, 2026

MBD2's Role in Silencing SFRP1 Identifies Potential CRC Therapeutic Targets

MBD2 suppresses SFRP1 expression in colorectal cancer by blocking MED19 binding to its methylated promoter.

ClinicalJune 30, 2026

Altered Immune Cell Interactions with Bacterial LPS in Colorectal Cancer Revealed

The study reveals distinct differences in immune cell interactions with bacterial lipopolysaccharide (LPS) between colorectal cancer (CRC) tumors and adjacent tissue.

ClinicalJune 30, 2026

Phase I Trial of ASTX727 with Paclitaxel and Pembrolizumab in Metastatic TNBC

A phase I trial is underway to evaluate the safety and efficacy of ASTX727 in combination with standard treatments for metastatic triple-negative breast cancer.

ClinicalJune 30, 2026

Study on SPECT-CT Bone Scintigraphy for Characterizing Solitary Bone Lesions

A study is investigating the effectiveness of SPECT-CT bone scintigraphy in characterizing solitary bone lesions to potentially exclude malignancy.

ClinicalJune 29, 2026

Lenvatinib Evaluated for Invasive Thyroid Cancer Surgery Outcomes

A study is underway to assess the safety and efficacy of neoadjuvant lenvatinib in patients with invasive differentiated thyroid cancer.

ClinicalJune 29, 2026

Tirabrutinib vs R-TMZ in Relapsed/Refractory PCNSL: IGNITE Study Launched

The IGNITE study is evaluating tirabrutinib's efficacy and safety against the R-TMZ regimen in relapsed/refractory PCNSL.

ClinicalJune 29, 2026

Study on 18F-FDOPA PET for Non-Invasive Glioma Characterization Initiated

A clinical trial is evaluating the use of 18F-FDOPA PET imaging for the characterization of gliomas, addressing the need for non-invasive diagnostic tools.

ClinicalJune 29, 2026

Phase 2 Study of Sitagliptin in Glioblastoma Patients to Enhance Immune Response

A Phase 2 study is evaluating sitagliptin's potential to improve immune response in glioblastoma patients by targeting MDSCs.

ClinicalJune 29, 2026

First-in-human Phase 1 Study of ML261 in R/R SCLC and NECs Initiated by Moonlight Bio

Moonlight Bio has initiated a first-in-human Phase 1 trial for ML261, targeting R/R SCLC and select NECs.

ClinicalJune 29, 2026

E-VIRTUE Trial to Evaluate Enfortumab Vedotin with Pembrolizumab in Rare Genitourinary Tumors

The E-VIRTUE trial is investigating the efficacy of enfortumab vedotin with or without pembrolizumab in patients with rare testicular and urinary tract cancers.

CompetitiveJune 29, 2026

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform

Roche has launched the AXELIOS 1 platform, a next-generation sequencing solution that offers high accuracy, speed, and cost efficiency.

RegulatoryJune 29, 2026

Datroway recommended for EU approval as 1st-line treatment for TNBC

Datroway has been recommended for approval in the EU as a 1st-line treatment for metastatic triple-negative breast cancer.

ClinicalJune 29, 2026

Feasibility Study of IV Contrast-Enhanced CBCT in Radiotherapy

A single-arm feasibility study is evaluating the use of intravenous contrast-enhanced CBCT for image guidance in radiotherapy.

ClinicalJune 28, 2026

Study on Digital Psychosocial Screening for Cancer Survivors Launched

A new study is assessing the feasibility of a digital psychosocial screening for cancer survivors to improve care access.

ClinicalJune 28, 2026

Phase IIA Trial of DCA in Recurrent Glioblastoma Multiforme Initiated

A multicenter Phase IIA trial of dichloroacetate (DCA) in recurrent GBM has been initiated, involving 40 patients.

CompetitiveJune 28, 2026

Bristol-Myers Squibb Evaluates Pumitamig vs Pembrolizumab in NSCLC Trial

A clinical trial is underway to compare the efficacy of Pumitamig and Pembrolizumab in advanced NSCLC patients with high PD-L1 expression.

ClinicalJune 28, 2026

Gilteritinib Study Launch for ALK-positive NSCLC Patients by Astellas Pharma

Astellas Pharma is initiating a study to evaluate gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) who have stopped responding to ALK inhibitors.

ClinicalJune 28, 2026

Phase 2 Study of Ivonescimab and Irinotecan Liposome in Relapsed SCLC

A phase 2 study is underway to evaluate ivonescimab combined with irinotecan liposome in relapsed small cell lung cancer patients.

ClinicalJune 28, 2026

Durvalumab and Cetuximab Combination Trial for Head and Neck Cancer

A clinical trial is underway to evaluate the efficacy of durvalumab combined with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

ClinicalJune 28, 2026

XYA02 Trial Initiated for Advanced Solid Tumors by XYone Therapeutics

XYone Therapeutics has initiated a clinical trial to evaluate the safety and efficacy of XYA02 in patients with advanced solid tumors.

ClinicalJune 28, 2026

BMS's Navlimetostat in NSCLC Trial vs. Placebo and Pembrolizumab

A clinical trial is underway to evaluate Navlimetostat combined with pembrolizumab and chemotherapy in NSCLC patients with MTAP deletion.

ClinicalJune 28, 2026

Phase 2 Study of TYRA-300 Shows Promise for FGFR3 Altered NMIBC

Tyra Biosciences is conducting Phase 2 study of TYRA-300 targeting FGFR3 alterations in low grade, intermediate risk non-muscle invasive bladder cancer.

ClinicalJune 28, 2026

Study on ctHPVDNA Response-Adapted Chemoradiation with Retifanlimab in Anal Cancer

A clinical trial is investigating the use of ctDNA to tailor chemoradiation doses in patients with locally-advanced anal cancer.

ClinicalJune 28, 2026

Review Highlights Inflammation's Role in Cancer and Small-Molecule Therapeutics Development

The review discusses the critical role of inflammation in cancer and recent advancements in small-molecule therapeutics targeting inflammatory pathways.

ClinicalJune 28, 2026

ABHD17C identified as a regulator of lenvatinib efficacy in hepatocellular carcinoma

The study investigates the role of ABHD17C in modulating the efficacy of lenvatinib for HCC treatment.

RegulatoryJune 28, 2026

Capivasertib plus Abiraterone Approved for PTEN-Deficient Prostate Cancer

The FDA approved the combination of capivasertib with abiraterone acetate for PTEN-deficient metastatic castration-sensitive prostate cancer, based on improved progression-free survival.

ClinicalJune 28, 2026

Phase 2 Trial of SX-682 and Docetaxel in Advanced Head and Neck and Prostate Cancers

A new trial is underway to evaluate the combination of SX-682 and docetaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma and advanced prostate cancer.

ClinicalJune 28, 2026

NiKang Therapeutics Initiates Study of NKT5097 in Advanced Solid Tumors

NiKang Therapeutics is conducting a dose escalation study of NKT5097 in adults with advanced/metastatic solid tumors, focusing on safety and tolerability.

StrategyJune 27, 2026

FDA Acceptance of Binimetinib Application by Alembic Pharmaceuticals

The FDA has accepted the application ANDA217678 for Binimetinib submitted by Alembic Pharmaceuticals.

ClinicalJune 27, 2026

Trial on Dual Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery

A randomized controlled trial is assessing the impact of dual bronchodilator therapy on COPD patients during lung cancer surgery.

ClinicalJune 27, 2026

Study Aims to Enhance Minority Representation in Prostate Cancer Trials

A study led by M.D. Anderson Cancer Center is addressing the lack of representation of racial and ethnic minorities in prostate cancer clinical trials.

ClinicalJune 27, 2026

TRIMELVax Vaccine Shows Neutrophils as Key Regulators of Antitumor Immunity

TRIMELVax induces a rapid inflammatory response and early neutrophil infiltration, crucial for its antitumor efficacy.

ClinicalJune 27, 2026

Study Reveals Impact of Blood Flow on Microwave Ablation Efficacy

The study introduces the Antenna-Blood flow Relative Angle (ABRA) to assess how blood flow direction and velocity affect ablation zone geometry.

ClinicalJune 27, 2026

SEC61G identified as a pan-cancer biomarker and potential therapeutic target

SEC61G exhibits independent oncogenic functions across multiple cancers and serves as a prognostic biomarker.

ClinicalJune 27, 2026

Novartis initiates pediatric long-term follow-up study for dabrafenib and trametinib

Novartis is conducting a rollover study to evaluate the long-term effects of dabrafenib and trametinib in pediatric patients.

ClinicalJune 27, 2026

Phase IIa Trial of Metformin for Preventing Oral Cancer in Premalignant Lesions

A phase IIa trial is investigating the efficacy of metformin hydrochloride in preventing oral cancer in patients with premalignant lesions.

ClinicalJune 27, 2026

Phase II Trial of Paclitaxel & Cyclophosphamide With/Without Trastuzumab in Breast Cancer

This phase II trial evaluates the efficacy and side effects of paclitaxel and cyclophosphamide with or without trastuzumab in previously untreated breast cancer patients.

ClinicalJune 27, 2026

Merck's Calderasib and Durvalumab Trial for KRAS G12C NSCLC Enters Phase

A clinical trial is investigating the combination of calderasib (MK-1084) and durvalumab in patients with unresected KRAS G12C-mutated NSCLC.

RegulatoryJune 27, 2026

FDA Approves Supplemental Application for Trodelvy (Sacituzumab Govitecan-Hziy)

The FDA has approved a supplemental application for Trodelvy, a drug developed by Immunomedics Inc.

ClinicalJune 27, 2026

SYS6010 in Combination with Anti-PD-(L)-1 for NSCLC: Study Launched

A clinical trial has been initiated to evaluate SYS6010 combined with anti-PD-(L)-1 monoclonal antibody in NSCLC patients.

RegulatoryJune 27, 2026

FDA Approves Supplemental Application for IBRANCE (Palbociclib)

The FDA has approved a supplemental application for IBRANCE, CDK4/6 inhibitor developed by Pfizer.

ClinicalJune 27, 2026

Clinical Trial Evaluates Alpha Interferon for Adjuvant Skin Melanoma Therapy

A clinical trial is assessing the efficacy of alpha interferon in preventing melanoma recurrence post-surgery, comparing six treatment approaches.

ClinicalJune 27, 2026

Ipilimumab vs High-Dose Interferon in High-Risk Melanoma Trial

A phase III trial is comparing the efficacy of ipilimumab against high-dose interferon alfa-2b in high-risk stage III-IV melanoma patients post-surgery.

RegulatoryJune 27, 2026

FDA Approves KEYTRUDA and Trodelvy Combination for First-Line TNBC Treatment

The FDA has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy for first-line treatment of PD-L1+ advanced TNBC.

ClinicalJune 27, 2026

Rising Bone Cancer Incidence Highlights Need for Improved Surgical Outcomes

The incidence of malignant bone tumors has increased significantly, with a projected rise in cases by 2050.

ClinicalJune 26, 2026

Age and Treatment Modality Impact Survival in Atypical Meningioma Patients

The study highlights that age influences treatment decisions and survival outcomes in atypical meningioma patients.

ClinicalJune 26, 2026

Axitinib and Survivin Vaccine Enhance PD-1 Therapy in Renal Carcinoma

Sequential treatment with axitinib followed by a survivin vaccine and PD-1 blockade leads to durable tumor control in renal carcinoma.

RegulatoryJune 26, 2026

FDA Accepts Supplement for Cysview Kit by Photocure ASA

The FDA has accepted a supplemental application for the Cysview Kit, which contains hexaminolevulinate hydrochloride.

ClinicalJune 26, 2026

Phase II Trial of Binimetinib with mFOLFOX6 in Advanced Biliary Tract Cancers

A phase II trial is evaluating the efficacy of binimetinib combined with mFOLFOX6 chemotherapy in patients with advanced biliary tract cancers.

RegulatoryJune 26, 2026

FDA Accepts Supplement Application for LUNSUMIO (Mosunetuzumab-axgb)

The FDA has accepted a supplemental application for LUNSUMIO, a bispecific T-cell engager.

ClinicalJune 26, 2026

RNA-LP Vaccine Study for Pediatric High-Grade Gliomas and Adult Glioblastoma Initiated

A clinical trial has been initiated to evaluate RNA-lipid particle vaccines for newly diagnosed pediatric high-grade gliomas and adult glioblastoma, focusing on safety and maximum tolerated dose.

ClinicalJune 26, 2026

BMS-986504 Trial Initiated for Recurrent Glioblastoma Patients with MTAP Loss

A Phase 0/1 trial of BMS-986504 is underway for recurrent glioblastoma patients with confirmed MTAP loss.

ClinicalJune 26, 2026

Phase II/III Trial Compares Weekly vs. Every Three Weeks Cisplatin in Advanced Head and Neck Cancer

A phase II/III trial is comparing the tolerability and efficacy of weekly versus every three weeks cisplatin combined with radiation in advanced head and neck cancer.

ClinicalJune 26, 2026

NCI Launches Hypofractionation Trial for Recurrent Glioblastoma Patients

The National Cancer Institute is conducting a trial to evaluate a safe re-irradiation schedule for recurrent glioblastoma.

ClinicalJune 26, 2026

BioNTech's Pumitamig Phase III Trial in Triple-Negative Breast Cancer Underway

BioNTech SE is conducting Phase III trial of Pumitamig in combination with chemotherapy for triple-negative breast cancer.

ClinicalJune 26, 2026

PREEMPT Trial Evaluates Radiation Therapy for High-Risk Asymptomatic Bone Metastases

The PREEMPT trial is assessing the efficacy of adding radiation therapy to usual treatment for patients with asymptomatic high-risk bone metastases.

ClinicalJune 26, 2026

Phase III Trial Compares Stereotactic Radiosurgery to HA-WBRT in Brain Cancer Patients

A phase III trial is underway to evaluate the efficacy of stereotactic radiosurgery versus hippocampal avoidance whole brain radiation therapy combined with memantine in patients with small cell lung cancer that has metastasized to the brain.

ClinicalJune 26, 2026

SBRT Combined with QL1706 Shows Promise in Second-Line Hepatocellular Carcinoma Therapy

A clinical trial is underway to evaluate the efficacy and safety of SBRT plus QL1706 in patients with hepatocellular carcinoma after prior systemic therapy.

ClinicalJune 26, 2026

Bayer's Study on Darolutamide in Japanese Men with Low-Volume mHSPC

Bayer is conducting an observational study to assess the safety and efficacy of darolutamide combined with ADT and docetaxel in Japanese men with low-volume metastatic hormone-sensitive prostate cancer.

ClinicalJune 25, 2026

Study on HER2 Expression in Breast Cancer Using [99mTc]Tc-ZHER2:4107 Initiated

[99mTc]Tc-ZHER2:4107 will be evaluated for its accumulation in breast cancer tumors with varying HER2 expression.

ClinicalJune 25, 2026

Psilocybin-Assisted Psychotherapy Trial for Cancer Survivors Launched

A clinical trial is underway to evaluate the feasibility and safety of psilocybin-assisted psychotherapy for cancer survivors experiencing depression and/or anxiety.

RegulatoryJune 25, 2026

FDA approves sacituzumab govitecan-hziy for first-line triple-negative breast cancer

The FDA has approved sacituzumab govitecan-hziy both as a monotherapy and in combination with pembrolizumab for the first-line treatment of triple-negative breast cancer.

ClinicalJune 25, 2026

Obecabtagene Autoleucel Trial for MRD-Negative B-cell ALL Initiated

A clinical trial is underway to evaluate the efficacy of obecabtagene autoleucel in patients with B-cell acute lymphoblastic leukemia in complete remission.

CompetitiveJune 25, 2026

Vironexis Biotherapeutics initiates Phase 1/2 trial for VNX-202 in HER2 positive cancers

Vironexis Biotherapeutics has launched Phase 1/2 trial to evaluate VNX-202 in HER2 positive cancer patients.

RegulatoryJune 25, 2026

FDA Approves Palbociclib with Trastuzumab for HR-positive, HER2-positive Breast Cancer

The FDA has approved palbociclib in combination with trastuzumab, with or without pertuzumab, for maintenance treatment in HR-positive, HER2-positive metastatic breast cancer.

ClinicalJune 25, 2026

New Registry for Recurrent Gynecologic Cancer Treatment Insights

A new international registry will collect data on treatment outcomes for recurrent gynecologic cancers post-radiotherapy.

ClinicalJune 25, 2026

Efficacy and safety of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer across altitudes

The study evaluates the efficacy and safety of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer across different altitudes.

ClinicalJune 25, 2026

Cost-effectiveness of Adjuvant Chemotherapy in Non-Metastatic Sarcoma Analyzed

A cost-effectiveness analysis was conducted comparing adjuvant chemotherapy to no chemotherapy for non-metastatic sarcoma.

StrategyJune 25, 2026

Insights on HPV Vaccine Hesitancy to Enhance Global Vaccination Strategies

A comprehensive review identifies socio-cultural and trust-related factors influencing HPV vaccine hesitancy.

ClinicalJune 25, 2026

miR-6833-3p Promotes Prostate Cancer Progression via NUMB-NOTCH Pathway Inhibition

miR-6833-3p drives prostate cancer progression by inhibiting the NUMB-mediated NOTCH signaling pathway.

ClinicalJune 25, 2026

OTUD5-SLC7A11 Axis Identified as Novel Target in AML Progression

OTUD5 promotes AML progression by stabilizing SLC7A11, suppressing ferroptosis and enhancing cell survival.

ClinicalJune 25, 2026

Phase I Trial of Utero-Ovarian Transposition in Pelvic Malignancies to Preserve Fertility

A Phase I clinical trial is assessing the feasibility and safety of utero-ovarian transposition in premenopausal women undergoing pelvic radiotherapy.

ClinicalJune 25, 2026

Study Identifies Biomarkers for Immunotherapy Response in Advanced Cervical Cancer

The study found that baseline CD4+ T-cell percentage and post-treatment levels of CA125/SCCA, CD8+ T-cells, and PD-1 expression are significantly associated with immunotherapy response in advanced cervical cancer.

ClinicalJune 25, 2026

Phase III Trial Evaluates Sargramostim and Vaccine Therapy for Melanoma Recurrence Prevention

A phase III trial is underway to compare the efficacy of sargramostim and vaccine therapy alone versus their combination in preventing melanoma recurrence post-surgery.

ClinicalJune 25, 2026

Phase III Trial of Pazopanib in Metastatic Kidney Cancer Post-Surgery

A phase III trial is evaluating the efficacy of pazopanib hydrochloride versus placebo in patients with metastatic kidney cancer post-surgery.

CompetitiveJune 25, 2026

Cadonilimab Targets PD-1/PD-L1 Blockade-Refractory MSI-H/dMMR Colorectal Cancer

Cadonilimab, a bispecific anti-PD-1/CTLA-4 antibody, is being evaluated for advanced colorectal cancer patients who are refractory to PD-1/PD-L1 blockade.

RegulatoryJune 25, 2026

European Commission Approves KEYTRUDA Plus Padcev for Cisplatin-Ineligible Bladder Cancer

The European Commission has approved KEYTRUDA in combination with Padcev for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

RegulatoryJune 25, 2026

FDA Approves Pfizer’s IBRANCE for HR+, HER2+ Metastatic Breast Cancer Maintenance

The FDA has approved IBRANCE in combination with trastuzumab and endocrine therapy for HR+, HER2+ metastatic breast cancer maintenance treatment, based on the Phase 3 PATINA trial results.

ClinicalJune 25, 2026

Phase 1 Study of PSMA/CD70 Bi-specific CAR-T Cell Therapy Initiated

A Phase 1 clinical trial is underway to evaluate the safety and efficacy of PSMA/CD70 bi-specific CAR-T cell therapy.

ClinicalJune 25, 2026

Phase Ib Trial of Niraparib and Copanlisib for Recurrent Gynecological Cancers

A phase Ib trial is underway to evaluate the safety and dosing of niraparib and copanlisib in recurrent gynecological cancers.

ClinicalJune 25, 2026

XTX301 Phase 1/2 Trial Initiated for Advanced Solid Tumors

Xilio Development, Inc. has initiated a first-in-human Phase 1/2 trial to evaluate XTX301 in patients with advanced solid tumors.

ClinicalJune 25, 2026

Boehringer Ingelheim Initiates Phase 1 Study of BI 1831169 in Advanced Solid Tumors

Boehringer Ingelheim is testing BI 1831169, both alone and in combination with an anti-PD-1 antibody, in patients with advanced solid tumors.

ClinicalJune 25, 2026

Universal CAR-T Cells Show Promise in Multiple Myeloma Study

A clinical trial is underway to evaluate universal CAR T cells for treating multiple myeloma, focusing on safety and efficacy.

ClinicalJune 24, 2026

Merck's Sacituzumab Tirumotecan Trial Targets High-Risk Breast Cancer

Merck is conducting a clinical trial to evaluate sacituzumab tirumotecan in combination with pembrolizumab and chemotherapy for high-risk early-stage breast cancer.

ClinicalJune 24, 2026

Olaparib Investigated as Neoadjuvant Treatment in Ovarian Cancer Study

A study is underway to evaluate olaparib as a neoadjuvant treatment for patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

ClinicalJune 24, 2026

Entrectinib Phase 1/2 Study in Pediatric Solid Tumors and CNS Tumors Initiated

A Phase 1/2 study of Entrectinib in pediatric patients with advanced solid tumors and CNS tumors has been initiated.

ClinicalJune 24, 2026

Epcoritamab Shows Promise in High-risk Burkitt Lymphoma with DA-EPOCH-R in Phase II Trial

The phase II BEDROCK study is evaluating the efficacy of epcoritamab combined with DA-EPOCH-R in high-risk Burkitt lymphoma patients.

ClinicalJune 24, 2026

Merck's KEYMAKER-U01 Study Explores Pembrolizumab in NSCLC with Chemotherapy

The KEYMAKER-U01 study investigates pembrolizumab alone and in combination with chemotherapy for NSCLC.

ClinicalJune 24, 2026

Gilteritinib vs Midostaurin Trial for FLT3 Mutated Acute Myeloid Leukemia

A clinical trial is comparing gilteritinib and midostaurin in untreated patients with FLT3 mutated AML.

ClinicalJune 24, 2026

KIF18A Inhibitor Shows Promise Against Osteosarcoma Growth

A KIF18A inhibitor has been shown to prevent growth in chromosomally unstable osteosarcoma by activating the spindle assembly checkpoint.

ClinicalJune 24, 2026

ADAR1-circRAB5A-BIP axis linked to radiotherapy resistance in colorectal cancer

The study identifies the ADAR1-circRAB5A-BIP axis as a key regulator of radiotherapy resistance in colorectal cancer by balancing autophagy and apoptosis.

ClinicalJune 24, 2026

Trial on Targeted Temperature Management to Reduce Delirium in Cancer Surgery Patients

A trial is investigating whether intraoperative targeted temperature management can reduce postoperative delirium and improve progression-free survival in older cancer surgery patients.

ClinicalJune 24, 2026

Purinergic Activity in Extracellular Vesicles Linked to Melanoma Progression

Higher CD73 activity in total extracellular vesicles correlates with disease progression in melanoma patients.

ClinicalJune 24, 2026

Phase III Trial Evaluates Bevacizumab with Chemotherapy in HER-2 Positive Metastatic Breast Cancer

A phase III trial is investigating the efficacy of adding bevacizumab to first-line chemotherapy and trastuzumab in HER-2 positive metastatic breast cancer.

ClinicalJune 24, 2026

Phase III Trial of Durvalumab Post-Surgery in Early-Stage NSCLC Shows Potential Benefit

The INSIGHT trial is comparing durvalumab to standard observation in patients with early-stage non-small cell lung cancer post-surgery.

ClinicalJune 24, 2026

Phase II Trial of Axelopran with Pembrolizumab in Head and Neck Cancer

A Phase II trial is underway to evaluate axelopran's safety and efficacy with pembrolizumab in R/M HNSCC patients.

ClinicalJune 24, 2026

Pfizer Reports Phase 3 Results for Sigvotatug Vedotin in NSCLC; No Overall Survival Benefit Observed

The Phase 3 SigVie-002 study of sigvotatug vedotin in previously treated metastatic NSCLC did not show a statistically significant improvement in overall survival compared to docetaxel, although a trend for better outcomes was noted in patients with only one prior therapy.

RegulatoryJune 24, 2026

Companies

Assets

Recent signals(1139)

FDA Accepts Supplemental NDA for Mekinist by Novartis

Phase 1 Trial of TSLPR-CART in Refractory B-ALL Shows Promise for Targeting TSLPR Overexpression

BI 764532 Dose Tolerance Study in DLL3-Positive Brain Tumor Patients Initiated

YH32364 Trial Targets EGFR Overexpressing Solid Tumors in Advanced Cancer Patients

FDA Accepts Supplement for Pluvicto (Lutetium Lu-177) by Novartis

VR Program for Heart Health Education in Breast Cancer Survivors Undergoing Treatment

Innovation Passports Granted for Liver Cancer and Dementia Products

Selinexor shows promise in high-risk multiple myeloma with XVRd regimen

Advancements in Prostate Cancer Diagnostics: AI and Liquid Biopsies Show Promise

Boehringer Ingelheim's Zongertinib NDA219042 Receives AP Status from FDA

FDA Accepts Supplement for LYNOZYFIC (BLA761400) from Regeneron

AIM/CD5L as a potential immunomodulator in feline injection-site sarcoma

Management of BRAF Inhibitors in Glioma: Addressing Toxicity and Resistance

Pfizer Raises 2026 Revenue Guidance by $500 Million Amid Strong Q2 Results

FDA Accepts Supplement Application for Sodium Thiosulfate by Hope Pharms

FDA Approval Process Update for Capecitabine ANDA204345 by Dr. Reddy's

FDA Grants Approval Status for Capecitabine ANDA204741 by Amneal Pharmaceuticals

NCI Launches Screening for High Genetic Risk Cancer Studies

Pilot Trial for Simulation-Free Celiac Plexus Pain Ablation Using SBRT Shows Novel Workflow

FDA grants approval status for Leuprolide Acetate ANDA215336

FDA Accepts Supplement Application for ELIGARD Kit by TOLMAR

FDA Approves Supplement for Leuprolide Acetate by PH Health

FDA Accepts Supplement Application for TECVAYLI (BLA761291)

FDA grants approval status for Leuprolide Acetate ANDA217957

FDA grants AP status for Leuprolide Acetate ANDA215826 by Zydus Pharms

Phase II Trial of Ivonescimab in High-Risk Localized Clear Cell Renal Cell Cancer

Study on Biomarkers in AML Patients Post-Stem Cell Transplantation with Menin Inhibition

Phase I Study of Inavolisib in PIK3CA-Mutant Solid Tumors and Breast Cancer

Study on Palbociclib Combinations in HR+HER2-MBC Initiated in Africa and Middle East

Study on NGS Testing to Monitor B-ALL Relapse Post CART Therapy in Children

HRS-5041 Tablets Show Promise in Advanced Prostate Cancer Therapy

RO7771950 Shows Promise Against Tucatinib in HER2-Positive Breast Cancer Trial

ASP1570 Study in Advanced Solid Tumors with Pembrolizumab and Standard Therapies

Study on mSEPT9 Biomarker for Early Detection of Hepatocellular Carcinoma in Cirrhosis Patients

Lilly's olomorasib receives FDA Breakthrough Therapy designation for advanced pancreatic cancer

FDA Accepts Supplemental NDA for Eligard Kit by Tolmar

FDA grants AP status for Leuprolide Acetate ANDA212963 by Eugia Pharma

FDA Accepts Supplemental BLA for TALVEY (TALQUETAMAB-TGVS) by Janssen

FDA Accepts Supplemental NDA for ZOLADEX by TERSERA

FDA Accepts Supplement for ZOLADEX (Goserelin) by TERSERA

FDA Grants AP Status for Sandoz's Leuprolide Acetate Supplement

FDA Grants AP Status for Leuprolide Acetate ANDA213829

FDA Accepts Supplemental NDA for Eligard Kit by Tolmar

Elranatamab and Iberdomide Combination Study in Relapsed/Refractory Multiple Myeloma Initiated

Study on ctDNA and HPV DNA Detection in High-risk Head and Neck Cancer Initiated

FDA Accepts Supplement for Leuprolide Acetate by Sun Pharma

FDA grants AP status for Leuprolide Acetate ANDA075471 by Meitheal

FDA Accepts Supplemental Application for ZOLADEX by TERSERA

FDA Accepts Supplement Application for ELIGARD Kit by TOLMAR

FDA Submission Update for Leucovorin Calcium by Epic Pharma

FDA Approves Leucovorin Calcium Supplement Application by Ingenus Pharmaceuticals

FDA Approval Process Update for Leucovorin Calcium by Hikma

FDA Grants Approval for Leucovorin Calcium ANDA072734 by Hikma

FDA Approval Process Update for Leucovorin Calcium by Hikma

FDA grants approval status for Leucovorin Calcium ANDA072736

ANI Pharmaceuticals receives AP status for Leucovorin Calcium supplement

FDA Approves Leucovorin Calcium Supplement Application by Barr

FDA Approval Process Update for Leucovorin Calcium by Barr

Study on PBMC Collection for T Cell Expansion in Cancer Therapy

FDA Approval Status for Leucovorin Calcium Supplement

FDA Approval Process Update for Ondansetron Hydrochloride Preservative Free

Phase II Trial of Cladribine and Rituximab for Hairy Cell Leukemia

Phase I Trial of Triapine in Uterine Cancers Shows Potential for Enhanced Treatment

Study on MR-Guided Adaptive Therapy for Endometrial Cancer Initiated

FDA Accepts NDA for Trabectedin by Apotex

Phase I Trial of ONC206 for Newly Diagnosed and Recurrent Malignant CNS Tumors

Phase II Trial of Carboplatin in Metastatic Prostate Cancer with HR Pathway Alterations

FDA Accepts NDA for Vepdegestrant by Arvinas Operations

Exploratory Study of SHR-A1811 in HER2-Positive Advanced Breast Cancer

Phase II Study of Alpelisib in PIK3CA-related Overgrowth Spectrum Initiated

FDA Accepts Supplement for Lazertinib Mesylate by Janssen Biotech

FDA Approves Methotrexate Sodium Application ANDA219865

Phase 1/2 Study of TROP2 CAR NK Cells with Belzutifan in Pancreatic Cancer

Phase II Trial on Adaptive Radiation Planning in NSCLC to Reduce Toxicity

FDA Approves Lutetium Lu 177 VIPIVOTIDE for Metastatic Prostate Cancer

Phase I/II Trial of Olaparib and Radium-223 in Advanced Prostate Cancer

Phase II Study on HIPEC's Impact on PD-L1 in Advanced Gastric Cancer